Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging mangers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most painful mistakes founders make is assuming that investor interest means investor fit.

The meeting goes well. The investor likes the company. They understand the problem. They ask thoughtful questions. They say the market is interesting. They ask to stay close. They may even introduce someone else on the team. The founder leaves the call thinking there is momentum.

But weeks pass.

The investor does not move. They ask for updates. They want to see more traction. They say the company is a little early. They say the round is not quite the right size. They say they like the founder, but the opportunity does not fit the current fund. They stay friendly, but the process never becomes real.

From the founder’s perspective, this feels confusing. If the investor likes the company, why do they not invest?

The answer is often fund fit.

A warm meeting does not mean the investor can write a cheque. A positive conversation does not mean the fund has the right mandate. An investor can genuinely like the company and still never invest because the stage is wrong, the cheque size is wrong, the geography is wrong, the sector is wrong, the ownership target is wrong, the reserve model is wrong, the fund cycle is wrong, or the company does not fit the way that fund is built to make money.

This is the fund fit problem.

Founders often spend too much time trying to convince investors who were never structurally likely to invest. They mistake interest for probability. They assume the barrier is the pitch, the deck, the story, the traction, or the amount of follow-up. Sometimes those things are the issue. But often the investor was simply not the right fund for the round.

That distinction matters because fundraising is not only about finding investors who like the company. It is about finding investors whose mandate, model, timing, cheque size, ownership needs, and decision process match the company’s financing need.

The wrong investor can like your company and still never invest.

Subscribe now

Liking the company is not the same as being able to invest

Founders often assume that investor decisions are purely conviction-based.

If the investor believes, they invest. If they do not invest, they must not believe.

That is too simple.

Investors operate inside constraints. Some are obvious. Some are hidden. A fund may only invest at seed, Series A, growth, or preclinical stage. It may only write cheques above a certain size. It may require a minimum ownership position. It may only invest in certain geographies. It may avoid certain regulatory categories. It may not invest in therapeutics, diagnostics, medical devices, services, digital health, or AI unless the company fits a very specific model.

The fund may also have internal constraints that are not visible from the outside. It may be near the end of its investment period. It may have limited reserves. It may already have exposure to a similar company. It may be focused on follow-ons. It may be raising its next fund. It may have changed strategy without updating the website. It may have a partner who likes the company, but no internal consensus.

None of this means the company is bad.

It means the investor cannot make the investment work inside their fund.

This is why founders need to separate investor enthusiasm from investor fit. An investor can be curious, helpful, warm, and intellectually engaged without being a real candidate for the round. They may enjoy the conversation. They may want to track the company. They may believe the founder is impressive. They may even think the company could become valuable.

But if the investment does not fit their fund, the conversation will not become capital.

The website is not the mandate

Founders often research investors by reading websites.

That is a start, but it is not enough.

A fund’s website may say it invests in healthcare, life sciences, AI, digital health, medtech, biotech, deep tech, or frontier technology. It may list portfolio companies that look relevant. It may publish thesis content that sounds aligned with the founder’s market. It may have partners who speak at the right conferences and write about the right trends.

But the public thesis is not always the active mandate.

A fund may say it invests in health, but only in software companies with clear revenue. Another may say it invests in life sciences, but mostly in therapeutics with strong IP and translational data. Another may say it invests in AI, but only in horizontal infrastructure. Another may say it invests in Europe, but only when there is a US expansion path. Another may say it invests at seed, but in practice only leads larger institutional seed rounds with ownership.

This is where founders lose time. They see sector overlap and assume fit. They get a warm meeting and assume probability. But the fund’s real investment pattern may not match the company’s round.

The investor’s actual behaviour matters more than the website.

What have they invested in recently? What stage? What cheque size? Did they lead or follow? What ownership did they likely take? What geographies did they back? What type of health risk do they understand? Do they invest before revenue, before clinical data, before regulatory clearance, before reimbursement, before commercial adoption, or only after those points?

The website tells you what the fund wants the market to know.

The portfolio tells you how the fund actually behaves.

Stage mismatch wastes time

Stage is one of the most common fund fit problems.

A founder may pitch a fund that invests in the right sector, but at the wrong stage. The fund likes the company, understands the market, and agrees the problem matters, but the company is too early for its model. The founder hears, “We like this, but come back after more traction,” and thinks they need to keep nurturing the relationship.

Sometimes that is useful.

But if the fund structurally does not invest before a certain stage, the founder should not treat that investor as a current-round prospect.

This happens often in health. A digital health company may speak to growth investors before it has repeatable revenue. A medtech company may speak to Series A funds before it has enough clinical or regulatory progress. A therapeutics company may speak to investors who need more preclinical validation. A diagnostics company may speak to funds that only invest once reimbursement or market access is clearer.

The investor may genuinely like the company. But liking an early version of the company is not the same as investing in the early version of the company.

Founders need to understand the difference between a future investor and a current investor. A future investor may be worth keeping warm. They may provide useful feedback. They may become relevant after the next milestone. But they should not consume the same time, urgency, or emotional energy as an investor who can act now.

The wrong stage investor can create the illusion of momentum while the real round remains underdeveloped.

Cheque size matters more than founders think

Another common mismatch is cheque size.

Founders often assume that if a fund has capital, it can write any cheque within a broad range. That is rarely true. Funds have target cheque sizes because cheque size connects to ownership, fund size, reserve strategy, portfolio construction, and how much work the investment justifies.

If a fund usually writes €3 million to €6 million initial cheques and the founder is raising €800,000, the round may be too small. If a fund usually writes €250,000 to €500,000 cheques and the founder needs a €5 million lead, the investor may be helpful but not sufficient. If the fund needs 10 percent ownership and the round structure only allows 3 percent, the economics may not work.

This is why a fund can like the company and still not be useful for the round.

A cheque that is too small may not solve the founder’s financing need. A cheque that is too large may not fit the dilution or ownership structure. A fund that cannot lead may only become relevant once a lead is found. A fund that only leads may not want to join as a small follower.

Founders should qualify cheque size early. Not vaguely, but specifically. What cheque size do they usually write at this stage? Do they lead or follow? What ownership do they need? How much of the round would they expect to take? Do they reserve for follow-ons? Is this round size large enough or too small for them?

These questions can save months.

A warm investor with the wrong cheque size is not a current solution.

Leave a comment

Ownership targets shape fit

Valuation is not the only number investors care about. Ownership matters because funds need each investment to have the potential to matter for the fund.

This creates another fund fit problem.

A founder may want to raise a small round at a high valuation with limited dilution. That may look attractive to the founder, but it may not allow a lead investor to build the ownership they need. The investor may like the company, but if they cannot own enough of the upside, the investment may not fit their model.

This is especially true for institutional funds. A larger fund usually needs larger outcomes and often needs larger ownership positions. A small position in a good company may not move the fund. That means the fund may pass, even if the company is promising.

Founders often interpret this as a valuation objection. Sometimes it is more accurately an ownership objection.

The investor is not only asking whether the company is worth the price. They are asking whether the cheque, price, dilution, and future financing path allow the fund to build a position that matters.

If the answer is no, the investor may stay interested but not lead.

This is why founders need to understand the investor’s ownership target before spending too much time in process. If the fund needs 10 percent and the round only offers 3 percent, there is a structural mismatch. If the company needs a lead but the fund only follows, there is a role mismatch. If the founder is protecting dilution so aggressively that no serious investor can build ownership, there is a financing design problem.

Fund fit is not only about whether the investor likes the company.

It is about whether the round works for the investor’s model.

Geography is still a real constraint

Founders often assume geography matters less than it used to.

In some cases, that is true. Many funds invest across borders. Some investors actively look for companies in Europe, the US, the Middle East, Asia, or global markets. Cross-border capital is more common than before.

But geography still matters.

A fund may only invest in companies incorporated in certain jurisdictions. It may need local legal familiarity. It may have LP restrictions. It may focus on specific ecosystems. It may require the company to have a US headquarters, European operations, local clinical sites, or a market entry path in a geography the fund understands. It may avoid regions where follow-on capital is harder to access.

In health, geography matters even more because regulation, reimbursement, procurement, healthcare infrastructure, clinical validation, market access, and buyer behaviour vary significantly by market. A fund that understands US healthcare may not want to underwrite European reimbursement. A European fund may like a US company but lack networks to support it. A Middle East investor may care about regional expansion. A China-connected investor may need a specific partnership path.

Founders should not assume that sector fit overrides geography.

A fund may like the company but not have the mandate, network, or confidence to invest in that jurisdiction. That is not necessarily a judgment on the company. It may simply be a geography constraint.

This is why founders need to ask where the fund actually invests, not only where it says it is interested.

Sector fit is more specific than category labels

Sector fit is often misunderstood because founders use broad labels.

Healthcare. Healthtech. Medtech. Biotech. Digital health. AI. Life sciences. Diagnostics. Platform. Infrastructure. Therapeutics.

These labels are useful, but they are not precise enough.

A fund that invests in healthcare software may not invest in regulated medical devices. A life sciences investor may not invest in services. A medtech investor may not invest before a certain regulatory stage. A digital health fund may require commercial revenue. A biotech fund may want drug development risk but not provider adoption risk. An AI fund may care about technical infrastructure, not healthcare workflow.

Founders often assume that because a fund invests in the broad sector, it fits the company. But investors underwrite specific types of risk.

What kind of health risk does the fund actually take? Clinical risk? Regulatory risk? Reimbursement risk? Adoption risk? Technology risk? Biology risk? Commercial risk? Market access risk? Platform risk? Services risk?

A company may sit in a category the fund likes, but carry a type of risk the fund avoids. That is a fund fit problem.

This is why founders should go deeper than labels. They should understand what risk the investor is built to underwrite. If the fund has never invested in reimbursement-heavy companies, it may not be the right investor for a reimbursement-dependent business. If the fund avoids clinical development, it may not be right for a company that needs clinical evidence before value inflection. If the fund only backs software margins, it may not fit a services-heavy operating model.

Sector fit is not about the headline category.

It is about risk fit.

Fund cycle changes availability

A fund’s ability to invest depends on where it sits in its own lifecycle.

A fund early in deployment may be actively looking for new positions. It may have fresh capital, open portfolio construction, and appetite to lead. A fund later in its investment period may be more selective. It may have limited room for new companies and more capital reserved for follow-ons. A fund near the end of its cycle may like the company but be unable to commit meaningfully.

This is one of the most frustrating fund fit issues because it is often invisible.

The fund’s website still looks active. The partners still take meetings. The thesis still appears relevant. The investor may genuinely want to track the company. But the fund may not have the capacity, timing, or internal permission to make a new platform investment.

Founders may mistake this for rejection.

Sometimes the company met the right investor at the wrong time.

This does not mean the relationship is useless. A fund that is not available now may become relevant in a future vehicle or later round. But the founder should not build the current process around investors who cannot act now.

Fund timing matters because fundraising is not only about fit in theory.

It is about fit at the moment the company needs capital.

Reserve strategy affects current decisions

Founders often think reserves only matter after an investment.

But reserves affect whether an investor can invest in the first place.

If a fund knows the company will require multiple rounds, it has to think about follow-on capacity. Can it support the company again? Can it maintain ownership? Will the future capital requirement be too large for the fund? Will the company need investors later that the current fund can help attract?

This is particularly important in health and life sciences, where capital requirements can be substantial. A company may need more capital for clinical work, regulatory milestones, market access, manufacturing, reimbursement, or commercial scaling. An investor may like the company but worry that the future financing requirement does not fit its reserve model.

The fund may ask, “If we invest now, can we support this company properly later?”

If the answer is no, the investor may pass.

Founders often experience this as vague concern about capital intensity. But underneath, it may be a reserve strategy issue. The fund may not want to start a journey it cannot support. It may not want to own too little after future dilution. It may not want to put the company into a position where it needs a larger follow-on than the syndicate can provide.

A founder who understands reserve logic can explain the financing path more clearly. They can show what each round is designed to prove, who the next investor universe is, and how the current investor can remain aligned.

Without that, a capital-intensive company may look difficult to fit, even if the opportunity is attractive.

Mandate is not flexible just because the investor likes you

Some founders believe a great company can make an investor stretch outside mandate.

Occasionally, that happens. But founders should not build their fundraising process around exceptions.

Most investors are constrained by mandate. The mandate may come from LP agreements, fund strategy, internal policy, partner expertise, geography, stage, sector, cheque size, ownership, or risk type. A partner may personally like the founder and still be unable to get the investment through internally.

This is especially true when an investor says, “This is not quite our mandate, but we would love to stay close.”

That may be sincere. It may also be a signal that the investor is not a current-round prospect.

The founder needs to listen carefully.

A mandate mismatch does not become a fit because the meeting was warm. It does not become a fit because the investor likes the founder. It does not become a fit because the company is impressive. If the fund is not built to invest in that type of opportunity, the probability remains low.

This is why founders should not overinvest in investors who require too many exceptions.

If the investor needs to stretch on stage, cheque size, geography, sector, ownership, risk, and timing, the founder is not running a high-probability process. They are hoping for a special case.

Special cases happen.

But they are not a fundraising strategy.

Warm conversations can become a trap

Warm investor conversations feel valuable because they reduce the emotional difficulty of fundraising.

It is easier to keep speaking with investors who like the company. It feels better than hearing no. It creates the sense that something is happening. It gives the founder updates to share with the team, board, or existing investors. It makes the round feel alive.

But warm conversations can become a trap if they are not actionable.

A founder can spend months with investors who are friendly, engaged, and curious, but structurally unlikely to invest. They ask smart questions. They offer feedback. They take the next call. They say the company is interesting. But they never define a decision process, discuss cheque size seriously, engage internally, or explain what it would take to move.

This drains the founder’s time and attention. It can also distort the founder’s view of the market. The founder believes there is momentum because there are conversations. But the round is not moving because the conversations are with the wrong investors.

This is why qualification is not rude. It is necessary.

Founders should be respectful, but clear. Is this a fit for your current fund? Do you invest at this stage? Do you lead rounds of this size? What ownership do you target? Are you actively making new investments? Is this within your mandate? What would need to be true for you to move forward?

These questions do not scare serious investors away.

They reveal whether the conversation is real.

Fund fit changes the quality of feedback

Another reason fund fit matters is that feedback from the wrong investor can be misleading.

An investor who is not a fit may still give feedback. Some of it may be useful. But founders should be careful about overcorrecting based on feedback from investors who were unlikely to invest anyway.

A growth investor may say the company needs more revenue. That may be true for them, but not for a seed specialist. A therapeutics investor may dislike a services component that a commercial healthcare investor understands. A generalist fund may struggle with regulatory complexity that a specialist fund can underwrite. A local investor may worry about geography while an international investor sees the cross-border opportunity differently.

Feedback is not neutral. It reflects the investor’s model.

This does not mean founders should ignore feedback from non-fit investors. Sometimes outsiders see real weaknesses. But founders need to interpret feedback through the lens of fund fit. Is the concern a real company issue, or is it an investor model issue? Are multiple fit investors raising the same concern, or only funds that were never structurally aligned?

This distinction protects founders from unnecessary pivots in the fundraising story.

A founder can waste time trying to become fundable to investors who were never the right audience.

The better goal is to understand what the right investors need to believe.

Share

How to qualify fund fit before you waste months

The deeper question is how founders can qualify fund fit early enough to protect the fundraising process.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Founders often think the next round is mostly about convincing new investors.

That is understandable. When a company goes back to market, the founder is focused on the new lead, the new syndicate, the new valuation, the new milestone, and the new investment case. The pitch deck is updated. The data room is prepared. The customer evidence is organised. The investor list is built. The founder starts telling the story of why the company is now ready for the next financing.

But new investors are not only listening to what the founder says.

They are watching what the existing investors do.

This is one of the most important signals in fundraising. Existing investors have been closest to the company. They have seen the updates. They know the founder. They understand the original plan. They have watched the company execute, miss, learn, adapt, and communicate. They know more than outside investors do.

So when a new investor looks at the round, they ask a simple question.

What are the insiders doing?

Are existing investors participating? Are they following their pro rata? Are they increasing ownership? Are they helping organise the round? Are they making introductions? Are they willing to bridge? Are they supportive but passive? Are they sitting out? Are they quietly stepping back? Are they saying positive things without putting in more capital?

Founders often underestimate how much this matters.

From the founder’s perspective, an existing investor who does not participate may have a reasonable explanation. The fund may be out of reserves. The investor may be late in its fund cycle. The cheque may be too small for their model. The partner may still be supportive but unable to invest. The investor may have portfolio concentration limits. The original angel may not have follow-on capacity. There may be no loss of conviction at all.

That can be true.

But from the outside, insider behaviour still creates a signal.

If the investors who know the company best are not investing again, a new investor will want to understand why. If insiders participate weakly, the new investor will ask whether they are constrained or unconvinced. If the previous lead is quiet, the new investor will wonder whether there is a hidden issue. If everyone is supportive in words but not in capital, the new investor will notice.

That is the inside round signal.

It is not always fair. It is not always simple. But it is real.

Subscribe now

Insiders have information outsiders do not

New investors know that existing investors have more information than they do. That does not mean insiders always make better decisions, but it does mean their behaviour carries weight.

An existing investor has seen the company between fundraises. They have read updates when things were not polished. They have watched how the founder communicates under pressure. They have seen whether milestones were reached, delayed, redefined, or missed. They know how the team operates. They know whether the company has become sharper or more chaotic. They know whether customer interest has turned into real movement. They know whether the founder has used capital well.

That is why insider participation is interpreted as information.

If existing investors continue to support the company, that can help outside investors build confidence. It suggests that the people closest to the company still believe the opportunity is worth backing. It does not guarantee the round will close, but it reduces one important question.

If existing investors do not participate, the opposite happens. New investors may not immediately pass, but they will ask more questions. Why are insiders not investing? Are they unable or unwilling? Did something change? Did they lose conviction? Is the company asking new investors to take risk that insiders no longer want to take?

Founders sometimes resist this logic because they know the full context. They know that fund mechanics, reserves, strategy, and timing can explain a lot. But the new investor does not start with that context. They start with the signal.

The founder’s job is not to complain that the signal is misunderstood. The founder’s job is to explain it clearly before it becomes a hidden concern.

Supportive is not the same as investing

One of the most common phrases in fundraising is “our existing investors are supportive.”

That can mean many things.

It can mean they are investing meaningfully in the new round. It can mean they are following pro rata. It can mean they are introducing new investors. It can mean they are helping prepare the company. It can mean they are willing to bridge if needed. It can mean they like the company but are not investing. It can mean they are emotionally supportive but financially unavailable. It can mean they have not yet decided.

New investors hear this phrase carefully.

They know that “supportive” is often used when the founder wants to avoid saying something more specific. If insiders are investing, the founder usually says they are investing. If the previous lead is taking a meaningful allocation, that becomes part of the round story. If insiders are not investing, founders often soften the language.

This does not mean founders should be harsh or defensive. But they should be precise.

There is a big difference between “our existing investors are supportive and participating pro rata,” “our existing investors are supportive but do not have follow-on capacity,” “our previous angels were helpful early but were not expected to follow,” and “our current lead is not investing because they no longer have conviction.”

These are not the same story.

Precision matters because vague language creates space for doubt. A new investor does not want to discover late in diligence that “supportive” meant “not participating.” That damages trust. It makes the investor wonder what else has been softened.

The strongest founders describe insider behaviour clearly. They do not hide behind ambiguous phrases. If insiders are investing, they say so. If insiders are not investing because of fund constraints, they explain that. If some are participating and some are not, they separate the categories. If there is a difficult story, they address it with discipline.

New investors can handle complexity. They struggle with surprise.

Weak insider participation raises questions

Inside participation does not need to be perfect. Many early syndicates are messy. Angels may not have more capital. Small funds may lack reserves. Strategics may not follow every round. Family offices may be unpredictable. A previous investor may have changed strategy. A fund may be at the end of its lifecycle. New investors understand that not every insider can or should participate.

But weak insider participation still raises questions.

If existing investors are not participating at all, the new investor will ask why. If they are participating only symbolically, the new investor will ask whether that is a capacity issue or a conviction issue. If the previous lead is not leading internally, the new investor will wonder whether the company has lost its strongest sponsor. If insiders are waiting for a new lead before committing, the new investor may ask why the people closest to the company are not willing to move first.

This is where founders need to understand how outsiders think.

New investors are not only evaluating the company. They are evaluating the behaviour of the people who already know the company best. If those people appear hesitant, the outsider has to decide whether they are seeing a normal financing constraint or a warning sign.

That distinction is critical.

A capacity issue is explainable. An investor with no reserves cannot follow, even if they love the company. A mandate issue is explainable. A fund that no longer invests at that stage may not be able to support the round. A portfolio construction issue is explainable. A small angel who cannot write another cheque is not necessarily a negative signal.

A conviction issue is different.

If insiders can invest but choose not to, or if they quietly distance themselves from the round, new investors will notice. The founder needs to be ready for that question.

The previous lead matters most

Not all insider signals are equal. The behaviour of the previous lead usually matters more than the behaviour of small followers.

The previous lead is expected to know the company deeply. They likely did the original diligence, negotiated terms, shaped the round, took board or governance responsibility, and became the investor most associated with the financing. If that investor remains actively supportive, it can strengthen the next raise. If that investor is absent, quiet, or unwilling to participate, it can create concern.

This does not mean the previous lead must always lead the next round. In many cases, a new lead is appropriate. A company may have outgrown the stage of the previous fund. The next round may require a different investor type. The prior lead may participate but not price the round. That can be fine.

The issue is whether the previous lead is still demonstrating conviction.

A previous lead can support the company in many ways. They can invest pro rata. They can make serious introductions. They can speak positively to new investors. They can help prepare the financing narrative. They can explain their own fund constraints if they are not investing. They can help bridge the company to the next milestone. They can show up when it matters.

If the previous lead is not doing any of this, the signal becomes harder to manage.

New investors will ask why the investor who knows the company best is not helping. They may not ask bluntly in the first meeting, but the question will sit in the background. If the founder does not address it, the investor may go looking for the answer elsewhere.

That is dangerous because the founder loses control of the interpretation.

Insider silence can be louder than a pass

Sometimes the problem is not that insiders openly refuse to invest. It is that they become quiet.

They do not commit. They do not introduce. They do not oppose the round, but they do not help shape it. They say they are supportive but need to see terms. They want to wait for a lead. They will consider participating once the round comes together. They are available for calls but not actively driving momentum.

This kind of silence can become a signal.

From the founder’s perspective, insider silence may feel manageable. The relationship is not broken. The investor has not said no. They still take calls. They still respond. They still say positive things. But new investors are watching for active support, not just polite availability.

A passive insider can create uncertainty because the outside investor does not know how to interpret the lack of movement. Is the investor constrained? Distracted? Unconvinced? Waiting for price discovery? Trying to avoid signalling? Managing internal politics? Hoping someone else takes the risk?

When insiders are quiet, the founder may need to clarify their position before going to market. Otherwise, the round can become stuck in ambiguity. New investors ask what insiders are doing. The founder gives vague answers. The investor becomes cautious. The insiders wait for the new investor. The new investor waits for the insiders.

That circularity can kill momentum.

A fundraising process needs clarity. Insider ambiguity makes the process harder because nobody knows who truly believes.

Existing investors can help or hurt the round

Existing investors shape the next round in more ways than founders realise.

A strong insider can help create confidence. They can tell new investors why they backed the company, what has changed since the last round, how the founder has performed, why the next milestone matters, and why they remain supportive. This kind of insider reference can be powerful because it comes from someone with real exposure to the company.

A weak insider can create friction. They may be slow to respond to new investor diligence. They may be unclear about whether they are participating. They may give cautious or inconsistent feedback. They may not understand the company well enough to help. They may focus too much on their own rights or preferences. They may create governance noise. They may be present on the cap table but absent from the process.

In health, this matters because financing rounds often require trust across long timelines and uncertain milestones. New investors want to know whether the company has people around it who understand the path. If the existing syndicate looks weak, misaligned, or disengaged, the new investor may feel they are being asked to carry too much alone.

This does not mean every existing investor needs to be deeply involved. Some early investors were never expected to play that role. But the founder should understand who can support the round and who cannot.

The best founders do not wait until new investors ask. They organise the insider story before the process begins.

Subscribe now

The explanation matters

Insider non-participation is not always fatal.

The explanation matters.

If existing investors are not participating because they lack reserves, that is very different from not participating because they lost conviction. If an angel cannot follow because the next cheque is too large, that is different from a fund choosing not to follow despite available capital. If a prior lead has reached the end of its fund, that is different from a prior lead stepping back because the company missed its milestones. If a strategic investor cannot invest because of internal policy, that is different from a strategic no longer seeing value.

New investors do not need the story to be perfect. They need it to make sense.

Founders should be able to explain insider behaviour with clarity and without defensiveness. They should know who is participating, who is not, why not, who can speak to new investors, who can provide written support, and who can help with introductions. They should know whether insiders are aligned on the round size, milestone, valuation range, and financing strategy.

If the founder cannot explain the insider position, new investors may assume the founder does not have control of the round.

That is a problem.

A clean explanation reduces uncertainty. It tells the new investor that the founder understands the financing dynamics and is not hiding from difficult questions. It also prevents the investor from filling in the gaps with worse assumptions.

Inside support is not only capital

Capital is the clearest insider signal, but it is not the only one.

An existing investor may support the round by introducing credible new investors, joining diligence calls, explaining the company’s progress, helping refine the financing strategy, participating in bridge discussions, recruiting advisors, or validating the founder’s execution. In some cases, this support can matter even when the investor cannot write a large follow-on cheque.

But the support has to be real.

New investors can tell the difference between an insider who is actively helping and an insider whose name is being used passively. A warm introduction from an engaged existing investor is different from a cold name on a cap table. A thoughtful reference from a board member is different from generic support. A clear explanation of fund constraints is different from silence.

If insiders cannot invest, they can still help manage the signal. They can say, “We are not participating because of fund capacity, but we remain supportive and are happy to speak with new investors.” That is far better than leaving the founder to explain the absence alone.

Founders should not assume existing investors know what is needed. They may need to ask directly. Can you participate? Can you make introductions? Can you speak to new investors? Can you explain your fund constraint? Can you help with the round narrative? Can you support the bridge if needed?

The answer may not always be yes.

But the founder needs to know before the market does.

Leave a comment

New investors watch alignment

Inside investor behaviour also reveals alignment.

Do existing investors agree with the next milestone? Do they believe the company is raising the right amount? Are they comfortable with the valuation range? Do they understand why the round is needed now? Are they aligned on the type of lead the company should bring in? Are they supportive of the founder’s strategy?

If insiders are misaligned, new investors may hesitate. They do not want to enter a company where the existing table is divided, unclear, or quietly sceptical. That creates risk beyond the current financing. It can affect governance, future financing, strategic decisions, and founder support.

This is especially important when the company has missed milestones or changed direction. A pivot, delay, bridge, or revised plan can still be fundable, but only if the insider story is coherent. If existing investors are split on whether the new plan makes sense, outside investors may struggle to build conviction.

Alignment does not mean everyone agrees on every detail. That would be unrealistic. But the founder needs enough alignment around the financing path that the round does not feel internally unstable.

A new investor wants to join a company that is moving toward the next stage, not one still fighting over what the last stage meant.

Managing the inside round signal before you go to market

The deeper question for founders is how to manage the inside round signal before it becomes a problem.

The first step is to have honest conversations with existing investors early. Do not wait until the round is in market to ask whether they will participate. Founders should know who can invest, how much they might invest, whether they intend to follow pro rata, whether they need a new lead first, and whether their decision is constrained by fund mechanics or conviction.

The second step is to separate capital support from relationship support. Some investors can write another cheque. Some cannot. Some can make introductions. Some can provide strong references. Some can help with strategy. Some are supportive but not useful for the raise. The founder should know which role each insider can realistically play.

The third step is to prepare a clear explanation for any non-participation. If an insider is not investing, the founder should know why and how to explain it. “They are supportive” is not enough. A better explanation might be that the investor is at the end of its fund, does not have follow-on reserves, has a mandate limitation, has portfolio concentration constraints, or was always a small angel without follow-on capacity. The explanation should be accurate, specific, and calm.

The fourth step is to ask supportive insiders to be visible. If they are investing, make that clear. If they are introducing, coordinate those introductions. If they are willing to speak with new investors, confirm that in advance. If they cannot invest but remain supportive, ask whether they are comfortable explaining that directly when appropriate. Visibility reduces ambiguity.

The fifth step is to avoid putting new investors in the position of discovering insider weakness late. If there is a difficult insider story, manage it directly. New investors may still invest, but they will be far more comfortable if the founder addresses the issue before it appears through diligence.

The sixth step is to understand whether the prior round created the right support system. If the cap table is full of passive investors, the founder may need to compensate by building a stronger new syndicate. If the previous lead cannot follow, the founder may need to explain why the new lead is the right investor for the next stage. If insiders are fragmented, the founder may need to create alignment before launching the raise.

The seventh step is to avoid overclaiming insider support. This is where founders damage trust. Do not imply existing investors are participating if they have not committed. Do not present a prior lead as actively supportive if they are simply not objecting. Do not describe pro rata participation as likely if it is still uncertain. New investors will check, and if the founder’s description does not match insider reality, the fundraising process becomes harder.

Managing the inside round signal is not about pretending everything is perfect. It is about reducing uncertainty. New investors know early companies are messy. They know cap tables are imperfect. They know fund mechanics can prevent good investors from following. They know angels may not have more capital. They know prior leads may not be the right lead for the next stage.

What they need is a story that makes sense.

If insiders are participating, show it. If insiders are not participating for structural reasons, explain it. If insiders are supportive in non-capital ways, make that support visible. If there has been a loss of conviction, understand it and decide how to address it honestly.

The strongest founders do not let insider behaviour become an unexplained signal. They clarify it before the market interprets it for them.

Because new investors are not only underwriting the company.

They are underwriting the confidence of the people already closest to it.

Final thought

New investors watch what your current investors do.

That may feel unfair, especially when there are good reasons insiders cannot participate. But fundraising is built on signals, and insider behaviour is one of the strongest signals in a round.

If existing investors are investing, helping, introducing, and speaking with conviction, that can strengthen the company’s financing story. If they are quiet, passive, vague, or absent, new investors will notice. They may still invest, but they will ask harder questions.

Founders need to understand this before they go to market.

The inside round signal is not only about capital. It is about confidence, alignment, support, and whether the people closest to the company still believe enough to help the next round happen.

The best founders manage that signal with precision. They know who is participating, who is not, why not, and how the current table supports the next financing. They do not hide behind vague language. They do not overstate insider support. They do not wait for new investors to discover the answer themselves.

Because in the next round, your existing investors are part of the pitch.

Whether you planned it or not.

Share

P.S. Want to Stay Informed? Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Subscribe now and operate like a pro.

Don’t forget to check out HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Until next time, keep venturing forward!

Subscribe now

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Most founders think the main negotiation in a financing round is valuation.

That is understandable. Valuation is visible. It affects dilution. It becomes a signal in the market. It appears in the term sheet. It shapes how founders feel about the company’s progress, ambition, and bargaining power. A higher valuation can feel like validation. A lower valuation can feel like weakness.

But investors are not only thinking about valuation.

They are also thinking about ownership.

This is one of the most misunderstood parts of fundraising. Founders often ask, “What valuation can we raise at?” Investors often ask a different question: “Can we build enough ownership for this investment to matter?”

Those are not the same question.

A fund may like the company, believe in the founder, understand the market, and still struggle to lead if the round structure does not allow it to reach a meaningful ownership position. The round may be too small. The valuation may be too high. The dilution may be too low. The company may need so much future capital that the investor worries about being diluted later. The cap table may already be crowded. The lead allocation may not be large enough for the fund’s model.

From the founder’s perspective, this can feel strange. If an investor likes the company, why does ownership matter so much? Why would a fund pass because they cannot own enough? Why does a cheque size need to match a percentage? Why does a valuation that feels attractive to the founder create hesitation for the investor?

The answer is portfolio construction.

Venture funds are not only picking good companies. They are building portfolios. They need each investment to have the potential to return enough capital to matter for the fund. If a fund owns too little of a company, even a strong outcome may not move the fund’s overall returns. That changes how investors think about round size, valuation, dilution, reserves, follow-on capacity, and whether they can lead.

That is the ownership problem.

Founders often think valuation is the main number. Investors are also calculating whether the round allows them to own enough of the upside.

Subscribe now

Investors need the investment to matter

A venture fund is judged by returns to its LPs. That means each investment has to be considered in relation to the size of the fund, the cheque written, the ownership acquired, the likely dilution over time, and the possible exit outcome.

A small angel can write a small cheque and be happy with a small ownership stake because their personal return threshold may be different. A micro fund may be able to make smaller ownership work because the fund size is smaller. A large institutional fund may need a much larger ownership position because the outcome has to matter at the fund level.

This is why different investors behave differently in the same round.

A €250,000 cheque may be meaningful for one investor and irrelevant for another. A 2 percent ownership position may be attractive for one fund and impossible for another. A €3 million round may be large enough for one investor to lead, but too small for a larger fund to build the ownership they need. A valuation that seems reasonable to the founder may leave the lead investor with too little of the company for the risk they are taking.

Founders often interpret this as a lack of conviction. Sometimes it is. But sometimes it is simply fund math.

The investor may believe the company could become valuable, but if they cannot own enough at entry, and if future dilution will reduce that position further, the investment may not fit their model. The company can be good and still not work for that fund.

This is especially important when founders speak to funds of different sizes. A small specialist fund, a large multi-stage fund, a family office, a corporate venture arm, an angel syndicate, and a seed fund may all look like “investors,” but they do not all need the same ownership. They do not all think about the same cheque size. They do not all have the same return requirements.

Fundraising gets easier when founders understand which ownership logic applies to the investor in front of them.

Valuation affects ownership

Valuation is not separate from ownership. It directly affects how much of the company an investor can buy with a given cheque.

If a fund wants to invest €2 million and the pre-money valuation is €8 million, that investment buys a meaningful position. If the same fund wants to invest €2 million and the pre-money valuation is €30 million, the ownership is much smaller. The company may still be attractive, but the investor’s economics have changed.

This is why a high valuation can create friction even when investors like the company.

Founders often see a higher valuation as less dilution and therefore a better deal. Investors may see the same valuation as reducing their ability to build ownership, increasing the future step-up required, and making the risk reward less compelling. The issue is not only whether the company is “worth” the price today. It is whether the ownership available at that price can produce the return the investor needs.

This does not mean founders should always accept lower valuations. Valuation matters. Founder dilution matters. Team ownership matters. Future option pools matter. A round that is priced too low can be painful and may create its own problems.

But valuation has to work for both sides of the table.

If the price is too high for a lead investor to reach its ownership target, the round may become harder to lead. If the lead cannot own enough, they may prefer to follow, wait for the next round, or pass entirely. The founder may still find capital, but the structure may not attract the investor they actually need.

This is one reason rounds can stall even when the company has interest.

The valuation may be founder-friendly, but not leadable.

Round size and ownership are connected

Founders often decide how much to raise based on runway.

They calculate the budget, team needs, product plan, clinical work, regulatory preparation, commercial activity, and operating costs. Then they decide the round size. That is a reasonable starting point, but it is not the whole financing design.

The round size also determines how much ownership is available to investors.

If the round is too small, a lead investor may not be able to invest enough to reach its target ownership. If the founder wants to raise €1 million, but the right lead fund usually writes €2 million to €4 million initial cheques, the fund may not fit the round. If the founder tries to keep dilution extremely low, they may reduce the space available for the investor who would otherwise lead.

This creates a difficult tradeoff.

Founders want enough capital to reach the next milestone, but they also want to manage dilution. Investors want enough ownership to justify the work, risk, and future support. A strong round structure has to balance both.

This is why a founder should not think about round size only as cash need. They should also think about what kind of investor the round is designed to attract. If the company needs a lead investor, the round must be large enough and structured enough for that lead to own a meaningful position. If the company only needs a small extension, the investor universe may be different. If the company needs specialist institutional capital, the ownership available has to match that capital.

The question is not only, “How much do we need?”

It is, “What round structure allows the right investor to say yes?”

Too little dilution can make the round harder

Founders often try to minimise dilution as much as possible. That instinct makes sense. Ownership is important. Founders should not give away unnecessary equity. A company that over-dilutes early can create long-term problems for the founder, team, and future investors.

But too little dilution can also create problems.

If a founder wants to raise a meaningful amount of capital while giving up very little ownership, the implied valuation may become too high for the stage. That can make the round harder to lead. It can also make the next round harder because the company must grow into the valuation before future investors can justify a step-up.

In venture, dilution is not only a cost. It is also how investors buy enough upside to make the risk worthwhile.

If the investor is taking early risk, doing deep diligence, helping build the syndicate, supporting the next round, and putting their reputation behind the company, they usually need enough ownership to justify that role. A founder who wants a lead investor but offers only follower-level ownership may create a mismatch.

This does not mean founders should accept excessive dilution. The goal is not to give investors as much as they want. The goal is to understand the ownership range that makes the round attractive, fair, and financeable.

A good round leaves founders motivated, employees properly incentivised, and investors meaningfully aligned.

That balance matters more than maximising valuation at all costs.

Subscribe now

Ownership targets shape investor behaviour

Many funds have ownership targets. They may want to own 5 percent, 10 percent, 15 percent, or more at entry, depending on stage, fund size, strategy, and whether they lead. Some funds are comfortable with smaller positions if they have a clear path to increase ownership later. Others need to build meaningful ownership immediately.

Founders rarely ask about this early enough.

They may spend weeks with an investor before discovering that the fund needs a larger allocation than the round can support. Or they may push for a valuation that makes the investor’s ownership target impossible. Or they may fill the round with smaller cheques before realising there is no room left for a lead.

This is why ownership should be part of fundraising qualification.

A founder should understand whether an investor leads or follows, what cheque size they typically write, what ownership they target, whether they require a board seat, whether they reserve for follow-ons, and whether they need room to increase ownership over time. These questions are not just technical. They determine whether the investor can realistically fit the round.

If the founder avoids this conversation, they may mistake interest for alignment.

An investor can like the company, but if the ownership does not work, the round may not work for them. That does not mean the company is bad. It means the financing structure and investor model are mismatched.

Future dilution changes the calculation

Investors do not only think about the ownership they get today. They think about what that ownership may become after future rounds.

This is especially important in health because companies often need multiple financings before reaching major value inflection. A medtech company may need more capital for clinical studies, regulatory clearance, manufacturing, and commercial launch. A diagnostics company may need validation, reimbursement work, and market access. A therapeutics company may need several rounds before clinical proof. A digital health company may need capital to prove repeatable sales and retention.

If an investor buys 8 percent today, they may not own 8 percent later. Future rounds will dilute them unless they follow on. The investor has to decide whether they have the reserves, conviction, and fund capacity to maintain or increase ownership over time.

This affects whether they are willing to lead now.

If the company is highly capital-intensive and the investor cannot support future rounds, they may worry that their ownership will shrink too much before the outcome. If the current round is priced too high, they may worry they are starting with too little ownership at too much risk. If the next round is likely to require a large institutional lead, they may worry about being diluted heavily unless they can participate.

This is why ownership is connected to downstream financing.

The investor is not only buying a slice of the company today. They are buying a position in a financing journey. They need to believe that position can remain meaningful enough to justify the investment.

Founders who understand this can have more sophisticated conversations. They can explain not only the current dilution, but how future rounds may work, what milestones will justify them, and how existing investors can remain aligned.

Pro rata rights are not just legal detail

Pro rata rights are often treated as a technical term, but they matter because they allow investors to maintain ownership in future rounds.

For investors, pro rata can be valuable. If the company performs well, the investor wants the right to keep investing and protect their ownership. Without that right, they may be diluted by future investors even if they want to continue supporting the company.

For founders, pro rata rights can also create trade-offs. Granting too many rights too broadly can make future rounds more complicated. If many small investors have rights, the company may have less flexibility when a future lead wants allocation. If strategic investors have rights, future investors may ask how those rights affect the financing or exit path. If existing investors have strong rights but no real ability to follow on, the rights may create administrative complexity without meaningful support.

The issue is not whether pro rata is good or bad. The issue is whether the rights match the role of the investor.

A lead investor with meaningful ownership and follow-on capacity may reasonably expect pro rata rights. A small passive investor may not need the same rights. A strategic investor may require careful thought. Founders should understand that allocation rights shape future financing flexibility.

Ownership is not only about the percentage on the cap table today.

It is about who has the ability to protect, increase, or complicate ownership tomorrow.

Ownership affects whether someone can lead

Leading a round is expensive in time, reputation, and internal effort.

A lead investor has to do deeper diligence, negotiate terms, build conviction, organise the syndicate, and often take a board role or governance responsibility. They are not simply adding capital. They are taking ownership of the financing process.

Because of that, a lead usually needs ownership that matches the responsibility.

If the lead can only own a small position, they may not be able to justify the work. They may like the company, but prefer to follow. They may tell the founder they are interested, but ask who else is leading. They may wait for a larger round. They may decide the company is attractive but not a fit for their model.

This is frustrating for founders because it can feel like investors are asking for too much. Sometimes they are. But often, they are simply applying their fund economics.

A lead investor needs the possibility of a return that matters. If the company succeeds and the fund owns too little, the outcome may not justify the risk. If the fund cannot get enough ownership now and expects to be diluted later, the investment may not make sense.

This is why ownership can decide whether a round has a lead.

Founders who want a strong lead need to create a round where a strong lead can participate meaningfully. Otherwise, they may end up with many followers and no investor willing to take responsibility.

Share

Ownership is not control

Founders sometimes hear investors talk about ownership and assume they are talking about control.

That is not always the case.

Most venture investors do not want to run the company. They want enough ownership for the investment to matter economically. They want alignment. They want governance appropriate to the stage. They want information rights, participation rights, and the ability to support the company over time. That is different from wanting to control the business.

Of course, founders should be thoughtful about governance, rights, board composition, vetoes, and investor behaviour. Not every investor is the right partner. Ownership terms matter. Control terms matter. The founder should understand what they are agreeing to.

But it is important not to confuse ownership economics with control ambition.

A fund may ask for 10 percent or 15 percent ownership because that is how its model works, not because it wants to dominate the company. A lead may ask for a board seat because governance and support come with the role, not because it wants to micromanage. A fund may ask for pro rata because it wants to maintain exposure to a company it believes in, not because it wants to block future financing.

Good founders understand the difference. They negotiate carefully, but they also understand why ownership matters to investors.

That makes the conversation more productive.

Ownership also matters to future investors

Future investors will look at the ownership structure too.

They will ask whether founders still own enough to be motivated. They will ask whether the employee option pool is sufficient. They will ask whether early investors own too much or too little. They will ask whether the cap table is clean. They will ask whether there are small shareholders, rights, or strategic investors that could complicate a future round. They will ask whether existing investors have enough ownership and conviction to support the company.

A company can become harder to finance if the ownership structure is already strained.

If founders have been over-diluted too early, future investors may worry about motivation. If no investor owns enough to care, future investors may worry about lack of support. If too many small investors have rights, future investors may worry about complexity. If a strategic investor owns a meaningful stake with special rights, future investors may worry about conflicts.

This is why ownership design matters from the beginning.

Every round changes the future cap table. Every cap table becomes part of future diligence. The ownership decisions a founder makes today can either create flexibility later or remove it.

The strongest founders do not treat ownership as a one-round negotiation.

They treat it as financing architecture.

Leave a comment

How to think about ownership before you price the round

The deeper question founders should ask is not only, “What valuation can we get?” It is, “What ownership structure makes this round leadable, financeable, and healthy for the next stage?”

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Founders usually think about the round in front of them.

Can we close this financing? How much do we need? Who can lead? What valuation can we defend? How much runway will it give us? Which investors are interested? What do we need to say in the deck? How do we create urgency before the cash runs out?

That is understandable. When a company is raising, the current round feels like the whole game. The founder needs capital to keep building, reach the next milestone, hire the next person, fund the next study, enter the next market, or survive the next phase of uncertainty.

But investors are not only asking whether this round can close.

They are asking whether the next round can happen.

This is one of the most important differences between how founders experience fundraising and how investors underwrite it. A founder sees the current financing as the urgent problem. An investor sees the current financing as one step in a longer financing path. They are trying to understand not only whether the company is worth backing today, but whether the company will become more financeable after this capital is spent.

That is the downstream financing problem.

It appears when a company can raise some money now, but the next round looks difficult. The milestone is unclear. The capital required is too high. The current syndicate may not be able to support the company again. Future investor appetite may be limited. The valuation may not leave room for the next financing. The round may extend runway, but not change the company’s risk profile enough to attract the next set of investors.

From the founder’s perspective, the round may look like progress.

From the investor’s perspective, it may look like a bridge to another problem.

This matters because venture investors do not want to finance a company into a dead end. They want to believe the capital they provide will move the company to a stronger position. A stronger evidence package. A clearer commercial story. A more credible regulatory path. A better syndicate. A more attractive next round. A company that new investors will want to finance.

If this round does not make the next round easier, the current round becomes harder to lead.

Subscribe now

Investors underwrite the financing path

A financing round is not just a cash event. It is part of a sequence.

Investors know that most early health companies will need more than one round of capital. Digital health companies may need time to prove adoption, sales repeatability, and customer retention. Medtech companies may need clinical evidence, regulatory progress, manufacturing readiness, and market access. Diagnostics companies may need analytical validation, clinical validation, reimbursement logic, and commercial proof. Therapeutics companies may need preclinical data, IND-enabling work, clinical trials, and strategic interest.

The investor is not only asking, “Can this company use our capital well?”

They are also asking, “What will this company look like when it needs to raise again?”

That question changes the analysis. A company may be interesting today, but if the next financing requires a large amount of capital before enough risk has been reduced, the investor may hesitate. A company may have a good product, but if the current round does not create a milestone that future investors care about, the round becomes less attractive. A company may have a strong founder, but if the syndicate cannot support the next phase, the financing risk increases.

This is not pessimism. It is venture underwriting.

Investors know that every round has to create the conditions for the next decision. The current round should not only buy time. It should buy progress that matters. It should move the company from one level of uncertainty to a better one.

If the company cannot explain how this capital improves downstream financeability, investors may worry that they are funding motion rather than value creation.

Runway is not the same as financeability

Founders often say the round gives them eighteen months of runway.

That may be true, but runway alone is not enough.

Investors want to know what happens during those eighteen months. What will be proven? What risk will be reduced? What milestone will be reached? What will the company be able to say at the next financing that it cannot say today? Who will care about that proof point? Why will the next investor believe the company is worth more?

A round that gives runway but does not create a stronger financing position is fragile. It postpones the problem instead of solving it.

This is one of the most common mistakes founders make. They explain how the money will be spent, but not how the spend changes the company. They describe hiring, product development, pilots, clinical work, regulatory preparation, sales activity, market expansion, and operations. Those may all be necessary, but the investor is trying to understand the financing consequence.

Will these activities make the company more fundable?

That is the real question.

A founder might say, “We are raising €3 million to fund the next eighteen months.” A stronger version is, “We are raising €3 million to reach a milestone that should allow the company to raise a Series A from specialist investors because we will have completed the evidence package, converted two pilots into paid contracts, and shown that the first customer segment can adopt the product repeatably.”

The second version is not just a budget. It is a financing path.

Investors need that path because they are judging this round by what it makes possible next.

The next investor must be visible

One of the questions investors quietly ask is: who funds this company next?

This does not mean the founder needs signed interest from future investors. It means the founder should understand the likely next investor universe. Which funds would care if this milestone is reached? What stage do they invest at? What evidence do they require? What cheque size and ownership do they target? Would they see this as a venture-scale opportunity? Would they understand the risk profile? Would the current round make the company more attractive to them?

If the next investor is not visible, the current investor may become nervous.

This is especially important when a company sits between categories. A health company may be too clinical for generalist SaaS investors, but too commercial for life sciences investors. Too capital-intensive for seed funds, but too early for growth funds. Too strategic for financial investors, but not mature enough for corporates. Too platform-like for single-asset investors, but not yet broad enough for platform investors.

These category gaps create downstream financing risk.

The founder may believe the company is attractive to many investor types. But if none of those investors clearly own the next stage, the current round becomes harder. Investors do not want to discover later that the company has no natural buyer for the next financing.

The strongest founders understand the next investor before they need them. They know which funds are likely to care, what those funds need to see, and how the current round is designed to create that evidence.

That does not guarantee the next round.

But it makes the current round more credible.

Milestones must change the financing case

A milestone is not just something the company achieves.

A real financing milestone changes how the company can be underwritten.

This distinction matters. Many founders list milestones that sound productive but do not necessarily change investor conviction. Launching a new website, hiring a commercial lead, attending conferences, adding features, signing exploratory partnerships, or running early pilots may all be useful, but they may not be enough to change the next financing decision.

Investors want milestones that reduce a specific risk.

If the main risk is clinical, the milestone should make the evidence stronger. If the main risk is commercial, the milestone should show that buyers will pay. If the main risk is regulatory, the milestone should clarify the pathway. If the main risk is adoption, the milestone should show that implementation works. If the main risk is platform credibility, the milestone should prove that the platform can produce repeatable outputs. If the main risk is financing, the milestone should make future investors more likely to lead.

This is where founders often become too vague. They say, “This round gets us to traction,” or “This round gets us to the next stage,” or “This round gives us enough runway to scale.” Investors need more precision.

What exactly changes?

The next round becomes easier when the company can say something stronger and more specific than before. We did not just build more product. We proved the first buyer will pay. We did not just run a pilot. We converted the pilot into a contract. We did not just generate data. We generated the data future investors told us they needed. We did not just expand the pipeline. We showed a repeatable pattern in one customer segment.

A milestone that does not change the financing case may still be progress.

But it may not be enough progress for venture capital.

Subscribe now

Capital intensity creates downstream risk

Health companies often require more capital than founders expect.

That does not automatically make them bad investments. Many valuable health companies are capital-intensive. Clinical development, regulatory work, evidence generation, manufacturing, reimbursement, market access, and enterprise sales all require capital. Investors understand this.

The issue is whether the capital intensity matches the value inflection.

If a company needs a lot of money before it can reach a meaningful proof point, the current round becomes harder. If the next round will need to be much larger but the milestone is not strong enough to attract larger funds, the financing path becomes fragile. If the company requires repeated bridge rounds just to survive, investors may worry that capital will be used to keep the company alive rather than move it to a new level of value.

This is why investors look ahead.

They want to know how much capital the company will need over time, not only how much it needs now. They want to understand whether each round gets the company to a stronger position or simply creates another financing need. They want to know whether the company can attract the type of capital required for its ambition.

A founder may think the current round is small and therefore easier. But if the company will need a very large follow-on before major proof, the small round may not solve enough. In some cases, raising too little can be as dangerous as raising too much because the company reaches the next fundraising conversation without enough progress.

The right round size is not only about dilution.

It is about reaching a fundable next point.

Valuation affects the next round

Founders often think valuation is mainly about the current negotiation.

Investors think about valuation downstream.

If the valuation is too high today, the company may struggle to raise the next round at a meaningful step-up. That creates risk for everyone. Future investors may hesitate because the company has not grown into the prior price. Existing investors may resist a flat or down round. The founder may lose flexibility. The company may spend time defending valuation instead of building conviction around progress.

This does not mean founders should accept unfairly low valuations. Valuation matters. Dilution matters. Founder ownership matters. But valuation has to fit the financing path.

A good valuation is not only the highest price a founder can get. It is a price that allows the company to raise the next round if it executes well.

This is especially important in health because value creation may not happen in neat software-style increments. A company may need to reach a clinical, regulatory, commercial, or strategic milestone before a real step-up is justified. If the current valuation already prices in future proof that has not yet been created, the next round becomes harder.

Investors know this. They may like the company but worry that the price creates downstream financing risk. They may pass not because they dislike the opportunity, but because they cannot see how the next round clears.

Founders should understand that valuation is not just a scoreboard.

It is part of the financing architecture.

Syndicate support matters downstream

The next round is not only shaped by the company’s progress. It is shaped by the behaviour of the current syndicate.

Investors want to know who will support the company if the next round takes longer. Who has reserves? Who can follow on? Who has credibility with future investors? Who can help bridge if needed? Who understands the sector? Who will remain engaged if progress is slower than expected?

A weak syndicate increases downstream financing risk. Passive investors may not help when the company needs support. Small cheque investors may lack follow-on capacity. Strategics may have narrow incentives. Existing investors who do not participate in the next round may create signalling concerns. A cap table without a credible lead may make future investors wonder who truly owns the financing risk.

This does not mean every company needs a perfect syndicate. Very few early companies have one. But the founder needs to understand how the current syndicate affects the next financing.

If the existing investors cannot support the company again, the next round has to rely entirely on new money. That may be possible, but it raises the bar. New investors will ask why insiders are not participating. They will want to know whether that is because of fund capacity, strategy, timing, ownership, or loss of conviction.

A strong syndicate does not guarantee the next round.

But a weak syndicate can make the next round harder before the founder even enters the market.

Share

Bridges can become warning signs

Bridge rounds are common. They are not automatically bad. Many companies use bridge capital to reach a milestone, extend runway, close a strategic discussion, complete a study, or prepare for a stronger round. In difficult markets, bridges can be rational and necessary.

But investors distinguish between a bridge to value and a bridge to delay.

A bridge to value has a clear purpose. It gets the company to a defined milestone that changes the financing case. A bridge to delay simply buys more time without making the company meaningfully more fundable. The first can be attractive. The second creates concern.

Downstream financing risk increases when a company appears to be moving from bridge to bridge without changing its risk profile. Investors may worry that the company is becoming dependent on insider support, temporary extensions, and survival capital rather than reaching milestones that attract new money.

Founders need to be honest about this. If the company is raising a bridge, the question is not only how much runway it creates. The question is what decision the bridge unlocks. Does it get the company to data? A contract? A regulatory milestone? A strategic term sheet? A lead investor process? A financing event with stronger evidence?

If the answer is unclear, investors may see the bridge as a sign that the company is not yet on a fundable path.

A bridge should lead somewhere.

Future investor appetite is not automatic

Founders sometimes assume that if they make progress, future investors will appear.

Progress helps, but it is not enough. The company needs to make the kind of progress that future investors care about. That depends on the investor universe, market conditions, sector appetite, stage expectations, capital intensity, and the type of risk being reduced.

A seed investor may care about different evidence than a Series A investor. A generalist fund may care about different metrics than a specialist healthcare fund. A pharma strategic may care about different proof than a financial VC. A growth investor may care about revenue quality, retention, margins, and repeatability. A life sciences investor may care about data quality, translational logic, IP, regulatory pathway, and clinical relevance.

If the founder does not know what the next investor needs, they may spend the current round proving the wrong things.

This is one of the biggest downstream financing mistakes. The company works hard. The team executes. The founder reaches the milestone they promised. But when they enter the next round, investors say the proof is not the right proof.

That is painful because the mistake happened earlier.

Founders need to reverse-engineer the next round. What will the next investor need to believe? What proof will matter? What objections will they have? What will they compare the company against? What will make them lead?

This does not mean building the company only for investors. It means understanding that financing is part of the company’s path. If the company will need more capital, the current round must be designed with the next financing decision in mind.

Leave a comment

The current round can make the next round harder

Some rounds solve today’s cash problem but create tomorrow’s financing problem.

A round can be too small to reach a meaningful milestone. It can be too expensive to allow a future step-up. It can bring in investors who cannot support the company later. It can create rights or preferences that complicate future financing. It can extend runway without resolving the main risk. It can produce enough progress for updates, but not enough progress for a new lead.

This is why investors judge the current round so carefully.

They are not only deciding whether the company deserves money. They are deciding whether this financing structure helps or hurts the company’s future.

A founder under pressure may accept capital on terms that seem manageable because the immediate need is urgent. Sometimes that is necessary. Survival matters. But founders should understand the tradeoff. Not every round makes the company stronger. Some rounds keep the company alive while making the next round more difficult.

The best financing rounds do more than extend runway. They improve the company’s position. They create a credible milestone. They strengthen the syndicate. They preserve future flexibility. They make the next investor easier to identify. They allow a future price that makes sense if the company executes.

That is what investors want to see.

P.S. Want to Stay Informed? Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Subscribe now and operate like a pro.

Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Making this round financeable downstream

The deeper question founders should ask is not, “Can we close this round?” It is, “Will this round make the company more financeable next time?”

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Founders often assume an investor’s decision is only about the company.

If the investor passes, the founder thinks the market was not compelling enough, the traction was not strong enough, the team was not ready, the deck was not clear, the valuation was too high, or the risk was too difficult to underwrite.

Sometimes that is true.

But sometimes the company met the right investor at the wrong moment in the investor’s own fund cycle.

This is one of the least understood parts of fundraising. Founders spend most of their time thinking about their own timing. How much runway is left? When does the round need to close? What milestone comes next? How quickly can the investor move? What does the company need to prove before the next financing?

All of that matters. But investors also have timing constraints.

A venture fund is not a permanent pool of flexible capital that behaves the same way every year. A fund has its own lifecycle. It raises capital from LPs, begins deploying, builds a portfolio, manages reserves, supports existing companies, prepares for future funds, and eventually slows down new investment activity. Where a fund sits in that cycle has a direct impact on how it behaves.

A fund early in deployment may be actively looking for new investments. It may have fresh capital, open portfolio construction, and a mandate to build exposure. A fund later in its investment period may be more selective. It may have limited room for new companies, more capital reserved for follow-ons, and less appetite to take new risk. A fund near the end of its cycle may like a company but be unable or unwilling to lead because the timing does not fit.

From the founder’s perspective, this can feel confusing. The investor likes the company, understands the sector, has invested in similar businesses, asks thoughtful questions, and seems like a perfect fit. Then they pass, delay, or stay vague.

The founder assumes the company was rejected.

But the answer may be simpler.

The fund may not have enough new investment capacity. The partner may not have enough remaining allocation. The fund may be focused on supporting existing portfolio companies. The investment period may be ending. The fund may be waiting for a new vehicle. The team may be fundraising from LPs and unable to move with conviction. The fund may still have capital, but not the right kind of capital for a new lead investment.

That is the fund cycle problem.

A good company can meet the right fund at the wrong time.

Subscribe now

Funds do not behave the same throughout their lifecycle

A fund’s behaviour changes as the fund matures.

At the beginning of a fund, investors usually need to deploy. They are building the portfolio, looking for the right companies, shaping the fund’s exposure, and deciding which themes they want to own. They may be more open to new conversations because the fund has room. They may have more flexibility to lead, set terms, and take ownership of a new investment.

This does not mean they will invest easily. Good funds are still selective. But the fund has a reason to look for new opportunities because its job at that stage is to build the portfolio.

In the middle of the fund, behaviour becomes more selective. The fund may already have several companies in the portfolio. The partners are thinking about diversification, concentration, ownership, reserves, and which gaps remain. They may still be making new investments, but they are more aware of what each new company does to the overall portfolio.

By the later stage of the fund, the situation changes again. The fund may have already made most of its planned new investments. The remaining capital may be reserved for follow-ons. The partners may need to support existing winners rather than add new risk. Even if they like a company, they may not be able to give it the same attention, cheque size, or follow-on support they could have given two years earlier.

This is why two meetings with the same fund can produce very different outcomes depending on timing.

The same company might have been highly relevant when the fund was early in deployment, but much harder to fit when the fund is mostly allocated.

Founders often do not see this because the fund’s website does not usually say, “We only have room for two more new investments,” or “Most of our remaining capital is reserved for existing portfolio companies,” or “We like this sector, but we are nearly done deploying this vehicle.”

So the founder reads the pass as a company problem.

Sometimes it is really a fund timing problem.

Dry powder does not mean available capital

Founders often hear that there is a lot of dry powder in venture capital and assume that investors must be able to invest.

But dry powder is not the same as available capital for your round.

A fund may have undeployed capital, but much of that capital may be reserved for existing portfolio companies. It may be committed to follow-on rounds, bridges, insider extensions, or future support for companies the fund already owns. The fund may also have portfolio construction rules that limit how much can go into new companies at a certain point in the cycle.

This matters because founders sometimes misread investor capacity. A fund can appear active, well-capitalised, and relevant, but still have limited ability to lead new investments. The capital exists, but it may already have a job.

This is especially important in health and life sciences, where follow-on needs can be significant. A company may require several rounds before major value inflection. Investors know this. A fund that leads a health investment has to think not only about the first cheque, but about the future capital the company may need. If the fund does not have enough reserve capacity, leading may be difficult even if the opportunity is attractive.

Founders often ask, “Does this investor have money?”

The better question is, “Does this investor have the right money, at the right moment, for this type of investment?”

That distinction matters.

Capital that exists but is reserved for existing companies will not help a new founder close a round. A fund that is active but late in deployment may be more focused on protecting current ownership than adding new positions. A partner who likes the company may still struggle to secure internal support if the fund’s remaining capacity is limited.

This is why fund timing can quietly shape investor behaviour.

Early funds need new positions. Late funds protect existing ones.

A fund early in its lifecycle is usually trying to create new positions. The partners are building the portfolio and deciding which companies will represent the fund’s core themes. They are looking for ownership, category exposure, and long-term upside.

A fund later in its lifecycle is often trying to protect existing positions. The partners are thinking about which portfolio companies deserve more capital, which companies need support, which winners require reserves, and which exposures are already large enough.

This changes how they evaluate new opportunities.

An early fund may ask, “Could this become one of the important companies in our portfolio?”

A late fund may ask, “Do we have enough room, time, and reserve capacity to make this new investment worth it?”

Those are different questions.

The company may be the same, but the investor’s internal context is different. That context can decide whether the conversation moves forward.

Founders often underestimate this because investors rarely explain it directly. They may simply say the company is too early, too late, too broad, too capital-intensive, or not quite right for the current fund. Sometimes that feedback is accurate. Sometimes it is a polite way of saying the fund’s own timing does not support the investment.

This is not dishonesty. It is often easier for investors to give company-facing feedback than to explain fund construction dynamics. But founders need to understand what may be happening underneath.

If a fund is late in its cycle, a founder should not assume that positive engagement means real investment capacity. The investor may enjoy the conversation, want to track the company, and genuinely believe it could be interesting later. But they may not be in a position to lead now.

Share

Fundraising mode changes investor behaviour

Another fund timing issue appears when the investor is raising their next fund.

When a venture firm is fundraising from LPs, its behaviour can change. The team may still meet companies, but internal attention may be divided. Partners may be spending significant time with LPs, portfolio performance, fund narrative, references, and closing commitments for the next vehicle. The firm may be careful about making new investments while the next fund is not fully raised.

This can create confusing signals for founders.

The investor may take the meeting because the company fits the thesis. They may want to maintain market visibility. They may want to track opportunities for the next fund. They may ask detailed questions because they are genuinely interested. But if the firm is between funds or uncertain about the timing of its next close, it may not be able to move quickly.

Founders can mistake this for investor hesitation about the company. In reality, the investor may be managing its own financing process.

This matters because fundraising is a timing game on both sides. The founder is raising from investors. The investors may also be raising from LPs. If those two timelines do not align, the company can fall into a gap.

A fund may say, “This is very interesting, but we would like to stay close.” That can mean many things. It may mean the company needs more proof. It may mean the investor is not convinced. It may also mean the fund is not ready to deploy from the next vehicle yet.

The founder needs to qualify this carefully. Otherwise, they may spend months nurturing an investor who is not currently capable of making the decision they need.

Fund cycle affects risk appetite

Where a fund sits in its cycle can also affect its risk appetite.

Early in a fund, investors may be more willing to take bold new positions because they are building the portfolio. They may be looking for companies that can define the fund. They may have time to support a business through early uncertainty and follow it into later rounds.

Later in a fund, the same investor may become more cautious. They may already have enough exposure to a sector. They may have learned from portfolio challenges. They may need new investments to show faster progress. They may prefer companies that are closer to clear milestones because there is less time left in the fund’s lifecycle to support long uncertainty.

This is especially relevant in health. A company with a long development path may be attractive to a fund with fresh capital and patience. The same company may be much harder for a late-cycle fund to underwrite if the value inflection is too far away.

The investor may still believe in the market. They may still like the founder. They may still respect the science, product, or opportunity. But the timing of value creation may not fit the timing of the fund.

Founders should understand that investor risk appetite is not fixed. It is shaped by mandate, portfolio construction, performance, LP expectations, partner priorities, and fund timing.

A pass does not always mean the investor thinks the company is weak.

It may mean the company does not fit what that fund needs now.

Leave a comment

Portfolio construction can close doors quietly

Every fund has a portfolio construction model, even if founders rarely see it.

The fund may plan to make a certain number of investments. It may target a specific cheque size. It may require a minimum ownership level. It may reserve a certain percentage for follow-ons. It may limit exposure to certain sectors, geographies, stages, or risk types. It may want a balance between platform, therapeutics, diagnostics, digital health, medtech, infrastructure, or services.

Once the fund has already made several investments, each new opportunity is evaluated against what is left.

This means a company may be rejected not because it is bad, but because the portfolio already has similar exposure. The fund may already have a company in the same category. It may have reached its internal limit for a type of risk. It may not want another long-development asset. It may not want more exposure to a specific geography. It may not want to create conflict with an existing portfolio company.

Founders often experience this as vague investor feedback.

The investor says, “We like it, but it is not quite a fit.” The founder wants to know what is wrong. Sometimes nothing is wrong in the way the founder thinks. The fund simply cannot or does not want to add that exposure at that point in the fund.

This is why researching fund fit matters, but even good research has limits. A fund’s public thesis may remain the same while its internal portfolio needs change. The website may say they invest in your sector, but the current fund may no longer need another company like yours.

The fund’s stated thesis tells you what they like.

The fund cycle tells you what they can still do.

Fund timing shapes the speed of the process

Founders often judge investor seriousness by speed. That can be useful, but speed also depends on fund timing.

A fund early in deployment and actively looking for new investments may move quickly when it sees a company that fits. A fund with limited remaining capacity may take longer because every new investment needs more internal justification. A fund raising its next vehicle may slow down because attention is divided. A fund with many portfolio issues may delay new investments because existing companies require capital and time.

The founder may read this as lack of conviction, and sometimes that is correct. But sometimes the delay is structural.

That does not mean founders should tolerate endless ambiguity. They should not. A slow investor is still a problem if the company needs to close. But founders should understand why the delay may be happening so they can manage the process more intelligently.

If a fund is not in a position to move now, the founder should not build the round around them. They may be useful later. They may be worth keeping warm. They may be relevant for the next fund or the next round. But they should not be treated as near-term capital unless there is a clear path to decision.

Fundraising discipline means knowing the difference between an investor who is slow because they are working through diligence and an investor who is slow because they are not able to act.

The outcome for the founder may look similar.

The strategy should be different.

Good company, wrong timing

One of the most important lessons for founders is that not every no is a judgment on company quality.

A good company can meet a good fund at the wrong time. The fund may have invested in similar companies before. The partner may understand the market. The conversation may be strong. The feedback may be thoughtful. The fit may look obvious from the outside.

But the fund may be too late in deployment. It may have no room left for new leads. It may be saving capital for existing portfolio companies. It may be between funds. It may have already made its bet in the category. It may require a different risk profile for the remaining investments in the fund.

This is frustrating because the founder cannot fix it with a better deck.

That does not mean the founder should ignore feedback. Every investor conversation can create useful learning. But founders need to separate company feedback from fund timing. If they treat every pass as proof that the company is not good enough, they may overcorrect. They may change the story unnecessarily, lower confidence, or chase the wrong signals.

A founder might hear ten different versions of “not now.” Some of those may mean the company needs more proof. Some may mean the round is not structured correctly. Some may mean the investor is not convinced. Some may simply mean the fund cannot act now.

The skill is learning to tell the difference.

The wrong timing can still become the right relationship

A fund that cannot invest now may still become valuable later.

If the investor genuinely understands the company and the reason for passing is timing, not conviction, the relationship may be worth maintaining. The fund may invest from its next vehicle. The partner may introduce other investors. The investor may become relevant at the next round. They may provide useful feedback, market insight, or customer connections. They may become a reference point when the company reaches a stronger milestone.

But founders need to be careful. Keeping investors warm is useful only when the relationship has a clear purpose. It should not become a substitute for finding investors who can act now.

A founder should know which investors are current-round prospects, which are future-round prospects, which are useful advisors, and which are simply polite observers. Those categories matter because they determine where the founder should spend time.

The fund cycle problem does not mean founders should become cynical. It means they should become more precise.

If a fund says, “This is interesting, but the timing is difficult for us,” the founder can ask what that means. Are they still making new investments from the current fund? Are they leading new rounds? Are they reserving mostly for existing companies? Are they raising a new fund? When would they realistically be able to invest? What milestone would make the company relevant for them later?

These questions help the founder understand whether the relationship is worth nurturing or whether it is simply not actionable.

How to qualify fund timing before you waste months

The deeper question is how founders can avoid spending months with investors who like the company but are not in a position to invest.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Most founders think fundraising is mainly about getting money into the company.

That is understandable. When the runway is tightening, the team is waiting, the product needs to move, the trial needs funding, the commercial plan needs support, and the next milestone depends on capital, the obvious goal is to close the round. Money in the bank feels like the win.

But investors are not only looking at how much capital a company raises.

They are looking at who is around the table.

This is one of the most underappreciated parts of fundraising. Founders often think of the syndicate as a list of names, cheques, and logos. Investors see something more complex. They see signals. They see future support. They see governance risk. They see follow-on capacity. They see alignment or misalignment. They see whether the company has attracted serious believers or convenient capital. They see whether the cap table makes the next round easier or harder.

That is the syndicate quality problem.

A company can raise money and still build a weak syndicate. It can fill the round with passive investors who will not help, small cheques that create complexity, strategic investors with misaligned incentives, angels with no follow-on capacity, funds that cannot support future rounds, or investors who like the company but are not willing to take real ownership of it.

From the founder’s perspective, this may still look like progress. The round closed. The company has more runway. The deck can say the company is backed by investors. The founder can move on from fundraising and get back to building.

But from the next investor’s perspective, the syndicate becomes part of the diligence.

Who led the last round? Did existing investors participate? Who has reserves? Who can support the company if the market slows? Are the investors aligned on strategy? Are there names on the cap table that create signalling risk? Is there anyone credible enough to help anchor the next financing? Does the syndicate make the company easier to believe, or does it create more questions?

Founders often underestimate this because the consequences do not appear immediately. A weak syndicate may not hurt on the day the round closes. It may hurt twelve months later, when the company needs the next round and new investors start reading the cap table.

That is when founders discover that not all capital behaves the same way.

Subscribe now

A syndicate is not just a financing event

A financing round is not only about raising capital. It is also about designing the ownership structure that will sit around the company during the next phase of risk.

That ownership structure matters.

In a strong syndicate, the investors understand the company, believe in the milestone, know their role, support the founder, have enough credibility to help with future financing, and behave in a way that strengthens the company. They do not all need to be large funds. They do not all need to be famous names. But they should have a reason to be there beyond writing a cheque.

In a weak syndicate, the opposite happens. Investors come in without a clear role. Some are passive. Some are misaligned. Some do not understand the sector. Some have no ability to follow on. Some bring complexity without value. Some create signalling problems because they are present on the cap table but absent when it matters.

The founder may not feel this at first because the money still arrives. But the syndicate starts shaping the company’s future almost immediately. It affects governance. It affects introductions. It affects investor updates. It affects the next fundraising process. It affects how new investors interpret the company’s momentum.

This is why syndicate design is part of company building.

A founder should not ask only, “Can this investor write a cheque?” They should also ask, “What does this investor do to the company after the cheque clears?”

That question changes everything.

New investors judge old investors

When a company raises the next round, new investors look backward before they look forward.

They look at who funded the company before. They look at whether the previous lead is credible. They look at whether insiders are participating. They look at whether the syndicate has the ability to support the company. They look at whether the cap table is clean or complicated. They look at whether previous investors are enthusiastic or quiet.

This is not because investors are lazy. It is because prior investor behaviour contains information.

If strong investors backed the company and continue to support it, that can help. It suggests that people who already know the company still believe. If existing investors are silent, absent, or unwilling to participate, that creates questions. It does not automatically kill the round, but it forces the founder to explain why.

New investors know insiders have more information than outsiders. If the people closest to the company are not supporting the next round, the new investor wants to understand whether that is because of fund limitations, portfolio construction, timing, internal policy, or loss of conviction.

These are very different explanations.

A good founder can explain the situation clearly. A weak explanation creates doubt. “They are supportive but not investing” may be true, but it is not enough. Why are they not investing? Do they lack reserves? Are they at the end of their fund? Are they overexposed? Did they change strategy? Did they lose conviction? Were they never meaningful investors in the first place?

The answer matters because the next investor is trying to understand not only the company, but the behaviour of the capital already around it.

Passive capital can create future weakness

Not all passive investors are bad. Some angels, family offices, and small funds write helpful early cheques and do not need to be deeply involved. Passive capital can be valuable, especially when the company is early and needs flexibility.

The problem is when the syndicate is mostly passive.

A company with many passive investors may have money but little support. Nobody is helping shape the next round. Nobody is preparing the founder for diligence. Nobody is using their network meaningfully. Nobody is helping recruit. Nobody is providing market intelligence. Nobody is willing to bridge. Nobody is willing to defend the company when things become harder.

This becomes dangerous in health because the path is rarely smooth. Timelines shift. Evidence takes longer. Customers move slowly. Regulatory questions appear. Commercial proof is harder than expected. The next round may require more education, more credibility, and more strategic support than the founder anticipated.

Passive capital does not solve those problems.

A weak syndicate can leave the founder alone at exactly the moment the company needs experienced help. The founder may have investors, but not partners. They may have names on the cap table, but no one willing to make the next financing easier.

That matters to new investors because they are not only evaluating the company’s progress. They are evaluating the support system around the company.

A company with passive capital can still succeed, but the founder needs to understand the gap. If the current syndicate will not help with the next round, the founder has to build that support elsewhere.

Share

Strategic investors can help or complicate

Strategic investors can be powerful. In health, they can bring credibility, market access, technical insight, commercial channels, clinical relationships, regulatory understanding, and potential exit relevance. A respected strategic investor can make a company easier to understand and more attractive to other investors.

But strategic capital can also create complications.

New investors will ask why the strategic investor invested. Is the relationship commercial, financial, defensive, exploratory, or option-driven? Does the strategic have rights that could limit future partnerships or acquisitions? Does their presence make other potential partners nervous? Are they helping the company, or simply watching it? Are they aligned with the founder’s long-term financing strategy?

This is especially important when a strategic investor comes in too early or with rights that narrow the company’s future. A corporate cheque can look impressive in the announcement, but if it creates perceived exclusivity, information rights concerns, commercial dependency, or exit complications, it may make the next round harder.

The issue is not strategic capital itself. The issue is strategic fit.

Founders should ask what the strategic investor changes. Does it reduce real risk? Does it open distribution? Does it support evidence generation? Does it create commercial access? Does it improve credibility with future investors? Or does it only create a logo for the deck?

Investors can usually tell the difference.

Too many small cheques can create noise

Founders often fill rounds with many smaller cheques because it feels easier than finding larger conviction. This can work, but it can also create problems.

A crowded cap table with many small investors can make governance more complicated. It can make communication harder. It can create unclear expectations. It can make the next round more difficult if there is no obvious investor with enough ownership or conviction to support the company meaningfully.

This does not mean founders should avoid angels or small cheques entirely. Some small investors can be highly valuable. A specialist angel with deep sector expertise, a founder-operator who can open doors, a clinician with real market influence, or a family office with strategic patience can be worth far more than their cheque size.

The issue is whether the cheque has a purpose.

If the company brings in many small investors without a clear reason, the cap table can become crowded without becoming stronger. Investors may ask why those people are there. They may wonder whether the founder lacked access to larger, higher-conviction capital. They may worry that the round was assembled through convenience rather than strategy.

Again, the point is not that every investor needs to be famous or large. The point is that the syndicate should make sense.

A good syndicate has logic. A weak syndicate is just a collection of money.

The lead matters, but the rest of the table matters too

The lead investor usually carries the strongest signal. A credible lead can set terms, anchor conviction, organise the round, and give other investors confidence. But the rest of the syndicate still matters.

A strong lead surrounded by useful co-investors can create a powerful financing base. The company may have one investor with ownership and governance responsibility, plus others who bring customer access, technical expertise, geographic reach, strategic relationships, or future financing support.

A strong lead surrounded by weak or misaligned investors may still create friction. The lead may have to manage more complexity. Future investors may still question parts of the cap table. The founder may still be dealing with too many voices, too little support, or conflicting incentives.

A weak lead with many passive followers is even more difficult. The founder may have closed a round, but no one has truly taken ownership of the company’s financing path. When the next round comes, there may be no investor with enough conviction, reserves, or credibility to help.

This is why founders should think of the syndicate as a system. Each investor plays a role. Some provide leadership. Some provide expertise. Some provide access. Some provide follow-on capacity. Some provide strategic relevance. Some provide credibility. Some should probably not be there.

The best founders are intentional about this. They do not treat all money as equal because they understand that the syndicate becomes part of the company’s story.

Leave a comment

Syndicate quality affects the next round

The real cost of a weak syndicate often appears at the next financing.

A new investor may like the company, but pause when they see that existing investors are not participating. They may worry if the previous round was filled with investors who cannot follow on. They may question why there is no credible institutional investor already involved. They may become concerned if the cap table includes strategic rights that complicate future exits. They may hesitate if the company has too many small investors and no clear governance structure.

These questions do not always lead to a pass, but they add friction.

Fundraising is already difficult. Anything that adds uncertainty makes the process harder. A poor syndicate can force the founder to spend time explaining the cap table instead of building conviction around the company.

In some cases, the syndicate can create signalling risk. If a well-known investor is on the cap table but not participating, new investors may wonder why. If insiders are quiet, new investors may worry. If previous investors were never truly committed, the founder may have to prove that the current round is different.

This is why founders should think about the next round when constructing this one.

The question is not only, “Will this cheque help us close today?” The better question is, “Will this investor make the company easier or harder to finance tomorrow?”

Health makes syndicate quality more important

In health and life sciences, syndicate quality matters because the company may need more than money.

It may need sector expertise. It may need patient capital. It may need investors who understand long timelines, evidence generation, regulatory pathways, clinical development, reimbursement, market access, enterprise sales, pharma partnerships, or strategic exits. It may need investors who can help the company survive periods when progress is real but slow.

A generalist investor may be helpful, but if they do not understand the sector’s timelines, they may become impatient. A small investor may be supportive, but if they cannot follow on, they may not help when the company needs bridge capital. A strategic investor may be useful, but if their incentives are too narrow, they may complicate broader market access. A passive investor may be easy to work with, but they may not provide enough support when the company faces a difficult financing environment.

Health companies often require a syndicate that understands the path.

That does not mean every investor must be a health specialist. Some companies benefit from a mix of specialist and generalist capital. But the founder needs to understand what the company’s risk profile requires. A diagnostic company, a digital health company, a medtech company, a biotech platform, and a healthcare AI company may each need different syndicate strengths.

The right syndicate should make the company more resilient, not just better funded.

Designing a syndicate investors can trust

The deeper question is not whether a founder can raise money. It is whether the founder can build a syndicate that strengthens the company’s future financing position.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Most founders think diligence happens in the obvious places.

The pitch meeting. The follow-up call. The data room. The financial model. The customer references the founder provides. The investor update. The partner meeting. The formal diligence process after a fund becomes serious.

All of that matters, but it is not the whole picture.

Investors do not only diligence the company through the materials the founder controls. They also diligence the company through the market. They speak to customers, former colleagues, advisors, operators, co-investors, sector experts, clinicians, executives, academics, founders, recruiters, strategic partners, and people who have seen the company from different angles.

Sometimes the founder knows those calls are happening. Sometimes they do not.

This is the reference call risk. It happens when the market is telling a story about the company before the founder realises diligence has already started. That story may reinforce the investment case. It may create doubt. It may explain why customers care. It may reveal that the product is harder to implement than the founder suggested. It may validate the founder’s reputation. It may surface concerns about execution, leadership, commercial maturity, science, adoption, or team quality.

Founders often underestimate this because they think diligence is linear. First meeting, second meeting, data room, formal references, investment committee. In reality, investor diligence is often happening around the process, not only inside it.

A fund may speak to someone who knows the buyer. A partner may message an operator in the space. An associate may call another founder who has sold into the same customer segment. A venture partner may know someone who worked with the founder before. A co-investor may have heard the company discussed in another round. A strategic may have seen the product in a pilot. A customer may have told someone the company is impressive, but not yet ready.

The market talks.

The question is whether the story it tells supports the story the founder is telling.

Subscribe now

Diligence does not wait for permission

Founders often assume that serious diligence begins only when an investor formally asks for references. That is not how many investors work. By the time a founder receives a detailed diligence request, the investor may already have spoken to several people around the market.

This is not always a bad thing. A strong market reputation can help the company. If customers speak highly of the product, if operators respect the founder, if former colleagues describe the founder as exceptional, if sector experts confirm the pain is real, and if other investors say the company has been thoughtful, the founder benefits from a story they did not have to push.

But the reverse is also true. If the informal market narrative is messy, investors may slow down before the founder understands why. They may ask more cautious questions. They may become harder to read. They may say they need more time. They may pass with polite language because the concern came from a conversation the founder never saw.

This is uncomfortable because founders like to believe they control the fundraising process. They control the deck. They control the narrative. They control the data room. They control which customer references are provided. They control the update cadence. They control what gets shared and when.

Informal diligence breaks that illusion.

Investors are trying to reduce uncertainty. If they can learn more about the company from people around the market, they will. That does not mean they are acting unfairly. It means they are doing their job. Early-stage investing often involves incomplete information, and investors use networks to test whether the founder’s version of reality matches what others are seeing.

The founder cannot control every reference call. But they can understand that the company is always creating references, whether intentional or not.

Your reputation is part of the data room

A data room contains documents. The market contains memory.

Founders often spend weeks polishing materials while ignoring the fact that many important people already have an opinion about the company. Customers remember how the team handled implementation. Advisors remember whether the founder listened or only collected names. Former employees remember whether the company was clear or chaotic. Co-investors remember whether updates were consistent. Operators remember whether the product solved a real problem or only sounded good in a pitch.

That memory becomes part of diligence.

This is why reputation is not a soft issue. It is not separate from the financing process. It influences investor trust, customer confidence, hiring, partnerships, and the willingness of others to help the company. A founder with a strong reputation can often move faster because the market gives them credibility before the meeting starts. A founder with a weak or unclear reputation may have to work harder because every claim needs more proof.

In health, this matters even more because the market is smaller than founders think. Specialists know each other. Clinicians speak to other clinicians. Investors compare notes. Strategic teams watch companies for years. People move between hospitals, pharma, venture funds, startups, universities, and advisory roles. A conversation in one corner of the market can reach another corner quickly.

That does not mean founders need to be paranoid. It means they need to be consistent. The story told in the deck should not be completely different from the story customers experience. The founder’s description of traction should not be dramatically stronger than what references would say. The partnership slide should not imply commitment where there is only exploration. The market access story should not depend on names that would not confirm the relationship.

When the external story and the market story diverge, diligence becomes harder.

Informal references test exaggeration

One of the reasons investors make reference calls is to test whether the founder is exaggerating. This does not always mean lying. More often, the concern is inflation.

A founder may call a customer conversation “traction.” The customer may describe it as early exploration. A founder may describe a pilot as highly engaged. The hospital may say the pilot is interesting, but not a priority. A founder may describe a strategic partner as excited. The corporate team may say they are watching the space but not moving yet. A founder may describe an advisor as deeply involved. The advisor may say they have only had two calls.

None of these gaps have to destroy the round, but they create doubt.

Investors understand that founders are optimistic. They expect some ambition in the story. But they become concerned when the founder’s version of reality is consistently ahead of what the market confirms. That gap makes the investor wonder what else may be overstated.

This is why precision matters. Founders should describe relationships, evidence, customer demand, pilots, partnerships, and investor interest accurately. It is better to say, “We are in early discussions with two hospital innovation teams,” than to imply those hospitals are already committed customers. It is better to say, “We have a clinical advisor who has helped us refine the use case,” than to imply that advisor is actively opening commercial doors if they are not.

Precision builds trust because it survives reference calls.

The strongest founders do not need to inflate. They understand that investors will check. They know that a clean, honest description of progress is more valuable than an impressive claim that becomes weaker once the market is contacted.

Share

References reveal how the company behaves

Formal diligence often tests what the company has done. Informal references often reveal how the company behaves.

This matters because early-stage companies are not fully formed. Investors are not only evaluating assets, but patterns. They want to understand how the founder handles pressure, feedback, complexity, and relationships. They want to know whether the company learns quickly, communicates clearly, follows through, and earns trust over time.

A customer reference may reveal whether the company understands workflow reality. An advisor reference may reveal whether the founder can filter advice. A former colleague may reveal whether the founder is resilient, difficult, disciplined, chaotic, or unusually effective. A co-investor may reveal whether the founder communicates well when things are not going perfectly. An operator may reveal whether the product is credible or fragile. A sector expert may reveal whether the market need is urgent or only academically interesting.

These signals are powerful because they come from outside the founder’s controlled narrative.

Investors know every founder is selling during fundraising. That is expected. The purpose of references is to understand what remains true when the founder is not pitching. Does the company still sound compelling when described by someone else? Does the founder’s reputation support the level of trust required? Do customers describe real pain? Do people who know the space agree that the wedge makes sense? Do people around the company believe the founder can execute?

The market does not need to be universally positive. No company is liked by everyone. But the pattern matters. One cautious comment may not mean much. Repeated concerns across several calls are different.

Investors listen for patterns.

The references you do not choose may matter most

Founders usually prepare formal references carefully. They select the customer who loves the product, the advisor who is supportive, the investor who believes in the company, and the operator who understands the market. Those references can help, but investors know they are selected.

The more revealing references are often the ones the founder does not choose.

Investors may speak to a customer who did not convert. They may speak to someone who used to advise the company. They may speak to a former employee. They may speak to an investor who passed. They may speak to a buyer in the same category who has not heard of the company. They may speak to a competitor’s customer. They may speak to someone who understands the workflow, reimbursement, regulatory, or procurement challenge better than the founder expects.

These conversations can be valuable because they provide texture. They help investors understand whether the company’s challenge is normal, serious, hidden, or misunderstood. A lost customer may still validate the pain. A passed investor may still respect the founder. A cautious operator may still confirm the market is moving. A former advisor may still say the founder is excellent, but early.

The danger is not that every reference must be perfect. The danger is when the founder has not thought about what unselected references might say.

If the founder knows why a customer did not convert, they can explain it. If they know why an investor passed, they can interpret the signal. If they know why a pilot stalled, they can show what was learned. If they know where the market is sceptical, they can address it directly.

Founders lose control when they are surprised by the market’s own version of the company.

Leave a comment

The market can validate what the deck cannot

Reference calls are not only a risk. They can also be one of the strongest assets in a fundraising process.

A deck can explain that the problem is urgent. A customer can confirm that it is urgent. A data room can show early usage. A buyer can explain why the workflow matters. A founder can describe the market gap. A sector expert can confirm that the gap is real. A company can claim that implementation is manageable. An operator can explain why the team has made the right tradeoffs.

This is powerful because investors trust independent confirmation. They know the founder has an incentive to make the company sound attractive. When people around the market confirm the same story, the investor’s confidence increases.

The strongest fundraising processes often have this kind of external reinforcement. The investor hears the founder’s story, then hears similar language from customers, advisors, operators, or sector experts. The same themes repeat. The pain is real. The founder is credible. The product is relevant. The team listens. The use case is clear. The market is early but moving. The risk is understood. The next milestone makes sense.

That consistency creates conviction.

This is why founders should think of references as part of company building, not only fundraising. Every customer conversation, advisor interaction, pilot, investor update, and partnership discussion is shaping what the market might say later. A founder who communicates clearly and behaves consistently creates a stronger informal diligence trail.

The company’s reputation is built before the investor starts checking it.

Health makes reference calls more important

In health, informal diligence matters because the market is complex. Investors often need help understanding whether a claim is credible. A generalist investor may need to speak to clinicians, health system leaders, reimbursement experts, regulatory advisors, pharma operators, or specialist investors. Even specialist investors use references to pressure test the practical reality behind the story.

A product may look compelling in a deck, but a clinician can explain whether it fits the workflow. A market may look large, but a buyer can explain whether there is budget. A diagnostic may show promising performance, but an expert can explain whether the evidence package is sufficient. A digital health product may claim ROI, but an operator can explain whether implementation would slow adoption. A therapeutic platform may look exciting, but a specialist can explain whether the translational logic is strong enough.

This is not a weakness of health investing. It is the nature of the sector.

Health companies sit inside systems that are regulated, budget-constrained, evidence-driven, politically complex, and slow to change. No investor can understand every piece from the deck alone. Reference calls help investors understand the reality around the company.

This is also why founder credibility matters so much. Investors know that health founders must navigate stakeholders who do not all think the same way. Clinicians, buyers, regulators, payers, pharma teams, patients, investors, and strategic partners may each see a different risk. A founder who earns trust across those groups becomes more backable. A founder who creates confusion across those groups becomes harder to underwrite.

In health, the market does not only validate the product. It validates the founder’s ability to navigate the system.

Your narrative has to travel without you

One of the most important tests in fundraising is whether the company’s story can travel without the founder in the room. Reference calls are one way investors test this.

When an investor speaks to someone around the market, they are not only asking, “Is this company good?” They are also asking, “Does the company mean the same thing to others as it means to the founder?”

If the founder says the company solves an urgent workflow problem, do customers describe the same urgency? If the founder says the product reduces burden, do users describe that value clearly? If the founder says a partnership is strategic, does the partner see it that way? If the founder says the next milestone matters, do experts agree that it changes the risk profile?

When the story travels cleanly, the investor gains confidence. When the story changes too much depending on who is speaking, the investor may worry that the company is not yet clear enough.

This is why founders need to make the company easy for others to describe. Customers should be able to explain the value. Advisors should be able to explain where the company fits. Existing investors should be able to explain the next milestone. Team members should be able to explain the wedge. Strategic partners should be able to explain why the company matters to them.

The founder does not need everyone to use the same words. But the meaning should be consistent.

A company becomes more investable when the market can repeat its logic.

Share

How to prepare for informal diligence

The deeper question is not how to control every reference call. You cannot. The better question is how to build a company whose market story can survive diligence.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most frustrating moments in fundraising is when the founder has a lot of investor interest, but no lead investor.

The meetings are happening. The feedback is positive. Investors like the market. They like the team. They like the problem. They ask for updates. They say they want to stay close. They ask who else is in the round. They say they could follow. They say the company is interesting. They may even say they would like to participate once the round comes together.

From the outside, this can look like momentum.

From the inside, it can feel like the round is almost working.

But the round is not really working until someone is willing to lead.

This is the lead investor problem. It happens when many investors are interested in the company, but no one is willing to take ownership of the round. Everyone wants to watch. Everyone wants to be kept updated. Everyone wants to know who else is involved. Everyone wants comfort from the market. But nobody wants to set the terms, anchor the round, take the first real risk, and become the investor others can organise around.

Founders often misunderstand this stage. They think the problem is lack of exposure. So they take more meetings. They send more updates. They widen the process. They speak to more funds, angels, family offices, strategics, and advisors. They assume that if enough people are interested, the round will eventually come together.

Sometimes that is true. But often, more interest does not solve the problem.

Because interest is not leadership.

A lead investor does more than write a cheque. A lead investor gives the round structure. They set or negotiate the terms. They define the valuation conversation. They validate the opportunity for other investors. They help create urgency. They become a signal that someone has done the work, taken the risk, and decided the company is worth backing now.

Without a lead, the round can drift. Investors wait for each other. Nobody wants to be first. Nobody wants to price the risk. Nobody wants to take responsibility for the terms. The founder keeps hearing positive language, but the company does not move closer to a signed term sheet.

This is one of the reasons fundraising can feel so confusing. A founder can have a full pipeline and still not have a round.

Subscribe now

Interest is easy. Leadership is hard.

Investor interest is not meaningless. It can be useful. It tells the founder that the company is worth discussing. It can create market feedback. It can help refine the story. It may turn into future participation. It can also be helpful once a lead is in place.

But interest is a low-commitment position.

An investor can be interested without being ready to invest. They can like the company without believing the price. They can like the founder without understanding the market deeply enough. They can like the sector but not have conviction on this specific opportunity. They can believe the company may become fundable later, but not want to take the risk now.

A lead investor has to cross a much higher threshold. They need enough conviction to move from observation to ownership. They need to believe the company is worth spending real time on. They need to defend the investment internally. They need to underwrite the risk. They need to decide what terms make sense. They need to be comfortable being the investor others look to for confidence.

That is a very different decision.

This is why founders should be careful with investor language. “We are interested” does not mean “we will lead.” “Keep us updated” does not mean “we are close.” “We could participate” does not mean “we are willing to anchor.” “We like the company” does not mean “we will take pricing risk.”

Investors are often polite because they do not want to close doors too early. They may genuinely like the opportunity but still not be ready to lead. The founder’s job is to understand where the investor sits on the spectrum between curiosity and conviction.

The fundraising process becomes much clearer when the founder stops treating all positive investor feedback as equal.

Followers behave differently from leads

Not every investor wants to lead. Some funds are designed to lead rounds. Others are designed to follow. Some angels can move quickly but cannot price or structure the round. Some family offices may be flexible, but still want an institutional lead. Some strategics may be interested, but not suitable to lead a priced venture round. Some funds may only participate once another investor has set terms.

This is not necessarily bad. Followers can be valuable. They can fill out a round, bring expertise, add networks, support later financing, or strengthen the syndicate. But followers rarely solve the hardest part of the raise.

The hardest part is getting the first investor to take responsibility.

Followers often ask the same question: who is leading? That question is not just administrative. It tells you how they think about risk. They may not want to do full diligence independently. They may not want to negotiate terms. They may not want to be the first institutional signal. They may not want to take reputational risk if the round does not come together.

Once there is a credible lead, many followers become more comfortable. The round has a price. The diligence has an anchor. The founder has validation. The process has urgency. The decision becomes easier.

This is why a founder can spend months collecting soft commitments and still feel stuck. A round full of conditional followers is not the same as a round with a lead.

The founder needs to know which investors in the process are capable of leading, which are willing to lead, and which are only likely to follow. Those are different categories. A fund may have the capital to lead but not the conviction. Another investor may have the conviction but not the cheque size. Another may like the company but not have the mandate. Another may want to wait until the next round.

If the founder does not separate these categories, the pipeline becomes misleading.

The lead investor creates the market for the round

A financing round is not just a collection of individual investor decisions. It is also a market. Investors are watching each other. They are interpreting who is involved, who is moving, who is delaying, who has conviction, who passed, who is leading, and who is following.

The lead investor helps create that market.

When a credible lead commits, the round becomes easier for others to understand. There is a term sheet. There is a valuation. There is a structure. There is a diligence reference point. There is a signal that someone with capital and judgment has decided the opportunity is worth anchoring.

This does not remove the need for other investors to do their own work. Good investors still make independent decisions. But the existence of a lead changes the psychology of the round. It reduces uncertainty. It creates a point around which other investors can organise.

Without a lead, the founder has to create all of that alone. They have to convince each investor individually, while also trying to prove that other investors are moving. This can become circular. Investors wait for a lead because there is no lead. No lead appears because everyone is waiting.

Founders often try to solve this with pressure. They say the round is moving. They imply there is strong demand. They mention investor names carefully. They try to create urgency. That can work if there is real movement behind it. But if the process is mostly soft interest, investors can feel the difference.

The strongest urgency comes from real conviction, not manufactured momentum.

A lead investor gives the round gravity.

Why investors avoid leading

It is useful to understand why investors avoid leading, even when they like the company.

Leading takes work. The lead has to do deeper diligence, negotiate terms, manage internal conviction, think about ownership, evaluate future financing risk, and often help organise the syndicate. It is much easier to follow someone else’s work than to lead from the front.

Leading also creates reputational risk. If a fund leads a round, other investors assume they have done serious diligence. If the company later struggles, the lead’s judgment is visible. This does not mean investors are afraid of risk. Venture capital requires risk. But investors are selective about which risks they want to own.

There is also pricing risk. Setting the valuation is difficult, especially in early health companies where evidence, market access, regulation, clinical development, reimbursement, and commercial adoption may still be uncertain. A follower can accept terms once they exist. A lead has to decide what those terms should be.

For funds, leading also affects portfolio construction. A lead investor usually needs meaningful ownership. That may require a larger cheque than the founder expects. The fund has to think about reserves, future follow-on needs, concentration, and whether the company fits its mandate. Even if the partner likes the company, the round may not work for the fund.

This is why founders should not assume that a lack of lead interest means the company is bad. Sometimes the issue is fund fit. Sometimes it is timing. Sometimes it is ownership. Sometimes it is stage. Sometimes it is the future capital requirement. Sometimes the company is interesting, but not yet leadable.

The key question is not only whether investors like the company.

The question is whether the company is ready for someone to own the risk.

Lead investors need a stronger case than followers

A founder can often persuade a follower with a good story, a credible lead, and a reasonable allocation. The follower may do diligence, but the decision is partly supported by the structure already created by the lead.

A lead needs more.

A lead needs to understand the company deeply enough to take responsibility for the investment case. They need to know why now, why this team, why this market, why this wedge, why this round, why this valuation, and why this risk is worth taking. They need to know what the company will prove with the capital and why that proof point matters for the next financing or strategic outcome.

This is where many founders struggle. They are able to create interest, but not enough conviction for leadership.

The company may be exciting, but the round logic is unclear. The market may be large, but the first buyer is not clear enough. The science may be strong, but the commercial path is still too broad. The team may be impressive, but the next milestone does not change the financing case. The founder may have many conversations, but no sharp answer to why this round should be led now.

A lead investor does not want to feel like they are financing activity. They want to feel like they are financing a specific value creation step.

This is especially important in health because the path can be long and capital-intensive. The lead has to believe that this round is not just keeping the company alive. It is moving the company to a stronger position. That could mean stronger evidence, clearer adoption, regulatory progress, commercial proof, strategic partnership readiness, or a financing milestone that makes the next round more credible.

If the round does not create a meaningful change in the company’s risk profile, it becomes harder to lead.

The “we have interest” trap

Founders often say, “We have a lot of investor interest.” That may be true, but it is not enough.

The important question is what kind of interest.

Is the investor willing to lead? Are they doing real diligence? Have they discussed cheque size? Have they talked about ownership? Have they introduced terms? Have they taken it to partnership? Have they asked for references? Have they given a process timeline? Have they explained what they need to believe in order to move forward?

Or are they simply staying close?

The difference matters. A founder can easily mistake polite investor engagement for real round momentum. This creates the “we have interest” trap. The founder keeps spending time with investors who are not likely to lead, while the round loses energy. The process feels active, but the central problem remains unsolved.

This can become dangerous because fundraising windows are emotional and strategic. If the founder waits too long to realise there is no lead, they may run out of time, lose leverage, or be forced to accept weaker terms. They may also burn investor attention by sending repeated updates without creating a real decision point.

The founder needs to qualify interest early.

A simple question can change the process: “Is this a round you would consider leading, or would you be more likely to participate alongside a lead?”

That question may feel uncomfortable, but it saves time. It allows the founder to understand the investor’s role. It also shows maturity. Good founders do not just collect conversations. They manage the financing process.

Not every round needs the same kind of lead

The lead investor problem looks different depending on the round.

At pre-seed, the lead might be an angel, operator, micro fund, family office, or specialist seed investor willing to anchor the first institutional cheque. At seed, the lead may need to set terms, help build the syndicate, and provide enough credibility for other investors to follow. At Series A, the lead usually needs deeper conviction, stronger ownership, and the ability to support future rounds. In life sciences and health, the lead may also need to understand regulatory, clinical, commercial, and capital intensity risk.

The founder needs to know what kind of lead the round requires.

Some founders are looking for a lead investor, but they are speaking mostly to followers. Others are speaking to funds that lead, but only at a later stage. Some are speaking to investors with sector interest, but not enough cheque size. Some are speaking to strategics who may be helpful, but cannot provide the venture signal the round needs. Some are speaking to family offices that can write capital, but do not want to set terms.

This creates confusion because the founder may think they are running a fundraising process, when they are actually running a broad investor awareness process.

A fundraising process needs a clear target. Who can lead this round? What cheque size is required? What ownership range makes sense? What stage does the investor lead? What kind of companies do they lead? What evidence do they need? What is their decision process? What is their fund timing?

Without this clarity, the founder may spend months in meetings that were never likely to produce a lead.

The lead investor is underwriting the next round too

A lead investor is not only thinking about this round. They are thinking about what happens after this round.

Can the company reach a milestone that attracts the next investor? Will the next round be financeable? Will the syndicate be strong enough? Will the company need too much capital before major proof? Will the market be ready? Will the valuation leave room for the next financing? Will there be enough future investor appetite?

This downstream financing risk matters. A lead does not want to anchor a round that leaves the company stranded. They want to believe that the company can become more fundable after the capital is deployed. If the next financing looks difficult, the current round becomes harder to lead.

This is one reason founders need to explain the round in terms of value creation, not just runway. “This round gives us 18 months” is not enough. The investor wants to know what the company will look like after those 18 months. What will be proven? What will be de-risked? What will be more valuable? What new investors will care? What strategic options will open?

The lead investor is thinking like the first buyer of the financing risk. If they lead now, they need to believe there will be a market for the company later.

That is why the round story matters so much.

Share

A weak syndicate can make leading harder

Lead investors also care about the rest of the syndicate. They want to know who else is coming in, who already owns the company, whether existing investors are supportive, and whether the cap table will help or hurt future financing.

A weak syndicate can make a round harder to lead. If existing investors are not participating, that creates questions. If the cap table is crowded with passive angels, that may create governance or signalling concerns. If strategic investors have rights that could complicate future financing or exit paths, that may create hesitation. If the founder is trying to fill the round with investors who bring no follow-on capacity, the lead may worry about future support.

This does not mean every company needs a perfect cap table. Early companies rarely do. But the lead investor wants to understand what they are joining.

They are not just investing in the company. They are joining the ownership structure around the company.

Founders sometimes underestimate how much this matters. They think capital is capital. Investors know that capital has behaviour. Some investors support. Some disappear. Some complicate decisions. Some create signalling risk. Some help recruit, finance, partner, and build. Some make the next round easier. Others make it harder.

A strong lead does not only care about getting into the round. They care about whether the round creates a company that can be financed again.

How to make a round leadable

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Many founders think the company becomes more impressive when it is doing more.

More markets. More customer types. More use cases. More partnerships. More pilots. More investor narratives. More strategic options. More product directions. More possible business models. More ways the company could win.

From the inside, this can feel like ambition. The founder sees the scale of the opportunity and wants investors to understand how much the company could become. They want to show the platform potential, the market breadth, the customer demand, the strategic relevance, and the number of doors that appear to be opening.

But from the outside, doing more can create a different signal.

It can make the company look less clear.

This is one of the most common problems in early-stage fundraising. The founder is working hard, the company is active, the story is full of potential, and there are many possible paths forward. But the investor struggles to understand what the company is actually choosing.

That matters because investors do not just fund activity. They fund focus. They need to believe that the founder understands which path creates the most value, which risk matters first, which customer matters now, which market should be prioritised, and which milestone the round is designed to unlock.

The strategic clarity problem appears when a company has motion but not enough direction. The founder can describe many opportunities, but not the sequence. They can explain many use cases, but not the wedge. They can talk about many customer types, but not the buyer. They can reference many partnerships, but not the commercial logic. They can show many investor narratives, but not one strong investment case.

This does not mean ambition is bad. Investors want founders who see large outcomes. They want companies with room to grow. They want businesses that can become much bigger than the first product, first customer, or first market. But ambition needs structure. Without structure, breadth starts to look like confusion.

The strongest founders do not make the company look bigger by saying yes to everything. They make the company look more investable by showing what matters first.

Subscribe now

Activity is not strategy

Early companies are full of activity. That is normal. Founders need to speak to customers, build product, test assumptions, recruit talent, raise capital, manage advisors, explore partnerships, and create momentum before the company has institutional support around it.

The problem begins when activity starts to replace strategy.

A founder may have twenty customer conversations, but no clear view of which customer segment matters most. They may have several pilot discussions, but no defined criteria for which one should move forward. They may speak to investors across different categories, but keep changing the story depending on who is listening. They may pursue partnerships because the logos look impressive, without knowing whether those partnerships reduce a real risk.

This can create the appearance of progress while hiding a lack of prioritisation. The company is busy, but the direction is still unclear. Investors can sense this quickly because fundraising forces the founder to explain not only what is happening, but why it matters.

When an investor asks what the next twelve months are meant to prove, the answer cannot be a list of activities. It needs to be a strategic argument. The company is choosing this market because it creates the cleanest path to evidence. It is prioritising this customer because they have the clearest pain, budget, and adoption pathway. It is building this product wedge because it reduces the most important risk. It is raising this amount because it gets the company to a milestone that changes the financing case.

That is strategy.

Strategy is not everything the company could do. It is the discipline to choose what the company should do now.

Too many markets create investor doubt

One of the fastest ways to lose investor confidence is to present too many markets at once. This happens often in health because many technologies genuinely have broad potential. A diagnostic platform may apply across several disease areas. A digital health product may help providers, payers, employers, and pharma. A medtech innovation may have multiple clinical use cases. A data platform may be relevant to hospitals, life sciences companies, insurers, and public health systems.

The founder sees this breadth as strength. The investor often sees it as unfinished thinking.

The issue is not whether the company could eventually serve multiple markets. The issue is whether the founder knows which market creates the strongest first investment case. Investors are not only asking where the company could go. They are asking where the company should start, why that starting point is credible, and what it proves about the larger opportunity.

If every market is presented as equally attractive, the investor has to do the prioritisation themselves. That creates friction. It also raises concerns that the founder may not understand the adoption path deeply enough. Different markets have different buyers, budgets, timelines, evidence needs, regulatory questions, pricing models, and sales motions. A company that tries to pursue all of them too early can spread itself thin and learn too slowly.

Focus does not make the company smaller. It makes the first path more believable.

A founder can still explain the broader vision, but the first market needs to be clear. The investor should understand why this market comes first, what evidence supports that choice, what will be learned, and how success there opens the next path. Without that sequence, the market story becomes a collection of possibilities rather than a strategy.

Too many customer types weaken the buyer story

The same problem appears with customer types. Many founders describe several possible buyers because they do not want to close off optionality. They say the product could be sold to hospitals, clinics, pharma companies, payers, employers, consumers, governments, or research institutions. In some cases, that may be true. But it also creates a serious problem.

Each customer type represents a different business.

A hospital buyer is not the same as a pharma buyer. A payer is not the same as an employer. A clinician is not the same as a procurement department. A patient user is not the same as an institutional customer. A research team is not the same as a commercial buyer. Each has a different problem, incentive, budget, decision process, implementation barrier, evidence requirement, and sales cycle.

When a founder describes too many customers at once, investors may worry that the company has not yet found its buyer. That is different from having a large market. A large market is useful only if the company knows how to enter it. Without a clear buyer, the go-to-market strategy becomes vague.

This matters because investors need to understand how demand becomes revenue. Interest is not enough. Clinical enthusiasm is not enough. Strategic curiosity is not enough. The buyer story has to explain who feels the pain strongly enough to act, who controls the budget, who influences the decision, what evidence they need, how long the process takes, and what makes the purchase urgent.

A founder who cannot answer this clearly may still have a strong product, but the commercial path will feel weak. The investor may like the opportunity and still pass because the company has not made a clear strategic choice about who it is serving first.

Too many use cases make the product harder to believe

Use case expansion is another common source of strategic confusion. Founders often want to show that the product can solve many problems. The platform can support many workflows. The technology can apply to many disease areas. The data can inform many decisions. The tool can serve several parts of the organisation.

Again, the founder sees this as upside. Investors may see it as a lack of discipline.

Every use case adds complexity. It may require a different workflow, different evidence, different user behaviour, different integration, different success metric, and different buyer conversation. Even when the underlying technology is the same, the adoption path may not be.

If the founder leads with too many use cases, the investor may struggle to understand what the company is actually building. Is this a product, a platform, a service, an infrastructure layer, a clinical tool, a workflow solution, a data asset, or a strategic capability? More importantly, which use case proves the company is valuable?

The strongest founders are able to separate future optionality from current focus. They can say, “This could apply more broadly, but this is the use case we are prioritising because it has the clearest pain, the strongest evidence path, the most urgent buyer, and the best route to adoption.”

That sentence creates confidence because it shows judgment. It tells the investor the founder is not trying to win every possible market at once. They are choosing the use case that can make the company easier to believe.

A narrow wedge is not a lack of ambition. It is often the only way to make ambition fundable.

Share

Partnerships can become strategic noise

Partnerships are often used to show momentum. Founders mention conversations with hospitals, pharma companies, universities, corporates, distributors, accelerators, innovation teams, strategic investors, and international partners. These relationships may be useful, but they can also create noise if the founder cannot explain their purpose.

Investors do not automatically value partnership activity. They want to know what each partnership changes.

Does it give access to customers? Does it reduce clinical risk? Does it support regulatory progress? Does it create distribution leverage? Does it generate revenue? Does it validate demand? Does it help with data access? Does it shorten the path to market? Does it make the company more valuable before the next round?

If the founder cannot answer those questions, the partnership may look like activity rather than strategy.

This is especially important in health because the sector is full of slow-moving partnership conversations. A company can spend months speaking to respected institutions without getting closer to revenue, adoption, evidence, or investment readiness. The logos may look impressive, but investors have seen enough exploratory conversations to know that not all strategic interest converts into company value.

A clear founder knows which partnerships matter and why. They do not collect logos for the deck. They use partnerships to reduce specific risks, open specific markets, or create specific proof points. That distinction is important.

Partnerships should sharpen the investment case, not make it harder to understand.

Too many investor narratives create confusion

Founders often adjust the story depending on the investor. A healthtech founder may present as a digital health company to one fund, an AI company to another, a data infrastructure company to another, a clinical workflow company to another, and a pharma services company to another. Some flexibility is useful. Different investors care about different parts of the story.

But too much narrative flexibility becomes dangerous.

If the founder changes the company too much depending on the room, investors may wonder whether there is a clear strategy underneath the pitch. A company can have multiple angles, but it should not feel like a different business each time. The narrative should adapt to the audience without losing the core investment logic.

This matters because investors need to carry the story internally. If the founder cannot explain the company with strategic clarity, the investor cannot easily explain it to partners, investment committees, advisors, or co-investors. The story becomes harder to defend. The company becomes harder to categorise. The decision becomes harder to make.

The founder’s job is not to say whatever sounds most attractive to each investor. It is to explain the company clearly enough that the right investors understand why it fits their mandate.

Not every investor needs to like the company. But the right investor needs to understand it.

Strategic clarity helps the founder stop chasing every possible interpretation of the business and start building conviction around the one that matters most.

Focus is not the opposite of ambition

Many founders resist focus because they worry it will make the company look smaller. They want to show a large market, a platform opportunity, multiple revenue streams, international potential, and strategic optionality. They worry that choosing one path will reduce investor excitement.

This is a misunderstanding of how investors think.

Focus does not make ambition smaller. Focus makes ambition believable.

Investors can understand that a company may expand over time. They can underwrite a wedge that opens into a larger market. They can believe in a platform if the first application proves something important. They can back a company with multiple future paths if the first path is strong enough to carry the financing case.

What they struggle with is a company that wants credit for every future possibility before proving one current path.

Strategic clarity is the bridge between ambition and belief. It tells the investor how the company moves from now to later. It explains which proof point comes first, why it matters, and how it changes the next decision. It gives the investor a way to understand risk, sequencing, capital use, and value creation.

The best founders can hold both ideas at once. They can explain the big vision and the immediate focus. They can show the long-term opportunity without pretending everything must happen now. They can make the company feel large without making it feel scattered.

That is the difference between ambition and strategic confusion.

Leave a comment

Strategic clarity is a leadership signal

Investors read strategic clarity as a leadership signal. It tells them how the founder thinks, not just what the company does. A founder who can prioritise clearly is more likely to use capital well. A founder who can say no is more likely to avoid distraction. A founder who can sequence risk is more likely to survive a difficult market. A founder who can explain tradeoffs is more likely to lead a team through uncertainty.

This is why strategic clarity matters before the company is fully mature. Investors know early companies will change. They are not expecting the founder to have every answer. But they do expect the founder to know what matters now.

A founder who says, “We are exploring several markets,” may sound open-minded. A founder who says, “We explored several markets, and we are prioritising this one because it gives us the strongest path to adoption and evidence,” sounds much stronger.

A founder who says, “There are many use cases,” may sound ambitious. A founder who says, “There are many possible use cases, but this one is the wedge because it creates the clearest buyer urgency,” sounds more investable.

A founder who says, “We have lots of partnership conversations,” may sound active. A founder who says, “These two partnerships matter because they reduce implementation risk and create access to the customer segment we are prioritising,” sounds strategic.

The difference is not effort. It is judgment.

The choices investors want to see

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Every early-stage company depends on the founder. That is normal. In the beginning, the founder carries the story, sells the vision, recruits the first team, speaks to customers, manages advisors, raises capital, builds the first partnerships, shapes the product, and keeps the company moving when there is not yet enough structure around it.

Founder force is often the reason the company exists at all.

But there is a point where founder force becomes founder bottleneck.

This is one of the most important transitions in company building. At the earliest stage, investors expect the company to move through the founder. They know the founder will be personally involved in every customer conversation, investor meeting, product decision, hiring discussion, and strategic choice. But as the company develops, investors start asking a different question. Can this company begin to operate beyond the founder’s personal intensity?

That is where many early health companies get stuck. The founder is still the only person who can sell the product, explain the science, manage the pilot, speak to investors, handle partnerships, make product decisions, recruit talent, update the data room, and interpret the market. Every important decision routes through one person. Every relationship depends on one person. Every piece of momentum requires the founder to push it personally.

From the inside, this can feel like leadership.

From the outside, it can start to look like fragility.

This is the founder bottleneck. It happens when the company has no real operating system beyond the founder’s effort. The founder is busy, committed, and often impressive, but the business itself has not yet learned how to move without them touching everything.

Investors worry about this because venture capital is not only funding what the founder can do personally. It is funding whether the company can become larger, stronger, more repeatable, and more valuable over time. A company that only moves through founder force may be exciting, but it can also be difficult to scale.

Subscribe now

Founder force gets you started

There is nothing wrong with founder force at the beginning. In fact, most companies need it. Early-stage companies do not have brand, process, reputation, systems, or institutional momentum. They have the founder’s conviction and the founder’s ability to create movement before the market gives movement back.

This is especially true in health. The first customer conversations are often founder-led because the founder can explain the nuance of the problem. The first investor meetings are founder-led because the founder can connect the story, the evidence, and the ambition. The first partnerships are often founder-led because trust is personal at the beginning. The first hires usually join because they believe in the founder’s clarity and energy.

That is expected. Investors know early companies are not mature organisations. They know the founder has to do uncomfortable things before the company has process around them. The founder may have to sell before there is a sales team, manage product before there is a product leader, discuss regulation before there is a regulatory hire, and handle fundraising while still running the company day to day.

But founder force is supposed to create the conditions for the company to become less dependent on founder force.

The danger is when the founder remains the only source of movement. If every pilot needs the founder, every customer needs the founder, every investor update needs the founder, every product tradeoff needs the founder, and every internal decision waits for the founder, the company is not becoming stronger. It is becoming more dependent.

That dependence may not look dangerous at first. The founder is often capable enough to keep things moving. But as the company grows, the number of decisions increases, the number of stakeholders increases, and the cost of founder dependency becomes harder to hide.

Investors look for repeatability

One of the things investors are trying to understand is whether early progress can repeat. A founder may be able to sell the first pilot because they are persuasive, credible, and deeply connected to the mission. But can someone else sell the second, third, and fourth? A founder may be able to hold the product together because they understand every customer conversation, but can the team make product decisions without waiting for the founder’s interpretation? A founder may be able to explain the company beautifully to investors, but can the materials, data room, and team carry the story when the founder is not in the room?

This is why founder dependency becomes an investor concern. The investor is not trying to take the founder out of the company. They are trying to understand whether the company has begun to convert founder knowledge into company capability.

There is a difference between a founder who is essential and a founder who is blocking scale. The founder should remain essential to the company’s direction, culture, judgment, and mission. But the company should not require the founder to manually push every function forward.

Investors want to see signs that the company is becoming repeatable. They want to know whether customer learning is being captured, whether sales conversations follow a pattern, whether product decisions are connected to evidence, whether hiring is filling real gaps, whether the team understands priorities, and whether the company can execute without everything becoming a founder decision.

This does not mean the company needs heavy process. Early-stage companies should not become bureaucratic. But they do need operating discipline. They need enough structure for learning, decisions, execution, and communication to compound beyond one person.

Without that, the company may look busy but not scalable.

The founder becomes the keeper of context

One of the most common signs of a founder bottleneck is that the founder becomes the keeper of all context. They remember what customers said. They remember why investors passed. They remember which advisor warned about regulatory risk. They remember why the product roadmap changed. They remember why one market was deprioritised, and another was chosen. They remember the history behind every decision.

At the beginning, this is natural. The founder is closest to the market and usually has the most complete understanding of the company. But over time, this becomes a problem if the context never leaves the founder’s head.

The team cannot make strong decisions because the reasoning behind previous decisions is not visible. New hires take longer to become effective because they are missing the market history. Advisors repeat old suggestions because they do not know what has already been tested. Investors ask for evidence, but the founder has to reconstruct the story from memory. Product discussions drift because the team does not have a shared view of what the market is teaching the company.

This creates hidden drag. Nothing appears broken immediately, but everything becomes slower. The founder has to explain more, approve more, correct more, remember more, and intervene more. The company becomes dependent on the founder not only for decisions, but for interpretation.

That is not scalable.

A company becomes stronger when founder context becomes company knowledge. Customer learning should inform the team. Investor objections should improve the fundraising story. Pilot lessons should shape product and implementation. Advisor input should be captured and filtered. Strategic choices should be documented enough that others understand why they were made.

This is how the company starts to operate beyond the founder’s memory.

Founder-led sales can hide weak sales maturity

Founder-led sales are normal at the beginning. In many health companies, they are necessary. The founder understands the problem deeply, can adapt the conversation in real time, and can build trust with early customers. In complex markets, early sales often require founder credibility.

But founder-led sales can also hide weak commercial maturity.

A founder may be able to get meetings because they are compelling, connected, or mission-driven. They may be able to create interest because they can explain the problem with intensity. They may be able to keep pilots alive because they personally follow up, solve issues, and maintain relationships. But investors will eventually ask whether this motion can scale.

If the founder is the only person who can sell, the company has not yet proven a sales motion. It has proven founder persuasion. That may be valuable, but it is not the same thing.

Investors will want to know whether the company understands the buyer, the budget, the objection patterns, the sales cycle, the implementation steps, and the conversion path. They will want to see whether the founder has turned early conversations into a repeatable process. They will want to know whether someone else could eventually follow the same logic and produce similar results.

This is especially important in health because early relationships can be highly personal. A clinician may support the company because they like the founder. A hospital may explore a pilot because the founder has built trust. A strategic partner may keep the conversation open because the founder is persistent. These are useful signals, but they are not enough unless the company can show that the relationship is becoming a repeatable commercial pattern.

The best founders use founder-led sales to learn the market, not to remain permanently at the centre of every sale.

Product decisions cannot all depend on the founder

The founder bottleneck also appears in product. Early product direction often depends heavily on the founder because the founder understands the original insight. They know the customer pain, the market gap, the scientific logic, the clinical workflow, or the technical opportunity that gave birth to the company.

But as the company grows, product decisions need to become more disciplined. If every feature, roadmap change, workflow adjustment, and implementation decision depends on the founder, the team cannot move quickly or confidently. The founder becomes the filter for everything.

This is dangerous because the founder may not always be the best product decision-maker at every stage. They may be too close to the original idea. They may overvalue certain customer conversations. They may resist narrowing the product because they see the full vision. They may add features because they want to keep every stakeholder happy. They may delay difficult tradeoffs because they personally feel the cost of saying no.

A good product process does not remove the founder’s judgment. It gives that judgment leverage. The team should understand the first wedge, the customer evidence, the adoption barriers, the success criteria, and the next milestone well enough to make decisions without waiting for the founder every time.

This matters to investors because product maturity is not only about what has been built. It is about how product decisions are made. A company that can explain why it is building one thing and not another shows focus. A company that keeps routing product through founder instinct alone may look less mature, even if the product itself is impressive.

Hiring should reduce founder dependency

Hiring is one of the clearest tests of whether a founder is building a company or simply adding people around themselves. Early hiring should reduce founder dependency. The right hire should take ownership of a real function, increase the quality of decisions, and create more leverage for the company. But many founders hire without actually letting go.

This happens for understandable reasons. The founder knows the company best. They have high standards. They worry that others will not explain the company correctly, manage customers properly, make the right product tradeoffs, or handle investors with enough care. So they hire people, but keep the real decision-making centralised.

The team grows, but the bottleneck remains.

Investors notice this. They look at the team and ask whether the company has real functional ownership or only support around the founder. Who owns product? Who owns commercial execution? Who owns clinical development? Who owns operations? Who owns finance? Who owns regulatory thinking? Who owns investor materials? Who is accountable for what?

At the early stage, not every role will be fully filled. That is fine. But the founder should understand which capabilities need to move out of their head and into the company. A founder who cannot delegate real ownership may struggle to scale, even with more capital.

This is why hiring is not just about adding talent. It is about changing how the company works.

Share

The board and advisors should not become another founder task

Advisors and boards can help reduce founder bottlenecks, but only if used properly. In many early companies, the founder manages advisors reactively. They reach out when there is a problem, ask for feedback, absorb conflicting opinions, and then try to decide what to do. The advisory structure becomes another thing the founder has to carry.

The same can happen with boards. Instead of using the board to sharpen decisions, the founder uses board meetings to report activity. The board hears updates, but the founder still carries all the decisions back into the company. The governance structure exists, but it does not create enough leverage.

This is a missed opportunity. Good advisors and board members should help the company see around corners, make better choices, pressure test assumptions, and reduce founder isolation. But they need context, structure, and clear asks. Otherwise, they become noise.

A founder who uses advisors well can reduce their own bottleneck. They can bring the right question to the right person at the right time. They can distinguish between advice that changes strategy and advice that should be noted but not acted on. They can use the board to clarify decisions, not just review progress.

This matters because investors want to know whether the founder can build around themselves. A founder who tries to solve every problem personally may be impressive, but they also create concentration risk. A founder who knows how to use people, process, and governance intelligently creates more confidence.

The company needs rhythm

One of the best ways to move beyond founder force is to build rhythm. Rhythm does not mean bureaucracy. It means the company has a consistent way of learning, deciding, executing, and communicating.

A company with rhythm captures customer learning. It reviews what the market is saying. It knows which risks matter this month. It connects product decisions to evidence. It understands what the next milestone requires. It communicates progress clearly to investors and advisors. It has a cadence for making decisions instead of letting every issue become a founder emergency.

This kind of rhythm creates trust because it shows the company is becoming more than a collection of founder reactions. It has a way of operating. Even if the team is small, the company starts to feel more mature.

In health, rhythm matters because progress is often slow. Without rhythm, slow progress can turn into anxiety. The founder starts chasing every signal, reacting to every delay, and pushing activity just to feel movement. With rhythm, the company can stay focused even when the market is moving slowly. It can keep learning, keep building evidence, and keep making disciplined decisions.

Investors are not expecting perfection. They are looking for signs that the founder can create a system around the work. A company with rhythm is easier to back because it suggests that capital will amplify discipline, not chaos.

Leave a comment

From founder force to company operating system

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Founders often think investors are only judging the company. They assume the investor is…

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most underestimated skills in fundraising is translation. Not translation between languages, but translation between decision-makers. Founders often explain the company in the language they are most comfortable with. Scientific founders explain the science. Clinical founders explain the patient need. Product founders explain the features. Commercial founders explain the market. Technical founders explain the architecture, data, model, or platform.

That is natural. Founders usually build from the world they understand best. The problem is that the people they need to convince do not all think from that same world. Investors do not think like clinicians. Clinicians do not think like procurement. Procurement does not think like strategic partners. Strategic partners do not think like founders. Boards do not think like product teams. Each group is trying to answer a different question before they say yes.

This is the boardroom translation problem. A founder can understand the company deeply, but still fail to translate it into the decision language of the person in front of them. The company may be strong, the problem may be real, and the opportunity may be meaningful, but if the explanation is trapped inside the founder’s preferred language, the audience may not know how to act.

This matters because health companies are rarely bought, funded, adopted, or partnered by one person. They move through rooms. Investor partner meetings. Hospital budget meetings. Procurement reviews. Clinical committees. Regulatory discussions. Strategic partnership reviews. Board meetings. Investment committees. The company needs to make sense in all of those rooms, especially when the founder is not there to explain it again.

A founder who cannot translate the company forces every stakeholder to do extra work. The investor has to translate the company for the partnership. The clinician has to translate it for administration. The innovation team has to translate it for procurement. The strategic partner has to translate it for business development, legal, commercial, and leadership. That slows everything down.

The best founders do not only explain what the company does. They explain it in the language of the decision that needs to be made.

Subscribe now

The same company has many different meanings

A health company does not mean the same thing to every stakeholder. To a clinician, the company may represent better care, less friction, faster diagnosis, improved workflow, or a reduction in patient risk. To a hospital executive, it may represent operational efficiency, quality improvement, staff capacity, compliance, budget impact, or institutional differentiation. To a payer, it may represent cost avoidance, evidence quality, risk reduction, or measurable outcomes. To a strategic partner, it may represent pipeline relevance, market access, distribution, data, technology leverage, or long-term competitive advantage.

To an investor, the company means something else again. It represents a risk profile, a financing path, a value creation opportunity, a future round, a possible exit, and a question of whether capital can turn current uncertainty into future value. The investor may care about the clinical problem, but they are also asking whether the company can build enough evidence, access the right market, protect its position, attract future capital, and create a return.

This is why founders get frustrated. They think they are explaining the company clearly, but they are often explaining it from the wrong angle for the room they are in. A founder may give a highly technical explanation to an investor who is trying to understand market entry. They may give a patient-impact explanation to a hospital finance team that is trying to understand budget ownership. They may give a product demo to a strategic partner who is trying to understand why the company matters to their corporate priorities.

The content may be true, but truth alone is not enough. The audience needs to understand why the truth matters to them.

This does not mean the founder should manipulate the story or tell different versions that contradict each other. The company should remain consistent. The problem, product, evidence, market, and milestone should not change from room to room. What changes is the framing. The founder needs to know which part of the company matters most to each decision-maker and explain the opportunity through that lens.

Translation is not changing the truth. It is making the truth usable.

Founder language is not always decision language

Founder language is often full of vision, history, intensity, and personal conviction. The founder explains why they started, how they discovered the problem, what they have built, what they believe the future should look like, and why the company matters. That can be powerful because founders need conviction. A company without founder conviction is hard to believe.

But founder language can also become too internal. It can include too much backstory, too many assumptions, too many emotional shortcuts, and too much context that the audience has not yet earned. The founder has lived with the problem for years, so they forget what a new listener needs first. They jump into the product before the problem is clear. They explain future scale before the first use case is understood. They talk about the mission before the buyer is defined. They describe the platform before the audience understands why the first wedge matters.

Decision-makers do not have the founder’s context. They need a clearer path into the company. They need to understand the problem in their own terms, the consequence of not solving it, the evidence that the solution matters, and the decision being asked of them.

This is why founder language often works better in origin stories than in boardrooms. It can create emotional connection, but it may not create action. A boardroom needs a decision. An investor meeting needs conviction. A hospital meeting needs operational logic. A strategic partnership meeting needs relevance. A procurement review needs risk control. A clinical committee needs evidence and workflow fit.

The founder’s job is to carry the conviction without forcing the audience to decode the company from the founder’s perspective.

Scientific language can impress without converting

Scientific language is one of the most common traps in health fundraising. A founder with deep scientific expertise may explain the mechanism, the data, the technical novelty, the biology, the model, the platform, the analytical method, or the research history in detail. This can be impressive, especially when the science is genuinely strong. But scientific strength does not automatically translate into investment clarity.

Investors may respect the science and still not understand the company. They may believe the mechanism is interesting but still wonder which indication comes first. They may understand that the platform is technically differentiated but still not know what the next financing milestone proves. They may see that the data is promising but still ask whether it changes the risk profile enough to justify the round.

Scientific founders sometimes believe more technical detail will create more confidence. Sometimes it does, particularly with specialist investors or scientific advisors. But in many fundraising conversations, too much scientific detail too early can create distance. The investor may not need a deeper explanation of the mechanism at that moment. They may need to understand why the mechanism creates a company.

The science has to be translated into value creation. What does the science make possible? What risk has already been reduced? What risk remains? What evidence is needed next? Who cares if this works? Why does this round matter? How does the company become more valuable if the next milestone is achieved?

That is the translation investors need.

The goal is not to make the science shallow. It is to make the business around the science legible. The best scientific founders can go deep when needed, but they do not start by making the investor prove they can keep up. They start by making the investment case clear enough that the technical depth has somewhere to land.

Clinical language does not always reach the buyer

Clinical founders often speak in the language of patient need, clinical workflow, physician frustration, care quality, and unmet need. That language is essential because health companies must solve real problems. If the product does not matter clinically, the company may not deserve to exist. Clinical insight gives founders credibility and helps them avoid building products that make sense in theory but fail in practice.

But clinical language can fail when the audience is not making a purely clinical decision. A doctor may understand why the product matters, but a hospital executive may ask how it affects budget, capacity, risk, staff time, quality metrics, or strategic priorities. Procurement may ask about vendor risk, implementation, contract terms, IT requirements, and liability. A payer may ask whether the product reduces cost, improves outcomes, or changes utilisation in a measurable way.

The clinical case may be necessary, but it is not always sufficient.

This is where many health founders lose momentum. They have strong clinical support, but they cannot translate that support into institutional action. They can explain why the product should be used, but not why it will be bought. They can explain why patients benefit, but not who pays. They can explain why the workflow is broken, but not what operational owner has the incentive and authority to fix it.

The best founders do not abandon clinical language. They connect it to decision language. They show how the clinical problem creates operational burden, financial cost, quality risk, compliance pressure, capacity strain, or strategic urgency. They help non-clinical stakeholders understand why the clinical issue matters to their decision.

That is how clinical value starts to move through the system.

Product language is not enough for investors

Product founders often explain what the product does. They show dashboards, workflows, features, user journeys, AI layers, integrations, reports, alerts, and modules. They demonstrate functionality because functionality is visible. A good demo can create excitement. It can make the company feel real. It can help investors understand how the product works.

But investors are not only asking what the product does. They are asking what the product proves.

A product may have many features, but the investor wants to know which feature creates value. A dashboard may look polished, but the investor wants to know who uses it, how often, and what decision it changes. An AI layer may sound advanced, but the investor wants to know whether it reduces risk, improves performance, or creates defensibility. An integration may look important, but the investor wants to know whether it is essential for adoption or just another implementation burden.

Product language can become too focused on capability. Investors need capability translated into evidence, adoption, buyer urgency, defensibility, and value creation. The question is not only whether the product can do something. The question is whether that thing matters enough for someone to change behaviour, pay, adopt, renew, expand, partner, or invest.

This is why product-led explanations can underperform in fundraising. The founder shows the product, but the investor still cannot see the business. The investor may like the interface and still wonder who buys. They may understand the workflow and still wonder how hard it is to implement. They may see the features and still wonder whether the company has a focused wedge.

The strongest founders use product language only after the decision context is clear. They show the product as proof of a specific business argument. The demo is not a tour. It is evidence.

Share

Investors need investment language

When founders speak to investors, the company needs to be translated into investment language. That does not mean using buzzwords or pretending everything is about exit multiples. It means explaining the company in terms of risk, evidence, milestones, capital, market entry, defensibility, future financing, and value creation.

Investors need to understand what risk they are being asked to take. They need to know why that risk is acceptable at this stage. They need to see what has already been proven and what remains uncertain. They need to understand what this round of capital is designed to change. They need to believe that if the company achieves the next milestone, the company will be more valuable, more fundable, more partnerable, or more strategically relevant.

This is often where founders struggle. They explain the company as a product or mission, but not as an investment. They talk about what they will build, but not what that build proves. They talk about market size, but not market entry. They talk about pilots, but not conversion. They talk about future potential, but not the sequence of value creation.

Investment language is not cold. It is simply the language investors need to make a decision. It helps the investor understand why the company deserves capital now and what the company should become after that capital is used.

A founder who can speak investment language does not stop being authentic. They become easier to underwrite.

Hospitals need institutional language

Hospitals do not make decisions in founder language either. A founder may see the hospital as a customer, but the hospital sees itself as an institution with constraints. It has budgets, staff shortages, compliance requirements, patient safety standards, IT systems, procurement processes, operational priorities, and political realities. Even when the clinical need is obvious, the institution still has to decide whether it can absorb the solution.

This means the company needs to be translated into institutional language. What does this product reduce, improve, protect, simplify, or enable for the hospital? Does it reduce workload? Does it improve patient flow? Does it support compliance? Does it create measurable quality improvement? Does it reduce avoidable cost? Does it help staff operate better? Does it fit existing systems? Does it create risk or reduce risk?

A founder who only explains the product’s clinical benefit may struggle to move the hospital. The clinical benefit matters, but adoption often depends on whether the institution can justify the decision across multiple stakeholders. The founder needs to help the hospital see the product not only as a clinical tool, but as an institutional decision.

This is difficult because hospitals contain many internal languages. Clinicians speak one language, IT another, finance another, compliance another, procurement another, and leadership another. The founder does not need to become an expert in every internal function, but they do need to understand that each function has its own concerns.

A product that cannot be translated across those concerns may remain liked but not adopted.

Strategic partners need strategic language

Strategic partners also need a different translation. A pharma company, medtech company, diagnostics group, insurer, corporate health player, or large healthcare organisation may be interested in innovation, but they are rarely interested in innovation in the abstract. They want to understand how the startup connects to their priorities.

A founder may explain the product as a solution to a market problem. A strategic partner may ask how it strengthens their pipeline, improves market access, creates a data advantage, supports distribution, opens a new category, complements an existing asset, reduces development risk, or helps them serve a customer segment they already care about. The same company may need to be framed differently depending on the strategic partner’s context.

This is where founders often overestimate partnership interest. They get a positive conversation with a strategic, but they do not translate the company into the strategic’s decision language. The founder explains why the company is exciting. The strategic partner is asking whether the company is relevant.

Relevance is not the same as excitement. A strategic partner may think the technology is impressive and still not see why it matters to their current priorities. They may admire the founder and still not know where the company sits inside their organisation. They may believe the category is important but have no internal owner for the relationship.

The best founders do the translation work before the meeting. They understand the strategic partner’s business, priorities, pressures, portfolio, and likely decision logic. They explain not only what the startup does, but why it could matter to that partner now.

Boards need decision language

Boards need yet another translation. A board is not there to receive every detail. It is there to help make better decisions. Founders often use board meetings to report activity, but boardrooms need clarity around choices, tradeoffs, risks, capital allocation, hiring, runway, milestones, and strategic direction.

This is especially important as companies mature. The founder may be deep in daily execution, but the board needs to understand what decisions matter. Should the company narrow the market? Should it delay hiring? Should it extend runway? Should it pursue a strategic partnership? Should it raise now or later? Should it focus on evidence, product, revenue, regulation, or team? What tradeoff is being made and why?

A founder who cannot translate operating complexity into decision language may have ineffective board meetings. The board hears updates but does not know where to help. The founder may leave with comments, but not decisions. The company loses the chance to use the board properly.

Boardroom translation is about turning information into judgment. What changed? What matters? What decision is needed? What are the options? What is the recommendation? What risk does the company accept if it chooses this path?

This same skill helps in fundraising because investors are also listening for decision quality. They want to know whether the founder can turn complexity into choices.

P.S. Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

The founder as translator

Read more

We’re partnering with TechBBQ 2026.

We’re excited to announce that HealthVC/Clarma Capital is partnering with TechBBQ 2026, taking place on 26–27 August at Bella Center Copenhagen.

TechBBQ brings together 10,000+ attendees, 1,500+ investors, 3,000+ startups, and 340+ speakers for two days focused on startups, capital, innovation, and the future of the European ecosystem.

Known as the home of founders, builders, and bold ideas, TechBBQ is where the people building and backing the next generation of companies come together.

For us, this partnership is about being part of the room where real conversations happen, connections are made, and new opportunities begin.

At HealthVC, we care about helping founders build better companies, understand capital, and connect with the investors and partners who can help them grow.

We look forward to joining the TechBBQ community in Copenhagen this August.

Join us at TechBBQ 2026
26–27 August
Bella Center Copenhagen

Tickets are limited:
https://techbbq.dk/buy-tickets/

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Some startups are not rejected because the opportunity is bad. They are rejected because the company is too hard to understand.

This happens more often than founders realise. The founder may be working on a serious problem. The product may be useful. The science may be strong. The market may be large. The team may be credible. The company may even have early traction, clinical interest, pilot activity, or strategic conversations. But when the founder explains the business, the story does not land. The investor cannot clearly understand what the company does, who it serves, why it matters now, what has been proven, what still needs to be proven, and why this round of capital changes the company’s value.

That is a problem because investors do not invest in what they cannot understand well enough to defend.

A founder may believe the investor should spend more time trying to understand the company. They may think the complexity is obvious because they live inside it every day. They may assume that once the investor sees the product, reads the deck, joins another call, or reviews the data room, the opportunity will become clear. Sometimes that is true. But often the issue is not lack of information. The issue is lack of clarity.

This is the company that cannot explain itself. It is not necessarily a bad company. It may be an early company, a technical company, a scientific company, a platform company, or a company operating in a difficult market. But if the founder cannot explain the problem, buyer, product, evidence, market, milestone, and investment case clearly enough, the company becomes difficult for investors to carry internally.

Clarity is not a cosmetic layer on top of fundraising. It is part of the investment case. A founder who can explain the company clearly signals that they understand the company deeply. A founder who cannot explain the company clearly creates doubt, even when the opportunity itself may be strong.

Subscribe now

Confusion creates investor friction

Investors are not only listening for excitement. They are listening for structure. They are trying to understand what kind of company this is, what risk they are being asked to underwrite, what evidence exists today, and what needs to happen next. If the founder makes that difficult, the investor has to work too hard before conviction can form.

This friction matters because investors see many companies. They are constantly deciding where to spend time, which opportunities deserve deeper work, which companies are ready for diligence, and which stories can be discussed with partners or investment committees. A company that is difficult to understand may not always receive the time needed to decode it.

The founder may think the investor has missed the point. In reality, the founder may not have made the point clearly enough.

In health, this is especially important because the underlying businesses can already be complex. There may be science, clinical validation, regulation, reimbursement, workflow change, data protection, procurement, behaviour change, and market access. Investors do not expect health companies to be simple, but they do expect the founder to make the complexity understandable. If the founder adds narrative confusion on top of business complexity, the company becomes harder to believe.

A clear explanation does not remove risk. It organises risk. It helps the investor understand which risks matter, which risks have been reduced, which risks remain, and why the next milestone is worth funding. That is why clarity is so valuable. It does not make the company less ambitious. It makes the ambition easier to underwrite.

The founder understands too much

One of the reasons companies become hard to explain is that the founder understands too much. This sounds strange, but it is common. The founder has spent months or years living inside the problem. They know the history, the edge cases, the product decisions, the scientific nuance, the customer feedback, the market context, the regulatory details, the investor objections, and every possible future direction.

Because the founder sees the whole picture, they often try to explain too much at once. They include every use case, every stakeholder, every feature, every market, every possible buyer, and every long-term application. The result is not a richer story. It is a heavier one.

Investors do not need the whole company at once. They need the entry point. They need to understand the first thing that matters. What is the problem? Who has it? Why does it matter now? What does the product change? What evidence supports that claim? Who pays? What does this round prove? If those questions are not clear, the rest of the detail becomes noise.

This is one of the hardest shifts for founders. Clarity often requires leaving things out. Not because they are irrelevant forever, but because they are not the first thing the investor needs to believe. A platform may have many future applications, but the investor still needs to understand the first wedge. A scientific company may have deep technical nuance, but the investor still needs to understand the first value inflection. A healthtech product may support many stakeholders, but the investor still needs to know who the initial buyer is.

The strongest founders know how to simplify without making the company shallow. They do not strip away the complexity. They sequence it.

The pitch has to travel

A founder is not only explaining the company to the person on the call. They are giving that person the language needed to explain the company to someone else. This is one of the most important parts of fundraising.

Your investor champion needs to carry the story internally. They may need to explain it to a partner. They may need to discuss it in a Monday meeting. They may need to write a memo. They may need to defend the deal to an investment committee. They may need to bring in advisors, co-investors, clinical experts, regulatory consultants, or strategic partners.

If the company is difficult to explain, the investor has to become the translator. That is a risky position for the founder. The investor may like the opportunity, but if they cannot explain it clearly to others, the deal becomes harder to move forward.

This is where many founders underestimate the importance of narrative discipline. They think the pitch is only about creating excitement in the first meeting. It is not. The pitch also needs to survive when the founder is not in the room. The story has to be clear enough that someone else can repeat it accurately, defend it under pressure, and explain why it matters.

A company that can be explained clearly is easier to share. A company that is easier to share is easier to discuss. A company that is easier to discuss is easier to diligence. A company that is easier to diligence is easier to fund.

That does not mean the story should be simplistic. It means the core logic should be strong enough to travel.

The problem is often not the deck

When founders struggle to explain the company, they often assume the deck needs to be redesigned. Sometimes it does. A clearer structure, better visuals, sharper slides, and better sequencing can help. But the deeper issue is often not the deck. It is the thinking beneath the deck.

If the founder cannot explain the company in a clear conversation, the deck will not fix the problem. It may make the company look more polished, but it will not make the strategy clearer. The investor may still struggle to understand the buyer, the market entry, the evidence, the milestones, or the business model.

This is why fundraising materials often expose founder confusion. A deck that tries to explain too many things usually reflects a company that has not made enough choices. Too many market slides may hide the fact that the first market is unclear. Too many product slides may hide the fact that the core use case has not been proven. Too many traction slides may hide the fact that the traction is not yet strong enough. Too many future applications may hide the fact that the first wedge is weak.

A good deck is not a collection of information. It is a sequence of belief. It should help the investor move from problem to solution, from solution to evidence, from evidence to market, from market to milestone, and from milestone to investment logic. If the founder cannot create that sequence, the investor may leave the meeting with interest but not conviction.

The goal is not to make the company sound simple. The goal is to make the investment case coherent.

Share

Health founders often speak in the wrong language

Another reason companies fail to explain themselves is that founders speak in the wrong language for the audience. Scientific founders often speak in scientific language. Clinical founders speak in clinical language. Product founders speak in product language. Commercial founders speak in sales language. Each language has value, but investors need the company translated into investment language.

Investment language does not mean hype. It means explaining the business through the questions investors are trying to answer. What risk exists today? What evidence reduces that risk? What does this round prove? Why does that proof matter? Who will care if the company succeeds? What makes the company more valuable after the next milestone?

A scientific explanation may show why the technology is impressive, but it may not explain why the company is fundable. A clinical explanation may show why the product is needed, but it may not explain who pays. A product explanation may show what the tool can do, but it may not explain why adoption will happen. A market explanation may show that the problem is large, but it may not explain the first customer.

This translation matters because investors are not only evaluating whether the company is meaningful. They are evaluating whether it can become valuable. That requires the founder to connect the product, market, evidence, team, and financing plan into one clear story.

The best founders can move between languages. They can explain the science to scientists, the workflow to clinicians, the value to buyers, and the investment case to investors. They do not force every audience to interpret the company through the founder’s preferred language.

Clarity is a sign of strategic maturity

Investors often treat clarity as a signal. A founder who can explain the company clearly usually understands the company better than a founder who needs twenty minutes to reach the point. Clear founders have usually made hard choices. They know what matters now and what can wait. They know the difference between the long-term vision and the current financing milestone. They know which risks are central and which are secondary.

This is why clarity feels like maturity. It shows that the founder has moved beyond raw possibility and into strategic discipline. They are not trying to make the company sound bigger by adding more use cases, more markets, more stakeholders, more features, and more future options. They are making the company more investable by showing where value begins.

This does not mean every clear company is a good investment. It also does not mean every complex company is bad. But a clear company is easier to evaluate. Investors can understand the assumptions. They can test the evidence. They can discuss the risks. They can see what the next round of capital is designed to change.

A company that cannot explain itself makes all of that harder. Investors may still be interested, but they will have to spend more energy just to understand what they are looking at. In a competitive fundraising market, that is not a small problem.

Clarity gives the founder an advantage because it reduces unnecessary friction. It lets investors spend their energy evaluating the opportunity rather than decoding the story.

The milestone is where clarity often breaks

One of the places where unclear companies struggle most is the milestone. The founder may be able to explain the product and the market, but when asked what the next round of capital actually proves, the answer becomes vague.

They say the money will be used to build the team, continue product development, run pilots, expand the market, strengthen partnerships, generate evidence, and prepare for the next phase. Some of that may be true, but it does not explain the value creation logic. Investors need to know what the company will become after the round that it is not today.

This is where clarity matters most. A milestone should not be a list of activities. It should be a change in the company’s risk profile. What will investors believe after this round that they cannot believe today? What evidence will exist? What decision will be made easier? What risk will be reduced? What next investor, customer, partner, or acquirer will care?

If the founder cannot explain that, the round becomes harder to fund. The company may need money, but investors do not fund need. They fund progress. They fund the possibility that today’s uncertainty can become tomorrow’s value.

A clear milestone gives investors something to underwrite. It tells them why this financing matters and what success looks like. An unclear milestone makes the company feel like it is raising to keep going rather than raising to become more valuable.

Leave a comment

Making the company easier to carry

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most underrated weaknesses in early-stage companies is not a lack of effort. It is a lack of memory.

Founders speak to customers, clinicians, advisors, investors, operators, consultants, strategic partners, pilot sites, hospital teams, pharma contacts, payers, and other founders. They collect feedback constantly. They hear objections, patterns, warnings, signals, requests, frustrations, and moments of real market insight. The company is learning every week, sometimes every day.

But too much of that learning stays inside the founder’s head.

A customer says something important on a call. An investor challenges the same part of the story three times. A clinician explains why the workflow will not change. A hospital contact reveals who really owns the budget. An advisor points out a regulatory risk. A pilot partner gives feedback that should shape the next milestone. The founder understands it in the moment, maybe even repeats it to the team later, but then the company moves on. The insight is not captured properly. It is not turned into a strategy. It is not turned into evidence. It is not turned into product direction, sales discipline, fundraising language, or operating decisions.

This is the founder's memory problem.

The company is hearing the market, but not storing what it learns in a way that changes the company.

That matters because early-stage companies are not only built by doing things. They are built by learning from what happens when they do those things. Every customer call, investor meeting, advisor conversation, pilot discussion, and partnership meeting should make the company sharper. The problem is that many founders are exposed to useful information constantly, but the learning remains informal, scattered, and founder-dependent.

The result is a company that keeps having conversations but does not compound insight.

Subscribe now

Conversations are not learning unless the company changes

Founders often confuse activity with learning. They say they have spoken with thirty customers, met twenty investors, had ten advisor conversations, and explored several pilots. That may sound productive, but the real question is what the company learned and what changed because of it.

A customer call is only useful if it clarifies the problem, buyer, workflow, urgency, budget, objection, or adoption path. An investor call is only useful if it reveals how the market is interpreting the company, where the story is unclear, which risks are not yet believed, or what evidence is missing. An advisor conversation is only useful if it helps the founder make a better decision. A pilot discussion is only useful if it teaches the company what must be true for adoption, implementation, conversion, or expansion.

The danger is that founders can have a lot of conversations without building a better company. They collect comments, but not conclusions. They gather opinions, but not patterns. They remember anecdotes, but not evidence. They leave meetings with a feeling that the market is interested, but not a precise understanding of what the market is actually saying.

This becomes a problem in fundraising because investors do not only ask whether founders have spoken to the market. They ask what those conversations proved. If the founder cannot explain the pattern clearly, the number of conversations matters less. Thirty customer calls that do not clarify the buyer, the pain, the budget, or the adoption path are not strong evidence. They are activity.

The best founders do not treat conversations as proof by themselves. They treat conversations as raw material. They capture what they heard, compare it across stakeholders, identify repeated patterns, separate signal from noise, and then make decisions. That is how learning becomes strategy.

The founder becomes the bottleneck for insight

In the earliest days of a company, it is normal for most learning to sit with the founder. The founder is taking the calls, hearing the objections, adjusting the pitch, interpreting the feedback, and making decisions in real time. That is part of the job. Early companies move through founder intensity.

But as the company develops, this becomes risky. If the founder is the only person who remembers why certain decisions were made, what customers really said, which investor objections keep repeating, what the pilot partner cared about, or why one market was chosen over another, the company becomes dependent on the founder's memory. The team cannot learn properly because the learning is not visible. New hires cannot understand the market quickly because the insight is not organised. Advisors repeat old advice because they do not see what has already been tested. Investors hear claims without the underlying evidence.

This is one of the hidden reasons early companies become inefficient. The founder keeps carrying the context personally. Every new discussion requires the founder to re-explain the market. Every strategic decision depends on what the founder remembers. Every investor update has to be rebuilt from memory. Every product debate returns to old conversations because the company has no shared source of truth.

A founder’s memory is not an operating system.

It may work for a while, especially when the company is very small. But it does not scale. As the company raises capital, hires people, runs pilots, manages advisors, builds product, and speaks to investors, the learning needs to become institutional. The company needs a way to remember what the market has taught it so that insight can compound.

This is not about bureaucracy. It is about discipline. If the company does not capture learning, it keeps paying for the same lessons again.

Investor feedback is often wasted

One of the biggest areas where founders lose value is investor feedback. Fundraising creates a huge amount of information. Every investor conversation tells the founder something about how the company is being perceived. Some investors misunderstand the story. Some focus on the same risk. Some ask the same question in different ways. Some react strongly to one part of the company and ignore another. Some pass because of fund fit, but others pass because the company has not yet answered a real concern.

Founders often leave these calls emotionally rather than analytically. A good call creates optimism. A bad call creates frustration. A pass creates disappointment. A positive follow-up creates energy. But the deeper value is in the pattern. What did investors consistently not understand? Where did they slow down? What did they challenge? What did they believe quickly? What did they discount? Which questions kept coming back?

If this feedback is not captured, the founder may keep repeating the same fundraising mistake. The deck gets adjusted superficially, but the underlying issue remains. The founder changes a phrase but does not change the logic. The company keeps hearing that the market entry is unclear, the evidence is too early, the buyer is not well defined, the platform story is too broad, or the use of funds does not connect to value creation. But because the feedback is not organised, it feels like an isolated investor opinion rather than a pattern.

This is dangerous because investors are not always good at explaining exactly why they are uncomfortable. Sometimes they ask questions about the real concern rather than naming it directly. It is the founder’s job to interpret the pattern. If five relevant investors hesitate around the same part of the story, that is not noise. That is market feedback.

The best founders treat fundraising as a learning process, not just a capital process. Even when they do not get the cheque, they extract insight from the conversation. They use investor feedback to sharpen the narrative, improve the data room, refine the milestone plan, and understand what the next round will need to believe.

Leave a comment

Customer learning disappears too easily

The same problem happens with customers and users. A founder may have dozens of conversations with clinicians, hospital leaders, patients, payers, pharma teams, or operational staff, but the learning stays too fragmented. One conversation reveals a workflow pain. Another reveals a budget issue. Another reveals a reason the product would not be adopted. Another reveals that the user and buyer are not the same person. Another reveals that the problem matters, but not enough to become a priority this year.

Each insight matters, but only if the company connects them.

Without a disciplined memory, the founder may overvalue the positive signals and forget the uncomfortable ones. The clinician who loved the product is remembered. The procurement concern is softened. The pilot interest is repeated in the deck. The lack of budget is treated as a later issue. The company remembers what creates momentum and forgets what creates friction.

This is human. Founders are trying to survive. They need energy. They need optimism. They need to keep moving. But selective memory can weaken the company. If the same objection appears across multiple customer conversations and the founder does not capture it properly, the product roadmap may move in the wrong direction. If budget concerns appear early and are ignored, the commercial model may be built on wishful thinking. If workflow resistance appears repeatedly and is not documented, the company may later discover that adoption is harder than expected.

In health, this is especially important because customer feedback often contains hidden complexity. A clinician may be describing workflow risk. A finance stakeholder may be describing budget priority. An IT contact may be describing the integration burden. A compliance person may be describing institutional risk. These comments may sound operational, but they often reveal whether the product can actually be adopted.

If the company forgets those signals, it will build around a version of the market that does not exist.

The company needs a learning discipline

A founder does not need a complicated system to solve this problem, but they do need a discipline. The goal is not to turn every conversation into a report. The goal is to make sure important learning does not disappear.

The discipline starts with capturing what was actually learned, not just what was said. This distinction matters. A transcript is not insight. A meeting note is not a strategy. The founder needs to ask what the conversation revealed about the problem, buyer, urgency, evidence, pricing, adoption, risk, milestone, or fundraising story. The value is not in recording everything. The value is in interpreting what matters.

The second part is pattern recognition. One comment may be noise. Repeated comments become evidence. If multiple clinicians describe the same workflow barrier, that matters. If multiple investors struggle with the same part of the story, that matters. If multiple buyers avoid pricing, that matters. If multiple pilot sites show interest but no budget, that matters. If multiple advisors disagree, the founder needs to understand whether the disagreement is contextual or strategic.

The third part is decision-making. Learning is only useful if it changes something. It may change the pitch, the product, the roadmap, the evidence plan, the target customer, the fundraising strategy, the hiring plan, or the next milestone. It may also confirm that the company should not change direction yet. Either way, the founder should be able to explain how market learning is being turned into company action.

This is what investors want to see. They want to know that the founder is not only collecting conversations but also becoming sharper because of them. A company that learns quickly is more investable than a company that simply works hard.

Share

Memory creates better fundraising materials

One of the most practical benefits of founder memory is that it makes fundraising materials stronger. A company that captures learning properly can build a better deck, a better data room, better investor updates, and better diligence answers because the evidence is not being reconstructed from memory at the last minute.

When customer conversations are captured well, the market section becomes more specific. The founder can explain who feels the pain, why it matters, how often it appears, who controls the budget, and what adoption barriers exist. When investor feedback is captured well, the fundraising narrative becomes sharper. The founder can see which claims are confusing, which risks need better explanation, and which parts of the story create conviction. When pilot learning is captured well, the traction section becomes more credible because the founder can explain what was tested, what was learned, and what still needs to be proven.

This is how insight becomes evidence.

Too many founders treat the data room as a place to upload documents after the fact. But the best fundraising materials are built from disciplined learning over time. The deck should reflect what the company has learned from the market. The data room should support the claims made in the story. The investor update should show progress against the risks that matter. The milestone plan should reflect what the company has learned about what needs to become true next.

A founder who has captured learning can answer investor questions with confidence because the answers are grounded in real conversations and real patterns. A founder who has not captured learning often answers from memory, and memory becomes vague under pressure.

The market is teaching you what to build

The market is always teaching the founder something. It teaches through enthusiasm, hesitation, delay, objections, confusion, silence, budget resistance, feature requests, pilot friction, investor questions, advisor disagreement, and customer behaviour. The challenge is that the market rarely teaches in a clean way. It does not hand the founder a strategy. It provides signals, and the founder has to interpret them.

This is why founder memory matters. If the company does not remember the signals, it cannot interpret the pattern. If it cannot interpret the pattern, it cannot make better decisions. It may keep building what the founder wants to build instead of what the market is showing it needs. It may keep selling to the wrong stakeholder. It may keep targeting the wrong use case. It may keep pitching the wrong story to investors.

The best founders understand that strategy is not only created in a planning session. It is built from what the company learns through contact with the market. The market may teach that the buyer is different from the user. It may teach that the strongest use case is narrower than expected. It may teach that the product is valuable, but only if implementation is simpler. It may teach that investors do not understand the platform until the first wedge is explained. It may teach that the company needs more evidence before the next round.

Those lessons are expensive. The founder should not have to learn them twice.

P.S. Don’t forget to check out HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Turning learning into company advantage

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the easiest mistakes for a founder to justify is building more product. It feels productive. It feels strategic. It feels like progress. A new dashboard gets added. A new module gets scoped. A new workflow gets supported. A new AI layer gets introduced. A new service wrapper is built around the product. Another feature is added because a clinician mentioned it, an advisor suggested it, a pilot customer asked for it, or the founder believes it will make the company look more complete.

From the inside, this can feel like the company is becoming stronger. The product looks more impressive. The demo becomes broader. The deck has more screenshots. The platform feels more substantial. The founder can point to more capability, more functionality, and more use cases. It becomes easier to say the company is building something big.

But investors often see something different.

They do not automatically treat more product as more progress. In many cases, more products make the company harder to understand, harder to underwrite, and harder to believe. Not because product development is bad, but because too much product too early can hide the fact that the founder has not yet proven which part of the business actually matters.

This is the overbuilt startup problem. It happens when founders keep building around the uncertainty instead of moving through it. They expand the product before they have proven the smallest valuable wedge. They add complexity before they have proven urgency. They build a platform before they have proven the first repeatable use case. They create more surface area before they know which part of the company customers, users, buyers, partners, or investors truly care about.

In health, this problem is especially common because the market is complex and the feedback is noisy. Clinicians want one thing. Hospitals want another. Patients need something else. Payers ask different questions. Investors focus on fundability. Advisors suggest future use cases. Strategic partners talk about optionality. The founder tries to respond to all of it by building more.

But building more is not always the same as learning more.

And when a startup becomes overbuilt before it becomes understood, the product can start to work against the fundraising story.

Subscribe now

More products can hide less clarity

The first danger of an overbuilt startup is that more product can hide less clarity. A founder may have many features, but still not know the first buyer. They may have a broad platform, but still not know the first market. They may have a polished dashboard, but still not know which decision it improves. They may have multiple use cases, but still not know which one creates urgency. They may have a product that can do many things, but not enough evidence that any one thing is valuable enough to drive adoption.

This is where investors become cautious. A large product surface area can look impressive at first, but it can also raise questions about focus. Why has the company built so much before proving the core use case? Which part of the product is actually driving demand? Which feature creates measurable value? Which user depends on it? Which buyer cares enough to pay? Which workflow is painful enough to change? Which part of the product would customers miss if it disappeared tomorrow?

Founders often assume that a broader product makes the company look more mature. Sometimes it does, especially if the company has already proven demand and is expanding from a strong base. But at the early stage, breadth can create doubt. It can make investors wonder whether the founder is building because the market has pulled the company forward or because the company is still searching for what matters.

The difference is important. A startup that expands after proving a wedge is scaling from insight. A startup that expands before proving a wedge may be avoiding the hard work of focus.

Investors are not trying to punish founders for building. They are trying to understand what the product has proven. If the answer is unclear, more product does not solve the problem. It often makes the problem harder to see.

Founders often build to avoid learning

Building feels safer than learning because building is controllable. A founder can open the product roadmap, define a new feature, assign tasks, brief engineers, update designs, and show visible progress. Learning is more uncomfortable. It requires exposing the company to the market. It requires asking whether customers care, whether buyers will pay, whether the use case is urgent, whether the workflow fits, whether the product removes enough pain, and whether the company is solving something that matters now.

Many founders do not avoid learning consciously. They genuinely believe they are improving the company. But product work can become a refuge from commercial truth. It is easier to build another module than to hear that the buyer is unclear. It is easier to improve the dashboard than to test whether anyone will pay for it. It is easier to add AI than to prove the workflow problem. It is easier to expand the platform than to choose a narrow use case and accept that the rest can wait.

This is especially true in health because customer discovery can be slow and ambiguous. A clinician may like the product but not be the buyer. A hospital may explore a pilot but not have a budget. A pharma team may say the platform is interesting but not have a defined use case. A patient group may validate the need but not the business model. These signals create uncertainty, and building can make the founder feel like they are still moving forward while the market remains unresolved.

Investors notice when product development is being used as a substitute for market clarity. They hear it when the founder talks in features instead of evidence. They see it when the roadmap is more detailed than the customer strategy. They feel it when the demo is impressive, but the adoption path is vague. They become concerned when the company has built a lot but still cannot answer the basic questions of who needs it most, why they need it now, and what they will do differently because it exists.

The best founders do not build to avoid learning. They build to test what they have learned.

The platform temptation

The word platform is one of the most dangerous words in early-stage health fundraising. It can be powerful when it is earned, but dangerous when it arrives too early. Founders like platforms because they suggest scale, optionality, and ambition. A platform can serve multiple use cases, multiple stakeholders, multiple conditions, multiple markets, and multiple revenue streams. It makes the company sound bigger than a point solution.

The problem is that investors often hear platform and immediately ask what has been proven first.

A platform without a wedge is hard to fund because the investor does not know what to believe. Is the company a clinical workflow tool, a diagnostic engine, a data infrastructure company, a patient engagement product, a provider solution, a pharma partnership platform, an AI decision support system, or a services-enabled technology business? The founder may believe the answer is all of the above, but early investors usually need the answer to be much sharper.

This does not mean platform ambition is wrong. Some of the most valuable health companies become platforms over time. But they rarely start by asking the market to believe the full platform at once. They begin with a painful use case, a specific user, a clear buyer, a narrow workflow, a defined evidence path, or a focused commercial wedge. Once that wedge works, the platform becomes more credible because it is expanding from proof rather than possibility.

A platform should be the result of repeated value, not a way to avoid choosing where value begins.

This is where founders need discipline. They can still explain the long-term platform vision, but the fundraising story needs to make the first wedge obvious. Investors should understand what the company is proving now, why that first use case matters, and how it creates the right to expand later.

Without that sequence, the platform story can feel like a product trying to be everything before it has proven anything.

Share

Feature requests are not strategy

Another reason startups become overbuilt is that founders confuse feature requests with market strategy. This is common in health because every stakeholder sees the product through their own workflow, incentives, and frustrations. A clinician asks for a different view. A hospital contact asks for another integration. An advisor suggests an additional use case. A pilot customer wants a specific reporting layer. A strategic partner asks whether the product could also support something adjacent.

Some of these requests may be valuable. Some may reveal real adoption barriers. Some may point toward a stronger wedge. But many are simply context-specific preferences. They reflect one user, one institution, one workflow, one stakeholder, or one hypothetical future customer. If the founder treats every request as strategic, the product becomes a collection of other people’s opinions.

That is dangerous because every feature has a cost. It adds engineering time, design complexity, implementation burden, support requirements, onboarding friction, and narrative complexity. It also makes the company harder to explain. The more the product tries to do, the harder it becomes to identify what is essential.

Investors are not impressed by a roadmap that responds to every external suggestion. They want to see that the founder can separate signal from noise. A feature request should not automatically become product direction. The founder needs to ask what the request proves. Is this a one-off preference or a repeated pattern? Does it reduce adoption friction or add complexity? Does it strengthen the first wedge or distract from it? Does the buyer care? Does it support the next milestone? Would the customer pay more because of it? Would the product fail without it?

The strongest founders do not ignore customers, clinicians, advisors, or partners. They listen carefully. But they do not let every voice shape the product equally. They understand that product discipline is part of company discipline.

Overbuilding can weaken the fundraising story

A fundraising story needs to be clear enough for investors to carry. This is not only about the deck. It is about whether the investor can explain the company to partners, advisors, investment committees, co-investors, and future stakeholders. An overbuilt product often makes that harder.

When a company has too many modules, markets, use cases, and claims, the investor has to work harder to understand the core business. They may like parts of the product but still struggle to know what the company really is. They may see interesting technology but not a clean wedge. They may respect the founder’s work but worry that the business has not yet found focus.

This matters because investors are not just funding effort. They are funding a path to value. More product does not automatically make that path clearer. In fact, it can blur the path if the product has expanded faster than the evidence.

A founder may say the company serves hospitals, patients, payers, pharma, providers, and researchers. That might sound large, but it also suggests multiple buyers, multiple sales motions, multiple evidence requirements, multiple pricing models, and multiple adoption pathways. A founder may say the product combines AI, workflow software, analytics, patient engagement, clinical decision support, and services. That might sound sophisticated, but investors will ask which part drives the business.

The risk is that the company starts to look like a solution searching for its market rather than a company built around a clear market need.

The best fundraising stories usually have a strong centre. The investor understands the problem, the first customer, the wedge, the evidence, the milestone, and the reason capital matters now. The product can be ambitious, but the story has to be focused.

Subscribe now

The smallest valuable wedge

The alternative to overbuilding is not underbuilding. It is finding the smallest valuable wedge. This is the narrow part of the product and market where the company can prove something meaningful. It is not necessarily the smallest feature, and it is not necessarily the smallest market. It is the smallest focused use case that can demonstrate real value, reduce a real risk, and create a credible path to expansion.

For a health company, the smallest valuable wedge might be one clinical workflow, one patient population, one provider segment, one decision point, one diagnostic use case, one therapeutic indication, one administrative pain point, one buyer group, or one measurable outcome. The key is that the wedge must matter. It should not be narrow for the sake of being narrow. It should be narrow because focus creates proof.

A good wedge helps the founder answer important questions. Who has the pain? Why does it matter now? What does the product change? Who needs to use it? Who needs to approve it? What evidence proves it works? What would make the customer continue, expand, pay, or partner? What does success in this wedge unlock next?

This is what makes a company easier to fund. Investors can understand what the current round is designed to prove. They can see how capital turns into evidence. They can understand why the wedge matters and how it could lead to a broader platform over time.

A founder who says, “We are building a platform for the entire market,” asks investors to believe a lot at once. A founder who says, “This is the first wedge, this is why it matters, this is what we have learned, this is what the next round proves, and this is how it expands,” gives investors a sequence of belief.

That is the difference.

More products can create more implementation risk

In health, more product does not only create more internal complexity. It can also create more implementation risk for the customer. Every additional feature, workflow, integration, dashboard, data field, reporting layer, user type, and service component can make the product harder to adopt.

Founders often think more functionality makes the product more valuable. Buyers may see more work. A hospital may ask who will train staff, who will manage the integration, who will maintain the workflow, who will interpret the data, who will change behaviour, who will be responsible if the product is not used properly, and who will measure success. A product that looks powerful in a demo may feel heavy in a real operating environment.

This is why overbuilt products can struggle in healthcare. The product may solve several problems, but if it requires too much change, the customer may delay adoption. The company may believe it has created more value, while the buyer sees more operational burden.

Investors understand this. They know healthcare systems are already under pressure. They know staff are overloaded, budgets are constrained, and procurement is slow. They know that adoption depends not only on whether a product is useful, but whether the organisation can absorb it.

A focused product with a clear use case can sometimes be easier to adopt than a broad product with many capabilities. It creates less confusion, less training burden, less implementation friction, and clearer success criteria. That does not mean the company must remain narrow forever. It means the first adoption path should be as clean as possible.

In health, a product that is easier to adopt is often easier to fund.

Leave a comment

The product should prove the business

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most underrated skills in fundraising is confidence. Not the loud version of …

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Health companies are naturally complex. That is part of the sector. A founder may need to manage science, product, clinical validation, regulation, reimbursement, procurement, market access, patient safety, data protection, stakeholder incentives, behaviour change, and long sales cycles before the company can become truly investable. Investors understand this. They do not expect health companies to look like simple software businesses, and they do not expect every risk to be removed at the earliest stage.

But there is a difference between necessary complexity and unfundable complexity.

Necessary complexity is the reality of building in health. It is the set of risks that naturally comes with the category, the product, the science, or the market. Unfundable complexity is what happens when a founder stacks too many unresolved risks on top of each other and expects investors to believe they will all be solved at the same time.

This is one of the most common reasons health companies become hard to fund. The company may be exciting. The mission may be important. The science may be promising. The product may be useful. The market may be large. But when investors look at the business, they see too many things that need to become true before the company can work.

The founder is asking investors to believe in new science, a new workflow, a new buyer, a new reimbursement model, a new regulatory pathway, a new behaviour change, a new data infrastructure, a new category, and a new commercial motion, all at once. Individually, each risk may be manageable. Together, they can make the company almost impossible to underwrite.

This is the unfundable complexity problem. It is not that investors dislike ambition. It is that ambition becomes difficult to fund when the company depends on too many unproven assumptions becoming true in the right order.

Subscribe now

Investors are not afraid of risk

A common founder's misunderstanding is that investors avoid risk. They do not. Venture capital exists because investors take risks. The entire asset class is built around uncertainty, incomplete information, and the possibility that a company may become much more valuable if the right risks are reduced over time.

The issue is not the risk itself. The issue is risk concentration.

Investors can often underwrite one major risk if they understand it clearly. They may take scientific risks if the team is exceptional and the market is meaningful. They may take commercial risk if the technology is already strong. They may take regulatory risk if the pathway is credible and the value creation potential is large. They may take adoption risk if the economic case is compelling. They may take early market risk if the category is forming and the company has a credible wedge.

What becomes difficult is when the company carries many major risks at the same time without a clear plan for reducing them. If the science is unproven, the buyer is unclear, the payment model is uncertain, the workflow is disruptive, the regulatory pathway is unresolved, and the market category still needs to be created, the investor is not evaluating one risky company. They are evaluating a chain of dependencies.

Every link in that chain has to hold.

That is where investors slow down. They are not only asking whether the opportunity is big. They are asking how many assumptions need to work before the company becomes valuable. The more assumptions that need to work at the same time, the harder the company becomes to fund.

This is why founders need to understand how investors think about risk. They do not simply count upside. They map the route between today’s uncertainty and tomorrow’s value. If that route requires too many unresolved things to go right, the company can become unfundable even when the idea is strong.

Complexity becomes dangerous when it is not sequenced

Complexity is not always a problem. Some of the best health companies are complex. They involve difficult science, regulated markets, clinical evidence, long development timelines, and sophisticated stakeholder environments. Complexity can even be an advantage if it creates defensibility. A company that solves a difficult problem may be harder to copy, more valuable to strategic partners, and more meaningful to the healthcare system.

But complexity has to be sequenced.

Sequencing means the founder understands which risks need to be reduced first, which risks can wait, which risks are connected, and which milestones will make the company more fundable. Without sequencing, the company feels like a pile of open questions. With sequencing, the same company starts to feel more investable because investors can see the path.

This is where many founders lose investors. They describe all the things the company will eventually do, but they do not explain which risk comes first. They talk about the full platform, the broad market, the future reimbursement opportunity, the international expansion, the strategic partnerships, the clinical outcomes, the regulatory route, the enterprise sales motion, and the long-term vision. The company sounds ambitious, but not staged.

Investors need staging. They need to know what this round proves. They need to know which risk is being reduced now and why that risk matters more than the others. They need to know what the company will look like after the round, what evidence will exist, what uncertainty will remain, and why the next investor, customer, partner, or acquirer will care.

A complex company becomes more fundable when the founder can turn complexity into sequence. The question is not whether everything is solved today. The question is whether the founder knows what must be solved next.

Too many new things at once

The most dangerous version of the unfundable complexity problem appears when a company is trying to introduce too many new things into the market at the same time. A new technology is hard enough. A new workflow is hard enough. A new buyer is hard enough. A new reimbursement model is hard enough. A new regulatory pathway is hard enough. A new clinical behaviour is hard enough. A new market category is hard enough.

When a company combines several of these, the adoption burden becomes much heavier.

For example, a founder may have a promising AI tool that requires hospitals to change workflow, trust a new type of clinical decision support, integrate with existing systems, create a new budget line, accept a new risk profile, and measure outcomes in a way they do not currently measure. The product may be useful, but the number of changes required from the customer is high. Investors will ask whether the market is ready to absorb that much change.

Another founder may have a diagnostic platform that needs new evidence, new clinician behaviour, payer acceptance, reimbursement clarity, lab adoption, and a new understanding of where the test fits in the care pathway. Again, the company may be important, but investors will ask whether too many stakeholders need to change before the business can scale.

A therapeutic platform may face a different version of the same problem. The science may be novel, but the company may also need to prove a new modality, choose the right first indication, build a clinical development strategy, attract strategic interest, protect IP, recruit specialised talent, and raise enough capital to reach a meaningful inflection point. Each of those risks may be normal, but together they can create a high proof burden.

This is not about discouraging innovation. Healthcare needs new science, new tools, new models, and new categories. But founders need to understand that every new thing adds friction. The more new things the company asks the market to accept, the more evidence investors need before they believe.

Share

The market does not adopt complexity just because the problem matters

One of the most painful truths in health is that important problems do not automatically create fast adoption. A problem can be serious, expensive, frustrating, and widely recognised, and still remain unsolved for years. Healthcare systems are full of problems that everyone agrees are real. That does not mean they are easy to fix, easy to fund, or easy to sell into.

This is where founders sometimes misread the market. They assume that because the problem is obvious, the system will act. But healthcare systems do not adopt solutions simply because the problem matters. They adopt when the solution fits the incentives, workflow, budget, evidence requirements, procurement process, regulatory environment, and operational capacity of the organisation.

A founder may say the current system is broken. The investor may agree. But agreement that the system is broken is not the same as a belief that this company can change it. The investor still needs to understand who has the power to act, why they will act now, what evidence they need, how the product fits into existing behaviour, how the company gets paid, and what makes the adoption path realistic.

This is why complexity can make a company less fundable even when the mission is strong. The founder is often focused on the size of the problem. Investors are focused on the path through the system. A large problem with no clear adoption route may be less fundable than a smaller problem with a sharper path to proof.

The market does not reward founders for identifying complexity. It rewards founders who can navigate it.

Broad platforms often carry hidden complexity

Platform companies are especially vulnerable to the unfundable complexity problem. A platform can sound exciting because it suggests scale, optionality, and multiple routes to value. It may be able to support many indications, many workflows, many customer types, or many commercial models. For founders, this breadth feels like strength.

For investors, breadth can create concern if the first path is unclear.

A platform with too many possible applications can become hard to underwrite because investors do not know which proof point matters. If the company could serve hospitals, pharma, payers, researchers, employers, and patients, the founder may believe the market is large. But the investor hears multiple buyers, multiple sales motions, multiple evidence requirements, multiple budgets, and multiple adoption pathways.

That is not always strength. Sometimes it is confusion.

The strongest platform founders do not try to make investors believe everything at once. They choose a first path that proves something important about the platform. They explain why that path is the right starting point, what evidence it creates, why the market cares, and how it opens future opportunities. They make the platform feel staged rather than scattered.

This is important because optionality without sequence is not strategy. It is complexity. Investors may believe the platform could be valuable someday, but they still need to understand what the company is doing now. If the founder cannot explain the first wedge clearly, the platform can feel more like a research direction than an investable company.

Subscribe now

The proof burden rises with every assumption

Every health company has a proof burden. The proof burden is the level of evidence investors need before they believe the company can move forward. That burden depends on the category, the claim, the customer, the risk, and the stage of the company.

A company making a low-risk workflow improvement may need to prove usability, adoption, time savings, and budget relevance. A company making clinical outcome claims needs stronger evidence. A diagnostic company needs to show analytical and clinical relevance, and often a path to payment. A regulated device company needs to show safety, performance, regulatory logic, and adoption potential. A therapeutic company may need to generate deep scientific, preclinical, clinical, and strategic evidence over time.

The proof burden rises when the company adds more assumptions. If the founder is asking investors to believe in a new technology and a new buyer, the proof burden rises. If the company also requires a new workflow, the burden rises again. If the company depends on a new reimbursement model, it rises again. If the company is trying to create a new category, it rises again.

This is why founders should be careful with ambitious claims. Every claim creates a proof requirement. If the company claims better outcomes, investors will ask for evidence. If it claims cost savings, investors will ask who saves money and whether the savings are measurable. If it claims workflow efficiency, investors will ask whether the workflow has been tested. If it claims strategic value, investors will ask who would care and why.

A founder may think they are making the company more attractive by expanding the ambition. But if the ambition adds too many proof requirements, it can make the company harder to fund.

Focus is not a lack of ambition

Some founders resist focus because they worry it makes the company look smaller. They want investors to see the full vision. They want to show all the markets, all the use cases, all the future partnerships, all the possible products, and all the ways the company could grow. That instinct is understandable, especially when founders are trying to raise venture capital and need to show scale.

But focus is not the enemy of ambition. Focus is how ambition becomes fundable.

A focused company is not saying the future is small. It is saying the first path is clear. It is showing investors where the company begins, what it proves, and how that proof unlocks the next stage. It reduces the number of assumptions investors need to believe immediately and gives the company a more credible way to create value.

This is especially important in health because broad ambition without a narrow entry point can make the company look naive. Investors know that healthcare systems do not move easily. They know that adoption is slow, evidence matters, stakeholders are fragmented, and budgets are difficult. When a founder claims the company can transform a large part of the system without explaining the first narrow path, investors become cautious.

The strongest founders can show both ambition and discipline. They can explain the big vision, but they do not ask investors to fund the entire vision at once. They show the first risk to reduce, the first stakeholder to win, the first evidence to create, and the first value inflection to reach.

That is what makes complexity investable.

How to make complexity fundable

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and emerging managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the most confusing parts of building a health company is that almost everyone has an opinion. Advisors have opinions. Clinicians have opinions. Professors have opinions. Investors have opinions. Operators have opinions. Consultants have opinions. Strategic partners have opinions. Mentors, accelerators, grant reviewers, hospital contacts, pharma scouts, regulatory experts, and fellow founders all have opinions.

At the beginning, this feels useful. The founder wants to learn, and the company is still forming. Every conversation seems to reveal something important. A clinician explains the workflow. A professor challenges the science. An investor questions the market. An operator points out a commercial risk. A consultant suggests a regulatory route. An advisor recommends a different use case. A hospital contact says the product needs another feature. Someone else says the company should focus on a completely different buyer.

The founder leaves each conversation with more information, but not always more clarity.

This is the expert feedback problem. Health founders are surrounded by smart people, but smart feedback does not automatically become a good strategy. In fact, too much expert feedback can make a company slower, more confused, and less decisive if the founder does not know which feedback actually matters.

The danger is not that experts are wrong. Many of them are genuinely helpful. The danger is that their advice is shaped by their own context, incentives, experience, risk tolerance, and view of the market. A clinician will usually see the company through the clinical workflow. A professor may see it through scientific validity. An investor may see it through fundability. A regulatory consultant may see it through compliance risk. A commercial operator may see it through selling difficulty. A strategic partner may see it through their own corporate priorities.

Each perspective can be useful. None of them is the whole truth.

The founder’s job is not to collect as much advice as possible. The founder’s job is to decide which advice should change the company.

Subscribe now

More feedback does not always create more clarity

There is a point where feedback stops helping and starts creating noise. Most founders do not notice this immediately because advice feels productive. The founder is taking meetings, learning from experienced people, validating assumptions, and building a network around the company. It can feel like progress, especially in health, where credibility matters and access to experts is often hard to earn.

But feedback can become a substitute for decision-making. Instead of choosing a first market, the founder keeps asking more people what they think. Instead of committing to a regulatory pathway, the founder keeps collecting opinions. Instead of testing pricing directly with buyers, the founder asks advisors whether the price feels reasonable. Instead of narrowing the use case, the founder adds more possibilities because each expert sees another opportunity.

This is how a company becomes heavier without becoming sharper.

The deck starts to change after every conversation. The product roadmap becomes crowded with features suggested by people who may never buy the product. The market narrative becomes broader because each expert sees a different application. The founder starts using phrases like “we have had very positive feedback from experts,” but struggles to explain what that feedback has actually proven.

Investors can feel this quickly. A founder who has absorbed too many opinions without filtering them often sounds less clear, not more clear. The company becomes difficult to understand because it is carrying the fingerprints of too many outside voices. The problem, customer, use case, evidence plan, regulatory logic, and commercial strategy all start to blur.

This is why more feedback does not always make a company more fundable. Fundability usually improves when the founder becomes clearer, not when the company becomes more crowded with perspectives.

Experts give advice from where they stand

One of the most important things founders need to understand is that expert feedback is never neutral. It may be thoughtful, experienced, and well-intentioned, but it still comes from a specific position. The expert is seeing the company through the lens of their own world.

A clinician may focus on whether the product fits real patient care, but they may not understand how the hospital will buy it. A professor may focus on scientific depth, but they may not understand what level of proof is needed for venture financing. A regulatory expert may focus on the safest pathway, but that path may not always match the company’s capital constraints. An investor may push for a sharper market narrative, but they may not fully understand the clinical complexity. A strategic partner may suggest a direction that is useful for their company, but not necessarily for the startup.

This does not mean the advice is bad. It means the founder has to interpret it properly.

The same piece of feedback can be valuable or dangerous depending on how it is used. If a clinician says the product needs a new feature, that may reveal a real workflow barrier. It may also reflect one institution’s preference. If an investor says the market is too narrow, that may mean the company needs to explain the expansion path better. It may also mean that the investor is not the right fit for the category. If a professor says the science needs more depth, that may be true for publication, but not necessarily for the next financing milestone.

Founders get into trouble when they treat all expert feedback as equally important. They start reacting to the status of the person giving the advice rather than the relevance of the advice itself. A well-known professor says something, so the company changes direction. A senior investor challenges the story, so the founder rewrites the whole narrative. A respected clinician asks for a feature, so it goes on the roadmap.

That is not a strategy. That is outsourcing judgment.

Advice can hide uncertainty

Sometimes founders keep collecting feedback because they are avoiding the discomfort of making a decision. This is common in health because decisions are expensive. Choosing the first indication, first use case, first customer segment, first product boundary, first evidence package, or first regulatory path can feel scary. Once the founder chooses, other possibilities must be delayed or ignored.

Expert feedback gives the founder permission to keep the decision open. There is always one more person to ask, one more advisor to consult, one more investor to speak with, one more clinician to interview, one more regulatory view to compare. The company appears to be learning, but in reality, it may be postponing commitment.

Investors are sensitive to this because venture-backed companies need decision-making discipline. They do not expect founders to know everything, but they do expect them to make hard choices with incomplete information. A founder who cannot filter advice may struggle when the company needs to move quickly, allocate capital, prioritise milestones, hire the right people, or say no to distracting opportunities.

This is where too much advice can make a founder less fundable. It can signal that the founder does not yet have the confidence or clarity to lead the company through uncertainty. The founder may be surrounded by impressive advisors, but if every external opinion changes the company’s direction, investors will worry that the business has no internal centre of gravity.

The strongest founders listen widely but decide narrowly. They gather input, understand the pattern, separate signal from noise, and then make a clear choice. They do not need every expert to agree before they act. They need enough evidence to move forward intelligently.

Subscribe now

The advisor problem

Health startups often build advisory boards early because credibility matters. A strong advisory board can help a company access clinical insight, regulatory understanding, scientific validation, market knowledge, investor confidence, and strategic relationships. Good advisors can save founders from expensive mistakes.

But advisory boards can also become a hiding place.

Some founders use advisors to signal credibility before the company has enough evidence. The deck becomes full of impressive names, but the business itself is still unclear. Other founders confuse having advisors with having execution capability. They assume that because the company has access to senior experts, it has solved the knowledge gap. Investors know the difference.

An advisor is not a strategy. An advisor is not a buyer. An advisor is not a management team. An advisor is not proof that the company can execute.

The real question is what the advisor actually changes. Are they helping the company make better decisions? Are they opening the right doors? Are they pressure-testing the evidence plan? Are they helping the founder understand the market? Are they reducing a real risk? Are they engaged enough to matter, or are they mostly a name on a slide?

Founders should be honest about this. A small number of deeply useful advisors is often more valuable than a long list of impressive but passive names. Investors care less about how many experts are attached to the company and more about whether the founder knows how to use expertise properly.

The best advisors make the company sharper. Weak advisory structures make the company look decorated, but not stronger.

The danger of building by committee

The expert feedback problem becomes most damaging when the company starts building by committee. This happens when the product, market, evidence plan, and narrative are shaped by too many external opinions without a clear founder-led strategy holding them together.

The product becomes a collection of requests. The pitch becomes a collection of investor comments. The clinical plan becomes a collection of advisor preferences. The market strategy becomes a collection of possible use cases. The result is a company that tries to satisfy everyone and ends up convincing no one.

This is especially dangerous in health because complexity is already high. A health company may already need to manage scientific risk, regulatory risk, clinical risk, reimbursement risk, data risk, adoption risk, and financing risk. If the founder adds too many competing opinions on top of that complexity, the company becomes harder to understand and harder to fund.

Investors do not want a company that has been shaped by consensus from every expert who has touched it. They want a founder who can explain why the company is making the choices it is making. They want to hear the logic behind the first market, the product scope, the evidence plan, the regulatory approach, the hiring sequence, and the financing milestone. They want to know that the founder is listening, but also leading.

This distinction is important. Being coachable does not mean being directionless. Listening to feedback does not mean changing the company after every conversation. A founder can be humble and decisive at the same time. In fact, that combination is often what investors are looking for.

Share

How to filter expert feedback

The best founders do not ask whether feedback is smart. They ask whether it is relevant to the decision in front of them. This is a different question. Smart people can give advice that is not useful for the current stage of the company. An expert may be right in general, but wrong for the milestone the company is trying to reach now.

The founder should first ask what type of decision the feedback relates to. Is it about clinical workflow, scientific validity, market demand, regulatory pathway, reimbursement, pricing, product usability, fundraising narrative, or strategic positioning? Once the founder understands the category, they can decide whether the person giving the feedback has the right context to influence that decision.

The founder should also ask whether the feedback is a pattern or an isolated opinion. If one clinician asks for a feature, that may be interesting. If ten clinicians across different institutions identify the same workflow barrier, that is more important. If one investor dislikes the market, that may reflect fund fit. If multiple relevant investors struggle with the same part of the story, the founder should pay attention. If one advisor suggests a new application, that may be optionality. If several market participants point to the same urgent use case, that may be a strategy.

Context matters. Pattern matters. Relevance matters.

The founder also needs to separate feedback that improves the company from feedback that merely expands the company. Some advice creates focus. Some advice creates more work. Some advice reduces risk. Some advice adds complexity. Some advice makes the investment story clearer. Some advice makes the company sound bigger but harder to underwrite.

The strongest founders are disciplined about this. They do not accept advice just because it sounds intelligent. They ask whether it helps the company become more focused, more credible, more fundable, or more valuable.

When feedback becomes a fundraising risk

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders, LPs, and Emerging Managers who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

Every founder has a part of the business they would rather not look at too closely. It is rarely because they are lazy or careless. More often, it is because that part of the company feels uncomfortable, uncertain, or outside the founder’s natural strength. For one founder, it is sales. For another, it is a regulatory strategy. For another, it is pricing, evidence generation, reimbursement, governance, hiring, market access, financial discipline, or the uncomfortable question of whether the company is focused enough.

This is the founder's blind spot. It is the risk that sits in the company long before the founder is ready to admit it. The founder can feel it, but they avoid giving it language. They work around it. They talk past it. They spend more time on the parts of the company where they feel strong and less time on the parts that keep creating tension.

The problem is that investors usually notice the blind spot very quickly. They may not see everything about the company in the first meeting, but they are trained to look for the gap between the story and the business. They listen to what the founder explains clearly and what they explain vaguely. They notice which risks are handled directly and which risks are softened, delayed, or avoided. They pay attention to the questions that make the founder more defensive, less precise, or more general.

This matters because fundraising is not only a test of ambition. It is a test of self-awareness. Investors do not expect early-stage companies to be perfect. They know there will be gaps, risks, unknowns, and open questions. What they want to know is whether the founder sees the company clearly enough to work through those risks in the right order. A founder who can name the weakness and explain how they are addressing it is much easier to trust than a founder who keeps pretending the weakness is not there.

The risk you avoid is often the risk investors notice first.

Subscribe now

Why founders avoid the hard part

Founders avoid different parts of the business for different reasons. Some avoid sales because they come from a technical, scientific, clinical, or product background, and selling feels uncomfortable. Some avoid regulatory strategy because it feels slow, expensive, and complex. Some avoid pricing because they do not want to hear that customers may not pay what the model assumes. Some avoid evidence generation because the truth may be that the company needs more proof before institutional capital will take it seriously.

In health, this avoidance is especially common because the company often contains many types of risk at once. A health founder may need to understand product, science, clinical evidence, regulation, reimbursement, procurement, market access, data protection, patient safety, stakeholder incentives, and venture financing. Very few founders are naturally strong across all of those areas. Most are excellent in one or two and much weaker in others.

That is not the problem. No founder is complete at the beginning. The problem begins when the founder does not recognise where the company is exposed. They may keep improving the deck while avoiding buyer discovery. They may keep adding product features while avoiding pricing conversations. They may keep talking about clinical value while avoiding reimbursement. They may keep raising the market size while avoiding the first narrow use case. They may keep discussing future partnerships while avoiding the fact that the current milestone does not create enough value.

Avoidance often disguises itself as progress. The founder is busy, but not addressing the hardest question. The company is moving, but not necessarily becoming less risky. The team is producing materials, building products, joining programmes, taking meetings, and updating investors, but the blind spot remains untouched. From the inside, this can feel like momentum. From the outside, investors can often see that the company is circling around the real issue.

This is why blind spots are so dangerous. They do not always stop a company immediately. They quietly shape the company’s decisions until the risk becomes too large to ignore.

The blind spot often hides inside the founder’s strength

The most difficult blind spots are not always the obvious weaknesses. Sometimes they are hidden inside the founder’s strongest area. A scientific founder may be so confident in the technology that they underinvest in market focus. A product founder may keep building because product progress feels more controllable than commercial validation. A clinical founder may rely too heavily on clinical need and underestimate buying complexity. A commercial founder may sell the vision well but underestimate the evidence burden required in health.

This is where investors become careful. They know that a founder’s strength can become a distortion if it dominates the entire company. The scientist may believe better data will solve every concern. The product builder may believe that more features will create adoption. The clinician may believe an obvious need will translate into demand. The salesperson may believe that narrative can outrun proof. Each of these strengths is valuable, but none of them can carry the company alone.

A founder’s background shapes what they notice first. It also shapes what they miss. That is why self-awareness matters so much. The strongest founders understand their own bias. They know what they are naturally drawn toward, and they know what they are likely to avoid. They can say, “This is where I am strong, and this is where the company needs support.” That level of honesty creates confidence because it shows the founder is not confusing personal expertise with company readiness.

Investors do not need the founder to be perfect. They need the founder to be coachable, precise, and honest about the company’s real risks. A founder who understands their blind spot can hire around it, advise around it, test it, and bring it into the operating plan. A founder who ignores it often lets it become the reason the round stalls.

Share

Investors listen for what is missing

During fundraising, founders often focus on what they want to say. Investors are listening for what is missing. This is one of the reasons blind spots become visible quickly. The founder may have a polished answer on the market, the product, the team, and the vision, but when the conversation moves toward the uncomfortable area, the answer becomes less clear.

If sales is the blind spot, the founder may talk about market need but struggle to explain the buyer, budget, urgency, sales cycle, or conversion path. If regulatory is the blind spot, they may talk about future approval but remain vague on classification, evidence requirements, timeline, cost, and decision points. If pricing is the blind spot, they may talk about value but avoid specific willingness-to-pay evidence. If financial discipline is the blind spot, they may talk about ambition but struggle to explain burn, runway, hiring sequence, or milestone-based capital use.

Investors notice these shifts. They notice when the founder becomes more abstract. They notice when answers become longer but less specific. They notice when the founder keeps returning to the same comfortable part of the story instead of answering the question directly. They notice when a key risk is described as something to figure out later, even though it should already be part of the strategy.

This does not mean every unknown is fatal. Early-stage companies are built around unknowns. But there is a difference between an unknown that is understood and an unknown that is being avoided. Investors can usually feel the difference. An understood risk has language around it. It has a plan. It has sequencing. It has a reason why it is not yet solved and a path for how it will be tested. An avoided risk stays vague.

The founder may think they are protecting the company by not drawing attention to the weakness. In reality, they may be making the weakness louder.

The blind spot becomes a diligence problem

A blind spot may not kill the first meeting, but it often becomes a problem in diligence. This is where the founder’s story gets tested against the company’s materials, conversations, model, evidence, and operating reality. If the blind spot has been avoided, diligence will usually expose it.

If sales is the blind spot, the investor will find that the pipeline is active but not qualified, the pilots have no conversion path, the buyer is unclear, and the revenue assumptions are not supported by real customer evidence. If regulatory is the blind spot, the investor will find that the pathway is more assumed than understood. If pricing is the blind spot, the model will depend on a price point that has not been tested. If governance is the blind spot, the data room may reveal messy ownership, weak documentation, unclear decision rights, or founder agreements that create future risk.

This is why blind spots damage momentum. The investor may like the company, but the diligence process starts to reveal that one part of the business is less developed than the pitch suggested. The round slows down because the investor has to decide whether the gap is normal early-stage risk or a sign that the founder does not understand the business deeply enough.

That distinction matters. Investors can invest through risk, but they are less comfortable investing through denial. Risk can be priced, staged, structured, diligenced, and managed. Denial is harder. If the founder does not see the problem, the investor has to worry that the company will keep making decisions around the problem rather than through it.

This is why founders should not wait for diligence to reveal the blind spot. They should identify it before the investor does and explain how they are working through it. That does not weaken the company. It often strengthens trust.

The blind spot changes by stage

Founder blind spots also change as the company matures. At the earliest stage, the blind spot may be market clarity. The founder has a technology, product, or scientific insight, but does not yet know the first customer, first use case, first buyer, or first proof point. At seed, the blind spot may be evidence quality. The company has interest, a prototype, early conversations, or pilot activity, but not enough proof that the product can create repeatable value. At Series A, the blind spot may be scalability. The company has early evidence, but investors want to understand whether the business can move beyond founder-led selling, one-off pilots, bespoke implementations, or narrow relationships.

This matters because some founders keep solving yesterday’s problem. They continue proving what investors already believe while avoiding the next risk that matters. A founder may keep improving the product when the real question has become distribution. A founder may keep collecting clinical feedback when the real question has become budget ownership. A founder may keep strengthening the science when the real question has become development sequencing. A founder may keep adding advisors when the real question has become execution capability.

The best founders understand that each financing stage requires a new level of honesty. What made the company credible at pre-seed may not be enough at seed. What helped the company raise seed may not be enough for Series A. The investor is always asking what risk needs to be reduced next. If the founder is still focused on the risk they already know how to solve, the company can start to look stuck.

This is one of the reasons fundraising is useful even when it is painful. It forces the company to confront the risks that the market sees, not only the risks the founder prefers to work on.

Leave a comment

The cost of not naming the problem

The cost of avoiding the blind spot is not only investor rejection. It also affects how the company operates. When the founder does not name the problem, the team cannot organise around it properly. Hiring becomes reactive. Advisors are chosen for reputation rather than gap-filling. Product decisions drift. Sales activity becomes noisy. Financial planning becomes disconnected from milestones. The company keeps moving, but it does not build enough discipline around the part of the business that most needs attention.

This is especially damaging in health because delays are expensive. A year spent avoiding the wrong question can cost the company more than money. It can cost evidence, momentum, credibility, market position, and future financing options. A company that avoids reimbursement for too long may build a product with no payment path. A company that avoids a regulatory strategy may generate data that does not support the right pathway. A company that avoids pricing may discover too late that willingness to pay is weaker than expected. A company that avoids governance may create legal or ownership issues that become difficult to clean up later.

Naming the problem early gives the company more options. It allows the founder to design experiments, hire the right people, ask better questions, and use capital more intelligently. It also changes the tone of investor conversations. Instead of appearing unaware, the founder appears disciplined. Instead of waiting to be challenged, the founder shows that they already understand where the company is exposed.

That is a different signal.

It tells investors the founder is not just selling the company. They are building it with clear eyes.

P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Subscribe now and operate like a pro.

How to find the risk you are avoiding

The hardest part of a blind spot is that it rarely feels like a blind spot from the inside. It feels like something that can wait. It feels like something that will become easier after the next hire, the next pilot, the next investor call, the next product release, or the next round. Founders are good at rationalising delay because delay often feels safer than confronting a difficult truth before the company has enough resources to solve it.

Read more

Welcome to the latest edition of the HealthVC newsletter.

HealthVC is the go-to newsletter for founders who want to master fundraising, build institutional-grade data rooms, and understand how investors actually make decisions.

One of the hardest transitions in health is the move from science to company. A discovery can be impressive. A mechanism can be novel. A platform can be technically strong. A patent can be defensible. A dataset can be valuable. A clinical insight can be meaningful. But none of those things automatically make the company investable.

This is where many health founders get caught. They believe the strength of the science should be enough to carry the fundraising story. They assume that if the technology is differentiated, if the research is credible, if the unmet need is obvious, and if the clinical potential is large, investors should understand why the company deserves capital. But investors are not only evaluating whether the science is interesting. They are evaluating whether the science can become a business.

That distinction matters because venture capital does not fund discovery alone. It funds the possibility that discovery can be turned into value. That means investors are asking a different set of questions. They want to know what the company is building, which market it is entering first, what evidence is needed, which risks need to be reduced, who the buyer or acquirer could be, what milestones increase value, and whether the team can move the asset from technical promise to commercial opportunity.

The science may be the reason the company exists, but it is not the whole investment case. A founder still needs to explain why this should become a company, why now is the right time, why this team can execute, why the first market makes sense, why the next milestone matters, and why capital will make the business more valuable.

This is the science-to-company gap. It is the space between having something technically or clinically promising and having something that investors can underwrite as a company.

Subscribe now

Strong science can still be an unclear company

One of the most common mistakes scientific founders make is assuming that technical strength creates commercial clarity. It does not. A company can have strong science and still be difficult to understand as an investment. The problem is not that the science is weak. The problem is that the business around the science has not yet been shaped clearly enough.

This happens often with university spinouts, platform technologies, diagnostics, medtech, computational biology, AI health tools, therapeutics, and research-led companies. The founder can explain the mechanism, the technical breakthrough, the data, the discovery process, or the clinical rationale, but struggles to explain the company in business terms. The pitch becomes heavy on what has been built and light on what will be proven next. The investor hears an impressive technical story, but not yet a clear investment story.

A scientific breakthrough may create many possible directions. It could support multiple indications, multiple customer types, multiple business models, multiple applications, or multiple partnership routes. From the founder’s perspective, this optionality can feel like strength. It shows that the technology is broad and powerful. From the investor’s perspective, too much optionality can feel like lack of focus. If everything is possible, it becomes harder to understand what the company is actually going to do first.

This is why investors often push founders toward sharper choices. They want to know the first use case, the first market, the first proof point, the first development path, and the first value inflection. They are not asking because they lack imagination. They are asking because companies do not become investable through theoretical optionality. They become investable when the founder can show how the first path creates evidence, value, and momentum.

Great science opens doors. Strategy decides which door to walk through first.

Investors need a company, not only an invention

An invention can be valuable, but a venture-backed company needs more than an invention. It needs a path. That path may be scientific, clinical, regulatory, commercial, strategic, or transactional, depending on the category. But it has to be visible enough for investors to believe that capital can move the company forward.

This is where some founders misunderstand the role of the investor. They think investors are there to appreciate the technical promise. In reality, investors are trying to understand whether the next round of capital can turn that promise into a more valuable asset. That requires more than a good idea or a strong patent. It requires a clear view of what the money will prove.

If the company is raising pre-seed or seed capital, the investor may not expect clinical proof or commercial revenue. But they will still want to know what the round is designed to de-risk. Is it proving technical feasibility? Is it generating early validation data? Is it clarifying the regulatory path? Is it narrowing the first indication? Is it building the right team? Is it creating a data package that could attract strategic interest or a stronger institutional round?

At Series A, the expectations become different. The investor may want to see stronger evidence, clearer milestones, more disciplined market selection, a credible development plan, and a more mature understanding of risk. The company does not need to have everything solved, but it needs to show that it is moving from research logic to company logic.

This is why the phrase “we have great science” is never enough. The investor needs to understand how the science becomes a company. They need to understand what the first product, asset, indication, customer, partner, or value inflection looks like. They need to see how the company moves from potential to proof.

The first market matters more than the total market

Founders often try to make the company look bigger by showing how many markets the science could serve. They explain that the platform could apply to multiple diseases, multiple workflows, multiple patient groups, multiple hospital departments, or multiple strategic partners. This may be true, but it can weaken the pitch if the founder cannot explain the first market clearly.

Investors do not only want to know how large the total opportunity could become. They want to know how the company enters the market. The first market is where the company learns, proves, focuses, and builds credibility. If the first market is poorly chosen, the company can spend years generating activity without creating a clear value inflection.

The first market should not be chosen only because it is large. It should be chosen because it gives the company the best chance to prove something that matters. For a therapeutic company, this may mean choosing an indication where biology, clinical development, unmet need, competitive dynamics, and strategic interest align. For a diagnostic company, it may mean choosing a use case where the test changes a decision and has a credible payment pathway. For a medtech company, it may mean choosing a workflow where the product solves a real problem without creating excessive adoption friction. For a platform company, it may mean choosing a focused application that proves the platform’s value without forcing investors to believe everything at once.

This is where many research-led founders struggle. They want the company to be understood through the full breadth of the science. Investors often want the company to be understood through the first investable path. Breadth may matter later, but focus matters first.

A company that can explain its first market clearly is easier to fund because investors can understand what progress looks like. They can see what evidence needs to be generated, what risks remain, who cares if it works, and why the next milestone changes the value of the business.

Optionality is useful only when the first path is credible

Optionality is one of the most overused ideas in early health pitches. Founders often say the platform can be used across many applications, diseases, customers, or partners. They believe this makes the company more attractive because it shows scale. Sometimes it does. But optionality only creates value when investors believe the company has a credible first path.

Without a clear first path, optionality can look like avoidance. It can feel like the founder has not made the difficult strategic choices yet. It can suggest that the company is trying to keep every door open because it does not know which one matters most. In science-led companies, this can become especially dangerous because the technical possibility is often much wider than commercial reality.

A platform may be able to do many things, but the company cannot prove all of them at once. A technology may have many theoretical applications, but the team cannot pursue every market, regulatory path, partnership model, and evidence package simultaneously. A founder may want to show ambition, but investors need to see sequencing.

Sequencing is what turns optionality into strategy. The founder needs to explain what comes first, what comes later, and why. They need to show why the first path is the right one, what it proves, how it creates value, and how it opens the next path. If the first path works, optionality becomes more credible. If the first path is vague, optionality becomes noise.

This is a critical difference. Investors are not against big visions. They are against unfocused visions. The best founders can hold both ideas at the same time. They can show the ambition of the platform while still being precise about the first evidence path.

The team has to change as the company changes

The science-to-company gap is not only about strategy. It is also about team evolution. A research project can be led by scientific excellence alone. A company cannot. As the company moves forward, it needs commercial judgment, regulatory understanding, clinical development experience, product discipline, operational structure, financial planning, and fundraising capability.

This does not mean scientific founders need to become experts in everything. It means they need to understand what the company is missing and bring in the right people at the right time. Investors do not expect early teams to be complete, but they do look for self-awareness. They want to know whether the founder understands the gap between where the company is today and what it will need to become.

A brilliant scientific founder can lose investor confidence if they cannot explain how the company will develop beyond the lab. The investor may believe in the technology, but worry about execution. They may ask who will lead clinical development, who understands regulatory strategy, who can build partnerships, who can manage a financing process, who can translate the science into a business case, and who has built something like this before.

This is especially important for academic spinouts. The academic environment rewards discovery, publication, technical depth, and scientific credibility. The company environment rewards focus, execution, milestone discipline, capital efficiency, and decision-making under uncertainty. Those worlds overlap, but they are not the same. A founder moving from one to the other needs to show they understand the shift.

The strongest founders are not defensive about this. They do not pretend that the science team already has every capability. They explain where the team is strong, where it needs to be strengthened, and what the next hires or advisors will unlock. That kind of honesty builds trust because it shows the founder is thinking like a company builder, not only a researcher.

The milestone has to create company value

A common weakness in science-led fundraising is that the use of funds is described as a list of activities instead of a value creation plan. The founder says the round will fund experiments, development, hiring, regulatory work, product build, clinical preparation, or market exploration. These may all be necessary, but investors need to understand why they matter.

Capital should not just pay for work. It should create value. That means the founder needs to explain what the company will know, prove, unlock, or de-risk after the round. If the company raises capital and spends it, what changes? Does the data package become stronger? Does the regulatory path become clearer? Does the first market become validated? Does the product become ready for clinical use? Does the company become attractive to strategic partners? Does the next financing become easier because a key risk has been reduced?

This is one of the most important shifts from science thinking to company thinking. In science, the next experiment may be valuable because it advances understanding. In venture, the next milestone must also advance the company. It needs to make the asset more fundable, more partnerable, more defensible, more credible, or more valuable.

Founders should be able to explain the value of each major milestone in investor language. Not just what they will do, but why it changes the risk profile of the company. Not just what data they will generate, but who will care about that data. Not just what development work will be completed, but how that work supports the next financing, partnership, regulatory step, or commercial pathway.

This is where many technically strong companies become weak fundraising stories. They know what they want to work on, but they do not explain why that work creates investable progress.

Leave a comment

The company must become easier to believe

The real job of the founder is to make the company easier to believe over time. That does not mean oversimplifying the science or pretending the risks are lower than they are. It means organising complexity so investors can understand what matters.

Health companies are naturally complex. There may be biology, engineering, clinical evidence, regulatory pathways, reimbursement questions, market access issues, manufacturing requirements, product adoption risks, data quality concerns, IP questions, and strategic partnership possibilities. The founder cannot remove all complexity, but they can structure it.

A founder who explains the company clearly creates confidence. They show investors where the science is strong, where the company is still early, what needs to be proven next, which risks matter most, and why the first path is credible. A founder who hides inside technical detail creates the opposite effect. The investor may respect the science but still feel unsure about the company.

This is one reason clarity matters so much in fundraising. Clarity is not a marketing trick. It is a signal of judgment. If the founder can explain a complex company simply without making it shallow, investors start to believe the founder understands the business deeply. If the founder cannot explain the company without drifting into technical detail, investors may worry that the company is not yet strategically formed.

The best health founders do not make investors do all the translation. They do not assume the science will speak for itself. They translate the science into a company narrative that can survive partner meetings, diligence, investment committees, strategic conversations, and future financing rounds.

What investors are really underwriting

Investors are not underwriting science in isolation. They are underwriting the path from science to value. That path is different depending on the company, but the underlying question is similar: can this team turn this technical or clinical insight into something that becomes significantly more valuable with capital?

That is why the investment case needs to connect the science, the team, the market, the evidence, the milestones, and the financing strategy. If one of those pieces is missing, the company becomes harder to fund. Strong science with no market focus is hard to underwrite. Strong science with no team evolution is hard to underwrite. Strong science with no milestone logic is hard to underwrite. Strong science with no credible first path is hard to underwrite.

This does not mean every early company needs to have all the answers. Investors know that early health companies are built through uncertainty. But they need to believe the founder knows how to move through that uncertainty in the right order. They need to see that the founder is not only asking for capital to continue the research, but to build the company.

That is the difference.

Research asks what is true.

A company asks what can be built, funded, adopted, defended, scaled, partnered, or acquired from what is true.

Both matter. But they are not the same.

P.S. Want to Stay Informed: Subscribe to HealthVC Pro, The Operating System for Founders & Emerging Managers

Stop guessing. Start executing.

HealthVC Pro gives founders, GPs, and LPs direct access to the most actionable tools in European venture capital today:
💥 A live, filterable database of 3,400+ investors, by stage, region, thesis, and type
📬 Proven outreach scripts to secure meetings with LPs, co-investors, and angels
📊 Real-world pitch decks, frameworks, and fundraising playbooks that actually work
🔍 Monthly updates to investor data, not some dusty PDF or scraped list
💬 Founding Members get async feedback on decks and messaging

Whether you’re raising your first round or deploying your third fund, this is your tactical edge.

Don’t forget to check out the HealthVC on YouTube and The Terminology of Venture Capital on Amazon.

YouTube

Book on Amazon

Twitter

Share

The real transition from science to company

Read more